RU2812280C1 - Pd-1 binding antibodies and methods of their use - Google Patents

Abstract

FIELD: biotechnology; medicine.

SUBSTANCE: invention discloses a vector based on a genetically modified herpes simplex virus type 1, which makes it possible to obtain an isolated monoclonal antibody that specifically binds to PD-1 with increased affinity.

EFFECT: invention can be used in medical practice as a medicinal product to suppress the growth of tumor cells in the treatment of various cancers.

8 cl, 2 dwg, 12 tbl, 10 ex

Description

TECHNICAL FIELD

[0001] The present invention generally relates to an isolated monoclonal antibody, particularly a murine, fusion or humanized monoclonal antibody, that specifically binds to human PD-1 with high affinity and functional activity. Also proposed is a nucleic acid molecule encoding the said antibody, an expression vector, a host cell and a method for expressing the said antibody. The present invention further provides an immunoconjugate, a bispecific molecule, an oncolytic virus and a pharmaceutical composition containing an antibody, as well as a method of diagnosis and treatment using an anti-PD-1 antibody according to the invention.

BACKGROUND OF THE ART

[0002] Programmed cell death protein 1, also known as PD-1 or CD279, is a member of the CD28 family of T cell regulators and is expressed on activated B cells, T cells and myeloid cells (Agata et al. , (1996) Int Immunol 8:765-72; Okazaki et al., (2002) Curr. Opin. Immunol. 14: 391779-82; Bennett et al., (2003) J Immunol 170:711-8). It contains a membrane-proximal immunoreceptor tyrosine inhibitory motif (ITIM) and a membrane-distal tyrosine switch motif (ITSM) (Thomas, ML (1995) J Exp Med 181:1953-6; Vivier, E and Daeron, M (1997) Immunol Today 18:286-91). Two PD-1 ligands have been identified—PD-L1 and PD-L2—both of which are B7 homologs that bind PD-1 but do not bind other CD28 family members.

[0003] Some evidence suggests that PD-1 and its ligands mediate negative regulation of immune responses. For example, PD-1 has been found to be present at high levels in various human cancers (Dong et al. , (2002) Nat. Med. 8:787-9). It has also been reported that the interaction between PD-1 and PD-L1 leads to a decrease in the level of tumor-infiltrating lymphocytes and T-cell receptor-mediated proliferation, as well as the evasion of cancer cells from immunosurveillance (Dong et al. , (2003) J. Mol. Med 81 :281-7; Blank et al. , (2005) Cancer Immunol. Immunother. 54:307-314; Konishi et al. , (2004) Clin. Cancer Res. 10:5094-100). Studies have also shown that inhibiting the local interaction of PD-1 with PD-L1 can reverse immune suppression, and this effect is enhanced by blocking the interaction also between PD-1 and PD-L2 (Iwai et al. , (2002) Proc. Nat'l Acad. Sci. USA 99:12293-7; Brown et al ., (2003) J. Immunol. 170:1257-66).

[0004] Animals with PD-1 deficiency may develop various autoimmune phenotypes, including autoimmune cardiomyopathy and lupus syndrome with arthritis and nephritis (Nishimura et al ., (1999) Immunity 11:141-51; Nishimura et al ., (2001) Science 291:319-22). Additionally, PD-1 has been found to be involved in autoimmune encephalomyelitis, systemic lupus erythematosus, graft-versus-host disease (GVHD), type I diabetes, and rheumatoid arthritis (Salama et al ., (2003) J Exp Med 198: 71-78; Prokunina and Alarcon-Riquelme (2004) Hum Mol Genet 13:R143; Nielsen et al ., (2004) Lupus 13:510). In a murine B cell tumor line, the ITSM motif of PD-1 was shown to be important for blocking BCR-mediated Ca ²⁺ current and tyrosine phosphorylation of downstream effector molecules (Okazaki et al ., (2001) PNAS 98:13866-71 ).

[0005] A number of anticancer immunotherapy agents that target PD-1 have been developed to treat the disease. One such anti-PD-1 antibody is nivolumab (marketed under the brand name OPDIVO® by Bristol Myers Squibb), which produced complete or partial responses in non-small cell lung cancer, melanoma and renal cell carcinoma in a clinical trial involving a total of 296 patients (Topalian SL et al ., (2012) The New England Journal of Medicine . 366 (26): 2443-54). It was approved in Japan in 2014 and by the US Food and Drug Administration (FDA) in 2014 for the treatment of metastatic melanoma. Another anti-PD-1 antibody, pemrolizumab (KEYTRUDA™, MK-3475, Merck), which targets PD-1, was also approved by the US Food and Drug Administration (FDA) in 2014 for the treatment of metastatic melanoma. It is used in clinical trials in the US to treat lung cancer, lymphoma and mesothelioma.

[0006] Although there are already developed and approved antibodies against PD-1, there is a need for additional monoclonal antibodies that have increased binding affinity for PD-1 and other desirable pharmaceutical characteristics.

BRIEF DESCRIPTION OF THE INVENTION

[0007] The present invention provides an isolated monoclonal antibody, e.g., a murine, human, hybrid, or humanized monoclonal antibody, that binds to PD-1 (e.g., human PD-1 and monkey PD-1) and has increased affinity for PD-1 and comparable or better antitumor effect compared to existing anti-PD-1 antibodies such as nivolumab.

[0008] The antibody of the invention can be used in a variety of applications, including detection of the PD-1 protein and the treatment and prevention of PD-1 associated diseases such as cancers, autoimmune cardiomyopathy, autoimmune encephalomyelitis, systemic lupus erythematosus, graft-versus-host disease " (GVHD), type I diabetes and rheumatoid arthritis.

[0009] Accordingly, in one aspect, the invention provides an isolated monoclonal antibody (e.g., a murine, fusion, or humanized antibody) or an antigen-binding portion thereof that binds PD-1 and comprises a heavy chain variable region containing a CDR1 region, a region CDR2 and a CDR3 region, wherein said CDR1, CDR2 and CDR3 regions contain amino acid sequences that are at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the sequences of (1) SEQ ID NO: 1, 2 and 3 respectively; (2) SEQ ID NO: 4, 5 and 6 respectively; (3) SEQ ID NO: 7, 8 and 9 respectively; (4) SEQ ID NO: 10, 11 and 12 respectively; (5) SEQ ID NO: 13, 14 and 15 respectively; (6) SEQ ID NO: 16, 17 and 18 respectively; (7) SEQ ID NO: 19, 20 and 21 respectively; (8) SEQ ID NO: 22, 23 and 24 respectively; (9) SEQ ID NO: 25, 26 and 27 respectively; (10) SEQ ID NOs: 28, 29 and 30, respectively, or (11) SEQ ID NOs: 31, 32 and 33, respectively, wherein said antibody or antigen binding fragment thereof binds PD-1.

[0010] In one aspect, the isolated monoclonal antibody or antigen-binding portion thereof of the present invention comprises a heavy chain variable region comprising an amino acid sequence of at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78 or 79, wherein the antibody or antigen-binding fragment thereof binds PD-1. The sequences SEQ ID NO: 67 and 69-79 may be encoded by the nucleic acid sequences SEQ ID NO: 102-113, respectively.

[0011] In one aspect, an isolated monoclonal antibody or antigen-binding portion thereof of the present invention comprises a light chain variable region that comprises a CDR1 region, a CDR2 region, and a CDR3 region, wherein said CDR1, CDR2, and CDR3 regions comprise amino acid sequences of at least at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the sequences of (1) SEQ ID NO: 34, 35 and 36, respectively; (2) SEQ ID NO: 37, 38 and 39 respectively; (3) SEQ ID NO: 40, 41 and 42 respectively; (4) SEQ ID NO: 43, 44 and 45 respectively; (5) SEQ ID NO: 46, 47 and 48 respectively; (6) SEQ ID NO: 49, 50 and 51 respectively; (7) SEQ ID NO: 52, 53 and 54 respectively; (8) SEQ ID NO: 55, 56 and 57 respectively; (9) SEQ ID NO: 58, 59 and 60 respectively; (10) SEQ ID NOs: 61, 62 and 63, respectively, or (11) SEQ ID NOs: 64, 65 and 66, respectively, wherein said antibody or antigen binding fragment thereof binds PD-1.

[0012] In one aspect, the isolated monoclonal antibody or antigen-binding portion thereof of the present invention comprises a light chain variable region comprising an amino acid sequence of at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95 or 96, wherein said antibody or antigen thereof the binding moiety binds to PD-1. SEQ ID NOs: 80 and 86-96 may be encoded by the nucleic acid sequences of SEQ ID NOs: 114-125, respectively.

[0013] In one aspect, an isolated monoclonal antibody or antigen-binding portion thereof of the present invention comprises a heavy chain variable region and a light chain variable region, each of which comprises a CDR1 region, a CDR2 region, and a CDR3 region, wherein the heavy chain variable regions CDR1, CDR2 and CDR3 and the light chain variable regions CDR1, CDR2 and CDR3 contain amino acid sequences that are at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the sequences of (1) SEQ ID NO: 1, 2, 3, 34, 35 and 36 respectively; (2) SEQ ID NO: 4, 5, 6, 37, 38 and 39, respectively; (3) SEQ ID NO: 7, 8, 9, 40, 41 and 42, respectively; (4) SEQ ID NO: 10, 11, 12, 43, 44 and 45, respectively; (5) SEQ ID NO: 13, 14, 15, 46, 47 and 48, respectively; (6) SEQ ID NO: 16, 17, 18, 49, 50 and 51, respectively; (7) SEQ ID NO: 19, 20, 21, 52, 53 and 54, respectively; (8) SEQ ID NO: 22, 23, 24, 55, 56 and 57, respectively; (9) SEQ ID NO: 25, 26, 27, 58, 59 and 60, respectively; (10) SEQ ID NOs: 28, 29, 30, 61, 62 and 63, respectively, or (11) SEQ ID NOs: 31, 32, 32, 64, 65 and 66, respectively, wherein the antibody or antigen-binding fragment thereof binds to PD-1.

[0014] In one embodiment, an isolated monoclonal antibody or antigen-binding portion thereof of the present invention comprises a heavy chain variable region and a light chain variable region, wherein said heavy chain variable region and light chain variable region comprise amino acid sequences of at least 80%, 85%, 90%, 95%, 98%, 99% or 100% sequence identical to (1) SEQ ID NO: 67 and 80, respectively; (2) SEQ ID NO: 68 and 81, respectively; (3) SEQ ID NO: 69 and 81, respectively; (4) SEQ ID NO: 68 and 82, respectively; (5) SEQ ID NO: 68 and 83 respectively; (6) SEQ ID NO: 68 and 84 respectively; (7) SEQ ID NO: 68 and 85 respectively; (8) SEQ ID NO: 68 and 86, respectively; (9) SEQ ID NO: 69 and 86, respectively; (10) SEQ ID NO: 70 and 87 respectively; (11) SEQ ID NO: 71 and 88 respectively; (12) SEQ ID NO: 72 and 89 respectively; (13) SEQ ID NO: 73 and 90 respectively; (14) SEQ ID NO: 74 and 91, respectively; (15) SEQ ID NO: 75 and 92, respectively; (16) SEQ ID NO: 76 and 93, respectively; (17) SEQ ID NO: 77 and 94, respectively; (18) SEQ ID NO: 78 and 95 respectively; or (19) SEQ ID NO: 79 and 96, respectively, wherein the antibody or antigen-binding fragment thereof binds to PD-1.

[0015] According to one embodiment of the invention, an isolated monoclonal antibody or antigen-binding portion thereof of the present invention comprises a heavy chain and a light chain, wherein said heavy chain comprises a heavy chain variable region and a heavy chain constant region, and said light chain comprises a variable region a light chain and a light chain constant region, wherein said heavy chain constant region contains amino acid sequences at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to the sequences of SEQ ID No: 97, 99 or 129, and said light chain constant region contains amino acid sequences that are at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to the sequences of SEQ ID No: 98 or 130, and said the heavy chain variable region and the light chain variable region comprise the amino acid sequences described above wherein said antibody or antigen binding fragment thereof binds PD-1. Said amino acid sequences SEQ ID NOs: 97 and 99 may be encoded by nucleic acid sequences SEQ ID NOs: 126 and 128, respectively. SEQ ID NO:98 may be encoded by SEQ ID NO:127.

[0016] An antibody of the present invention, in accordance with some embodiments of the present invention, contains or consists of two heavy chains and two light chains, wherein each heavy chain contains a heavy chain constant region, a variable region, or the heavy chain CDR sequences listed above, and each light chain contains a light chain constant region, variable region, or light chain CDR sequences listed above, wherein said antibody binds to PD-1. The antibody of the invention may be a full-length antibody, for example an IgG1, IgG2 or IgG4 isotype. The antibody of the present invention, in accordance with other embodiments, may be a single chain antibody or antibody fragments, such as Fab or Fab'2 fragments.

[0017] The antibody or antigen-binding portion thereof of the present invention has increased binding affinity to human PD-1 compared to prior art anti-PD-1 antibodies, such as nivolumab, which binds to human PD-1 with a K _D of 6 ,36×10 ^-9 M or less, and inhibiting the binding of PD-L1 to PD-1. The antibody or antigen-binding portion thereof of the invention also provides comparable or better antitumor effect compared to existing anti-PD-1 antibodies such as nivolumab.

[0018] The invention also provides an immunoconjugate comprising an antibody of the invention or an antigen-binding moiety thereof coupled to a therapeutic agent, such as a cytotoxin. The invention also provides a bispecific molecule comprising an antibody or antigen-binding portion thereof of the invention linked to a second functional moiety (eg, a second antibody) having a binding specificity different from that of said antibody or antigen-binding portion thereof. In another aspect, the antibody or antigen-binding portions thereof of the present invention may be formulated as part of a chimeric antigen receptor (CAR). The antibody or antigen-binding portions thereof of the present invention may also be encoded by an oncolytic virus or used in conjunction with an oncolytic virus.

[0019] Also provided are compositions containing an antibody or an antigen-binding portion or immunoconjugate thereof, a bispecific molecule, an oncolytic virus or CAR according to the invention and a pharmaceutically acceptable carrier.

[0020] The invention also includes nucleic acid molecules encoding antibodies or antigen-binding portions thereof of the invention, as well as expression vectors containing such nucleic acids, and host cells containing said expression vectors. Also provided is a method for producing an anti-PD-1 antibody using a host cell containing an expression vector, comprising the steps of (i) expressing the antibody in the host cell and (ii) isolating said antibody from the host cell or cell line thereof.

[0021] According to another aspect, the invention provides a method of modulating an immune response in a subject, comprising administering to said subject an antibody or antigen-binding portion thereof according to the invention such that modulation of the immune response in said subject is achieved. Preferably, the antibody of the invention enhances, stimulates or positively regulates the immune response in a subject. According to some embodiments of the present invention, the method includes administering a composition, bispecific molecule, immunoconjugate, CAR-T cell or antibody-encoding or antibody-containing oncolytic virus according to the invention or, alternatively, a nucleic acid molecule capable of causing expression of the antibody in the specified subject.

[0022] According to a further aspect, the invention provides a method of inhibiting tumor growth in a subject, comprising administering to said subject a therapeutically effective amount of an antibody or antigen-binding moiety thereof according to the present invention. The tumor may be a solid or non-solid tumor, including, but not limited to, lymphoma, leukemia, multiple myeloma, melanoma, colon adenocarcinoma, pancreatic cancer, colon cancer, gastrointestinal cancer, prostate cancer, bladder cancer , kidney cancer, ovarian cancer, cervical cancer, breast cancer, lung cancer, renal cell cancer and nasopharyngeal cancer. According to some embodiments of the present invention, the method includes administering a composition, bispecific molecule, immunoconjugate, CAR-T cell or antibody-encoding or antibody-containing oncolytic virus according to the invention or, alternatively, a nucleic acid molecule capable of causing expression of the antibody in the specified subject.

[0023] According to another aspect, the invention provides a method of treating an infectious disease in a subject, comprising administering to said subject a therapeutically effective amount of an antibody or antigen-binding moiety thereof according to the present invention. According to some embodiments of the present invention, the method includes administering a composition, bispecific molecule, immunoconjugate, CAR-T cell or antibody-encoding or antibody-containing oncolytic virus according to the invention or, alternatively, a nucleic acid molecule capable of causing expression of the antibody in the specified subject.

[0024] The invention also provides a method of enhancing an immune response to an antigen in a subject, comprising administering to said subject: (i) an antigen and (ii) an antibody or an antigen-binding portion thereof such that the immune response to said antigen in the subject is enhanced. The antigen may be, for example, a tumor antigen, a viral antigen, a bacterial antigen, or a pathogen antigen.

[0025] Antibodies of the invention can be used in combination with at least one additional agent, such as an immunostimulatory antibody (for example, an anti-PD-L1 antibody and/or an anti-CTLA-4 antibody), a cytokine (for example, IL-2 and/or IL-21) or a co-stimulatory antibody (eg, anti-CD137 antibody and/or anti-GITR antibody).

[0026] Other features and advantages of the present invention will be apparent from the following detailed description and examples, which do not limit the present invention. The contents of all references, Genbank inputs, patents, and published patent applications cited in this application are expressly incorporated herein by reference.

BRIEF DESCRIPTION OF GRAPHIC MATERIALS

[0027] Figure 1 shows the melting curve of the humanized anti-PD-1 antibody huC1E1-V10.

[0028] Figure 2 shows the size exclusion chromatography result of the humanized anti-PD-1 antibody huC1E1-V10.

DETAILED DESCRIPTION OF THE INVENTION

[0029] For easier understanding of the present invention, specific terms will first be described. Additional definitions are set forth in the detailed description.

[0030] The term “PD-1” refers to programmed cell death protein 1. The term “PD-1” includes variants, isoforms, homologs, orthologs and paralogs. For example, an antibody specific for human PD-1 protein may, in certain cases, cross-react with PD-1 protein from non-human species, such as monkey. In other embodiments, an antibody specific for human PD-1 protein may be absolutely specific for human PD-1 protein and not cross-react with other species or other types, or may cross-react with PD-1 from specific other species, but not all other species.

[0031] The term “human PD-1” refers to a PD-1 protein having a human amino acid sequence, such as the human PD-1 amino acid sequence having Genbank accession number NP_005009.2. The terms “monkey or rhesus PD-1” and “mouse PD-1” refer to monkey and mouse PD-1 sequences, respectively, for example, sequences having the amino acid sequences having Genbank accession numbers NP_001107830 and CAA48113, respectively.

[0032] The term "immune response" refers to the action of, for example, lymphocytes, antigen-presenting cells, phagocytes, granulocytes and soluble macromolecules produced by the above cells or the liver (including antibodies, cytokines and complement components), which leads to selective damage, destruction or elimination from the human body of invading pathogens, pathogen-infected cells or tissues, cancer cells, or normal human cells or tissues in cases of autoimmune reaction or pathological inflammation.

[0033] The term “antigen-specific T cell response” refers to a T cell response that results from stimulation of the T cell with an antigen for which the T cell is specific. Non-limiting examples of responses made by a T cell upon antigen-specific stimulation include proliferation and cytokine production (eg, IL-2 production).

[0034] The term “antibody” as described herein includes full-length antibodies and any antigen-binding fragment (ie, “antigen-binding portion”) or single chain of an antibody. Full-length antibodies are glycoproteins containing two heavy (H) chains and two light (L) chains linked by disulfide bonds. Each heavy chain consists of a heavy chain variable region (abbreviated herein as _VH ) and a heavy chain constant region. The heavy chain constant region consists of three domains - C _H1 , C _H2 and C _H3 . Each light chain consists of a light chain variable region (abbreviated herein as V _L ) and a light chain constant region. The light chain constant region consists of one domain, C _L . The V _H and V _L regions can be further divided into regions of hypervariability called complementarity determining regions (CDR), interspersed with regions that are more conserved called frame regions (FR). Each V _H and V _L consists of three CDRs and four FRs, organized from amino terminus to carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The heavy and light chain variable regions contain a binding domain that interacts with the antigen. Antibody constant regions can mediate the binding of immunoglobulin to host tissues and factors, including various cells of the immune system (eg, effector cells) and the first component (C1q) of the classical complement system.

[0035] The term "antigen-binding portion" of an antibody (or simply "antibody portion") as used herein refers to one or more antibody fragments that retain the ability to specifically bind an antigen (eg, PD-1 protein). It has been shown that the antigen-binding function of an antibody can be carried out by fragments of a full-length antibody. Examples of binding fragments included in the term “antigen-binding portion” of an antibody include ₍ i) a Fab fragment—a monovalent fragment consisting of the VL, _VH , _CL , and _CH1 domains; (ii) F(ab') ₂ fragment - a bivalent fragment containing two Fab fragments linked by a disulfide bridge in the hinge region; (iii) Fd fragment consisting of V _H and C _H1 domains; (iv) an Fv fragment, consisting of the V _L and V _H domains of one antibody chain, (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546), which consists of a V _H domain; (vi) a dedicated complementarity determining region (CDR); and (viii) a nanobody - a heavy chain variable region containing one variable domain and two constant domains. Moreover, despite the fact that the two domains of the Fv fragment - V _L and V _H - are encoded by separate genes, they can be joined using recombinant methods using a synthetic linker, which ensures their production in the form of a single protein chain in which the V _L regions and _VH combine to form monovalent molecules (known as single chain Fv (scFv); see, for example, Bird et al., (1988) Science 242:423-426; and Huston et al., (1988) Proc. Natl. Acad Sci USA 85:5879-5883). Such single chain antibodies are also intended to be included within the term “antigen-binding portion” of an antibody. Such antibody fragments are prepared using standard methods known to those skilled in the art, and the fragments are screened for their utility in the same manner as intact antibodies are screened.

[0036] An "isolated antibody" as used herein is intended to refer to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds to the PD-1 protein is substantially free of antibodies that specifically bind to antigens other than PD-1 proteins). An isolated antibody that specifically binds to human PD-1 protein may, however, be cross-reactive with other antigens, such as PD-1 proteins from other species. Moreover, the isolated antibody may be substantially free of other cellular material and/or chemicals.

[0037] The terms “monoclonal antibody” or “monoclonal antibody composition” as used herein refer to a preparation of single-molecule antibody molecules. A monoclonal antibody composition exhibits a single binding specificity and affinity for a particular epitope.

[0038] The term “mouse antibody” as used herein is intended to include antibodies containing variable regions in which both framework and CDR regions are derived from murine germline immunoglobulin sequences. In addition, if the antibody contains a constant region, then the specified constant region is also derived from murine germline immunoglobulin sequences. Mouse antibodies of the invention may include amino acid residues not encoded by murine germline immunoglobulin sequences (eg, containing mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo ). However, the term “mouse antibody” as used herein is not intended to include antibodies in which CDR sequences derived from the germ line of other mammalian species have been grafted onto mouse framework sequences.

[0039] The term "hybrid antibody" refers to an antibody created by combining genetic material from a non-human source with human genetic material. More generally, a hybrid antibody is an antibody that contains genetic material from a specific species with genetic material from other species.

[0040] The term “humanized antibody” as used herein refers to an antibody from a non-human species whose protein sequences have been modified to increase the degree of similarity to naturally occurring antibody variants that are produced in humans.

[0041] The term “isotype” refers to a class of antibodies (eg, IgM or IgG1) that are encoded by heavy chain constant region genes.

[0042] The phrases “antigen-recognizing antibody” and “antigen-specific antibody” are used interchangeably herein with the term “antibody that specifically binds an antigen.”

[0043] As used herein, an antibody that "specifically binds to human PD-1" is intended to refer to an antibody that binds to human PD-1 protein (and possibly PD-1 protein from one or more species non-human) but does not substantially bind to non-PD-1 proteins. Preferably, the antibody binds to human PD-1 protein with "high affinity", namely a K _D value of 5.0 x10 ^-8 M or less, more preferably 1.0 x10 ^-8 M or less, and more preferably , 7.0 x 10 ^-9 M or less.

[0044] The term “substantially does not bind” to a protein or cells as used herein means no binding or no high affinity binding to the specified protein or cells, i.e. refers to binding to a protein or cells with a K _D value of 1.0 x 10 ^-6 M or more, more preferably 1.0 x 10 ^-5 M or more, more preferably 1.0 x 10 ^-4 M or more, more preferably 1.0 x 10 ^-3 M or more, more preferably 1.0 x 10 ^-2 M or more.

[0045] The term "high affinity" when referring to an IgG antibody refers to an antibody having a K _D value for the target antigen of 1.0 x 10 ^-6 M or less, more preferably 5.0 x 10 ^-8 M or less, more preferably 1.0 x 10 ^-8 M or less, more preferably 7.0 x 10 ^-9 M or less, more preferably 1.0 x 10 ^-9 M or less. However, "high affinity" binding may vary for other antibody isotypes. For example, “high affinity” binding for an IgM isotype refers to an antibody having a K _D value of 10 ^-6 M or less, more preferably 10 ^-7 M or less, more preferably 10 ^-8 M or less.

[0046] The term "K _assoc " or "K _a " as used herein is intended to refer to the rate of association for a particular antibody-antigen interaction, while the term "K _dis " or "K _d " as used herein refers to to the dissociation rate for a particular antibody-antigen interaction. The term “K _D ” as used herein is intended to refer to the dissociation constant, which is derived from the ratio of K _d to K _a (ie, K _d /K _a ) and expressed as molar concentration (M). K _D values for antibodies can be determined using methods generally recognized in the art. A preferred method for determining the K _D of an antibody is the use of surface plasmon resonance, preferably using a biosensor system such as the Biacore™ system.

[0047] The term "EC ₅₀ ", also known as half-maximal effective concentration, refers to the concentration of an antibody that produces a response whose intensity is midway between the baseline level and the maximum level after a certain time of exposure.

[0048] The term "IC ₅₀ ", also known as half-maximal inhibitory concentration, refers to the concentration of an antibody that results in inhibition of a specific biological or biochemical function by 50% relative to the inhibition in the absence of the antibody.

[0049] The term "subject" includes any animal, whether or not human. The term "non-human animal" includes all vertebrates, such as mammals and non-mammals, such as non-human primates, sheep, dogs, cats, cows, horses, chickens, amphibians and reptiles, with mammals being preferred, such non-human primates, sheep, dogs, cats, cows and horses.

[0050] The term “therapeutically effective amount” means an amount of an antibody of the present invention sufficient to prevent or reduce symptoms associated with a disease or condition (such as cancer) and/or reduce the severity of the disease or condition. It is intended that the therapeutically effective amount be considered in the context of the condition being treated, and those skilled in the art will readily determine the actual effective amount.

[0051] Various aspects of the present invention are described in more detail in the following subsections.

[0052] Anti-PD-1 antibodies having increased binding affinity to human PD-1 and better antitumor effect

[0053] The antibody or antigen-binding portion thereof of the invention specifically binds to human PD-1 and has increased binding affinity and comparable or better antitumor effect compared to previously described anti-PD-1 antibodies, in particular compared to nivolumab .

[0054] The antibody or antigen-binding portion thereof of the invention preferably binds to human PD-1 protein with a K _D value of 7.0 x 10 ^-9 M or less, more preferably with a K _D value of 5.0 x 10 ^-10 M or less. Antibodies of the invention also bind to cynomolgus PD-1 with a K _D value of about 1.0 x 10 ^-7 M to 1.0 x 10 ^-10 M.

[0055] Additional functional properties include the ability to block PD-1/PD-L1 interaction. Antibodies of the present invention, in one embodiment, can inhibit the binding of PD-1 and PD-L1 at a concentration similar to nivolumab.

[0056] Other functional properties include the ability of the antibody to stimulate an immune response, such as an antigen-specific T-cell response. This ability can be tested, for example, by assessing the ability of the antibody to stimulate the production of interleukin-2 (IL-2) in an antigen-specific T-cell response. In specific embodiments, the antibody binds to human PD-1 and stimulates an antigen-specific T cell response. In other embodiments, the antibody binds to human PD-1 but does not stimulate an antigen-specific T cell response. Other ways to evaluate the ability of an antibody to stimulate an immune response include testing its ability to suppress tumor growth, for example, in an in vivo tumor graft model, or its ability to stimulate an autoimmune response, for example, the ability to promote the development of an autoimmune disease in an autoimmune model, for example, the ability to promote the development of diabetes in NOD -mouse model.

[0057] Preferred antibodies of the invention are human monoclonal antibodies. Additionally or alternatively, the antibodies may, for example, be hybrid or humanized monoclonal antibodies.

[0058] Monoclonal antibody against PD-1

[0059] A preferred antibody of the invention is a monoclonal antibody having the structural and chemical characteristics described below and in the following Examples. The amino acid sequence of the anti-PD-1 antibody _VH is shown in SEQ ID NO: 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78 or 79. The amino acid sequence of the anti-PD- ₁ antibody VL 1 is shown in SEQ ID NO: 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95 or 96. Variable amino acid sequence identification numbers The antibody heavy/light chain regions are summarized in Table 1 below, with some clones containing the same V _H or V _L region. The heavy chain constant region for all clones may be an IgG heavy chain constant region having the amino acid sequence shown, for example, in SEQ ID NO: 97 or 129, and the light chain constant region for all clones may be a kappa chain constant region having the amino acid sequence set forth, for example, in SEQ ID NO: 98 or 130. The Fab antibody may comprise a heavy/light chain variable region, a heavy chain CH1 region (such as the region set forth in SEQ ID NO: 99), and light chain constant region.

[0060] The heavy chain CDR variable regions and the light chain CDR variable regions from Table 1 were defined using the IMGT numbering system and the Kabat numbering system, respectively. However, as is well known in the art, CDR regions can also be determined using other systems, such as the Chotia numbering system and the CCG system/method, based on heavy/light chain variable region sequences.

Table 1. ID numbers of amino acid sequences of variable regions of the heavy/light chain Clone/SEQ ID NO VH-CDR1 VH-CDR2 VH-CDR3 VH VL-CDR1 VL-CDR2 VL-CDR3 VL C1E1 1 2 3 67 34 35 36 80 huC1E1-V1 1 2 3 68 34 35 36 81 huC1E1-V2 1 2 3 69 34 35 36 81 huC1E1-V3 1 2 3 68 34 35 36 82 huC1E1-V4 1 2 3 68 34 35 36 83 huC1E1-V5 1 2 3 68 34 35 36 84 huC1E1-V6 1 2 3 68 34 35 36 85 huC1E1-V7 1 2 3 68 34 35 36 86 huC1E1-V10 1 2 3 69 34 35 36 86 D1F2 4 5 6 70 37 38 39 87 C1F5 7 8 9 71 40 41 42 88 D1A1 10 eleven 12 72 43 44 45 89 D1F1 13 14 15 73 46 47 48 90 C1E2 16 17 18 74 49 50 51 91 C1A1 19 20 21 75 52 53 54 92 C1F4 22 23 24 76 55 56 57 93 D2C2 25 26 27 77 58 59 60 94 2G2 28 29 thirty 78 61 62 63 95 C1C5 31 32 33 79 64 65 66 96

[0061] The V _H and V _L sequences (or CDR sequences) of other anti-PD-1 antibodies that bind to human PD-1 can be “matched and combined” with the V _H and V _L sequences (or CDR sequences) of the anti-PD antibody -1 according to the present invention. Preferably, when V _H and V _L chains (or CDRs within such chains) are combined and combined, the V _H sequence from a particular V _H /V _L pair is replaced with a structurally similar V _H sequence. Likewise, the V _L sequence from a particular V _H /V _L pair is preferably replaced with a structurally similar V _L sequence.

[0062] Accordingly, according to one embodiment of the invention, an antibody of the invention or an antigen-binding portion thereof comprises:

(a) a heavy chain variable region containing the amino acid sequence listed above in Table 1; And

(b) a light chain variable region containing the amino acid sequence listed in Table 1 above, or V _L of another anti-PD-1 antibody, wherein said antibody specifically binds to human PD-1.

[0063] According to another embodiment of the invention, an antibody of the invention or an antigen-binding portion thereof comprises:

(a) the CDR1, CDR2 and CDR3 regions of the heavy chain variable region listed above in Table 1; And

(b) the CDR1, CDR2 and CDR3 regions of the light chain variable region listed above in Table 1, or the CDR regions of another anti-PD-1 antibody, where the antibody specifically binds to human PD-1.

[0064] In another embodiment, the antibody or antigen-binding portion thereof comprises the heavy chain variable region CDR2 of an anti-PD-1 antibody combined with CDR regions of other antibodies that bind to human PD-1, such as CDR1 and/or CDR3 from the heavy chain variable region and/or CDR1, CDR2 and/or CDR3 from the light chain variable region of another anti-PD-1 antibody.

[0065] In addition, it is well known in the art that the CDR3 domain, independently of the CDR1 and/or CDR2 domain(s), can separately determine the binding specificity of an antibody to a cognate antigen and that it is possible to create multiple antibodies based on a common CDR3 sequence having the same binding specificity. See, for example, Klimka et al., British J. of Cancer 83(2):252-260 (2000); Beiboer et al., J. Mol. Biol. 296:833-849 (2000); Rader et al., Proc. Natl. Acad. Sci. USA 95:8910-8915 (1998); Barbas et al., J. Am. Chem. Soc. 116:2161-2162 (1994); Barbas et al., Proc. Natl. Acad. Sci. USA . 92:2529-2533 (1995); Ditzel et al., J. Immunol. 157:739-749 (1996); Berezov et al., BIAjournal 8: Scientific Review 8 (2001); Igarashi et al., J. Biochem (Tokyo) 117:452-7 (1995); Bourgeois et al., J. Virol 72:807-10 (1998); Levi et al., Proc. Natl. Acad. Sci. USA 90:4374-8 (1993); Polymenis and Stoller, J. Immunol. 152:5218-5329 (1994) and Xu and Davis, Immunity 13:37-45 (2000). See also, US Patent No. 6,951,646; 6,914,128; 6,090,382; 6,818,216; 6,156,313; 6,827,925; 5 833 943; 5,762,905 and 5,760,185. Each of these references is incorporated herein by reference in its entirety.

[0066] Accordingly, according to another embodiment of the invention, antibodies of the invention comprise CDR2 of an anti-PD-1 antibody heavy chain variable region and at least CDR3 of an anti-PD-1 antibody heavy and/or light chain variable region or CDR3 of an anti-PD-1 antibody heavy and/or variable region or the light chain of another anti-PD-1 antibody, wherein said antibody is capable of specifically binding to human PD-1. These antibodies preferably (a) compete for binding to PD-1; (b) maintain functional characteristics; (c) bind to the same epitope and/or (d) have similar binding affinity compared to the anti-PD-1 antibody of the present invention. In another embodiment, the antibodies may further comprise a light chain variable region CDR2 of an anti-PD-1 antibody or a light chain variable region CDR2 of another anti-PD-1 antibody, wherein said antibody is capable of specifically binding to human PD-1. In another embodiment, the antibodies of the invention may comprise a heavy and/or light chain variable region CDR1 of an anti-PD-1 antibody or a heavy and/or light chain variable region CDR1 of another anti-PD-1 antibody, wherein said antibody is capable of specifically binding to PD -1 person.

[0067] Conservative modifications

[0068] In another embodiment, the antibody of the invention comprises heavy and/or light chain variable region sequences CDR1, CDR2 and CDR3 that differ from the anti-PD-1 antibody sequences of the invention by one or more conservative modifications. It should be understood in the art that certain conservative sequence modifications are possible that do not eliminate antigen binding ability. See, for example, Brummell et al., (1993) Biochem 32:1180-8; de Wildt et al., (1997) Prot. Eng. 10:835-41; Komissarov et al., (1997) J. Biol. Chem. 272:26864-26870; Hall et al., (1992) J. Immunol. 149:1605-12; Kelley and O'Connell (1993) Biochem , 32:6862-35; Adib-Conquy et al., (1998) Int. Immunol, 1 0:341-6 and Beers et al., (2000) Clin. Can. Res. 6:2835-43.

[0069] Accordingly, according to one embodiment of the invention, the antibody comprises a heavy chain variable region comprising the sequences CDR1, CDR2 and CDR3, and/or a light chain variable region comprising the sequences CDR1, CDR2 and CDR3, wherein:

(a) the CDR1 heavy chain variable region sequence contains the sequence listed in Table 1 above and/or conservative modifications thereof; and/or

(b) the CDR2 heavy chain variable region sequence contains the sequence listed in Table 1 above and/or conservative modifications thereof; and/or

(c) the CDR3 heavy chain variable region sequence contains the sequence listed in Table 1 above and conservative modifications thereof; and/or

(d) the light chain variable region sequences CDR1 and/or CDR2 and/or CDR3 comprise the sequence(s) listed in Table 1 above; and/or its conservative modifications; And

(e) the antibody specifically binds to human PD-1.

[0070] The antibody of the present invention has one or more of the following functional properties described above, such as high binding affinity to human PD-1 and the ability to cause antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) against PD-1-expressing cells.

[0071] In various embodiments, the antibody may be, for example, a murine, human, humanized, or hybrid antibody.

[0072] As used herein, the term “conservative sequence modifications” is intended to refer to amino acid modifications that do not significantly affect or alter the binding characteristics of an antibody containing the specified amino acid sequence. Such conservative modifications include amino acid substitutions, additions and deletions. Modifications can be introduced into the antibody of the invention using standard methods known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are substitutions in which an amino acid residue is replaced by an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been identified in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), amino acids with uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), amino acids with non-polar side chains (e.g. alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), amino acids with beta-branched side chains (e.g. threonine, valine, isoleucine) and amino acids with aromatic side chains (eg, tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues within the CDR regions of an antibody of the invention can be replaced with other amino acid residues from the same side chain family, and the retention of function of the altered antibody (i.e., the functions set forth above) can be examined using functional assays described in this application.

[0073] Engineered and modified antibodies

[0074] Antibodies of the invention can be produced by using an antibody containing one or more of the V _H /V _L sequences of the anti-PD-1 antibody of the present invention as starting material for constructing the modified antibody. An antibody can be constructed by modifying one or more residues within one or both variable regions (i.e., V _H and/or V _L ), for example, within one or more CDR regions and/or within one or more framework plots. Additionally or alternatively, an antibody can be constructed by modifying residues within the constant region(s), for example, to change the effector function(s) of the antibody.

[0075] In certain embodiments, CDR grafting can be used to construct antibody variable regions. Antibodies interact with target antigens primarily through amino acid residues that are located in the six complementarity determining regions (CDRs) of the heavy and light chains. For this reason, amino acid sequences within CDR regions vary more widely between individual antibodies than sequences outside the CDRs. Because CDR sequences are responsible for most antibody-antigen interactions, it is possible to express recombinant antibodies that mimic the properties of specific natural antibodies by constructing expression vectors that contain CDR sequences from a specific natural antibody grafted onto scaffold sequences from another antibody with different properties ( see, for example, Riechmann et al., (1998) Nature 332:323-327; Jones et al., (1986) Nature 321:522-525; Queen et al., (1989) Proc. Natl. Acad . See (see also US Patent Applications 86:10029-10033; US Patent Nos. 5,225,539; 5,530,101; 5,585,089; 5,693,762 and 6,180,370).

[0076] Accordingly, another embodiment of the invention relates to an isolated monoclonal antibody or antigen-binding portion thereof comprising a heavy chain variable region that contains CDR1, CDR2 and CDR3 sequences containing the sequences of the present invention as described above, and/or a variable a light chain region containing the sequences CDR1, CDR2 and CDR3, which contain the sequences according to the present invention, as described above. While these antibodies contain the V _H and V _L CDR sequences of the monoclonal antibody of the present invention, they may contain different framework sequences.

[0077] Such framework sequences can be obtained from publicly available DNA databases or published references that include germline antibody gene sequences. For example, germline DNA sequences for the human heavy and light chain variable region genes can be found in the human germline sequence database "VBase" (available on the Internet at www.mrc-cpe.cam.ac.uk/vbase), as well as in Kabat et al., (1991), cited above; Tomlinson et al., (1992) J. Mol. Biol. 227:776-798; and Cox et al., (1994) Eur. J. Immunol. 24:827-836; the contents of each of which are specifically incorporated herein by reference. As another example, germline DNA sequences for the human heavy and light chain variable region genes can be found in the Genbank database. For example, the following germline heavy chain sequences found in the mouse HCo7 HuMAb are available under the accompanying Genbank accession numbers: 1-69 (NG--0010109, NT--024637 & BC070333), 3-33 (NG--0010109 & NT--024637) and 3-7 (NG--0010109 & NT--024637). As another example, the following germline heavy chain sequences found in the mouse HCo12 HuMAb are available under the accompanying Genbank accession numbers: 1-69 (NG--0010109, NT--024637 & BC070333), 5-51 (NG --0010109 & NT--024637), 4-34 (NG--0010109 & NT--024637), 3-30.3 (CAJ556644) & 3-23 (AJ406678).

[0078] The antibody protein sequences are compared to a database of compiled protein sequences using one of the sequence similarity search methods called Gapped BLAST (Altschul et al., (1997), supra), which is well known to one skilled in the art.

[0079] Preferred framework sequences for use in the antibodies of the invention are sequences that are structurally similar to the framework sequences used in the antibodies of the invention. The CDR1, CDR2 and CDR3 V _H sequences can be grafted into framework regions that have sequence identical to the sequence found in the germline immunoglobulin gene from which the framework sequence is derived, or the CDR sequences can be grafted into framework regions that contain one or more mutations compared to germline sequences. For example, it has been found to be advantageous in certain examples to introduce mutations to residues within framework regions to maintain or enhance the ability of an antibody to bind antigen (see, for example, US Pat. Nos. 5,530,101; 5,585,089; 5,693,762 and 6,180,370 ).

[0080] Another type of variable region modification is the mutation of amino acid residues within the CDR1, CDR2 and/or CDR3 regions of V _H and/or V _L to thereby improve one or more binding properties (eg, affinity) of the antibody of interest. To introduce mutation(s), site-directed mutagenesis or PCR-mediated mutagenesis can be performed, and the effect on antibody binding or other functional property of interest can be assessed using in vitro or in vivo assays, as is known in the art. Preferably, conservative modifications are introduced (as known in the art). Mutations may be amino acid substitutions, additions or deletions, but are preferably substitutions. Moreover, typically no more than one, two, three, four or five residues within the CDR region are changed.

[0081] Accordingly, according to another embodiment, the present invention provides isolated anti-PD-1 monoclonal antibodies or antigen-binding portions thereof comprising a heavy chain variable region comprising: (a) a CDR1 V _H region containing a sequence of the present invention or an amino acid a sequence containing one, two, three, four or five amino acid substitutions, deletions or additions; (b) a CDR2 V _H region containing a sequence according to the present invention or an amino acid sequence containing one, two, three, four or five amino acid substitutions, deletions or additions; (c) a CDR3 V _H region containing a sequence according to the present invention or an amino acid sequence containing one, two, three, four or five amino acid substitutions, deletions or additions; (d) a CDR1 V _L region containing a sequence according to the present invention or an amino acid sequence containing one, two, three, four or five amino acid substitutions, deletions or additions; (e) a CDR2 V _L region containing a sequence according to the present invention or an amino acid sequence containing one, two, three, four or five amino acid substitutions, deletions or additions; and (f) a CDR3 V _L region containing a sequence according to the present invention or an amino acid sequence containing one, two, three, four or five amino acid substitutions, deletions or additions.

[0082] Engineered antibodies according to the invention include antibodies in which modifications have been made to framework residues within the V _H and/or V _L , for example, to improve the properties of the specified antibody. Typically, such modifications of the framework residues are carried out to reduce the immunogenicity of the antibody. For example, one approach is to “back-mutate” one or more framework residues to the corresponding germline sequence. More specifically, an antibody that has undergone a somatic mutation may contain framework residues that differ from the germline sequence from which the antibody originated. Such residues can be identified by comparing the framework sequences of the antibody with the germline sequences from which the antibody originated.

[0083] Another type of framework modification involves mutating one or more residues within the framework region or even within one or more CDR regions to remove T cell epitopes, thereby reducing the potential immunogenicity of the antibody. This approach is also called "deimmunization" and is described in more detail in US Patent Publication No. 20030153043.

[0084] As a complement to or alternative to modifications made within the framework or CDR regions, antibodies of the invention can be engineered to include modifications within the Fc region, typically to alter one or more functional properties of the antibody. such as serum half-life, complement fixation, Fc receptor binding and/or antigen-dependent cellular cytotoxicity. Moreover, the antibody of the invention may be chemically modified (eg, one or more chemical moieties may be attached to the antibody) or modified to alter its degree of glycosylation, also to alter one or more functional properties of the antibody.

[0085] According to one embodiment of the invention, the C _H1 hinge region is modified such that the number of cysteine residues in the hinge region is changed, for example, increased or decreased. This approach is further described in US Pat. No. 5,677,425. The number of cysteine residues in the C _H1 hinge region is varied, for example, to facilitate the assembly of light and heavy chains or to increase or decrease the stability of the antibody.

[0086] In another embodiment, mutations are introduced into the Fc hinge region of an antibody to reduce the biological half-life of the antibody. More specifically, one or more amino acid mutations are introduced into the C _H2 -C _H3 boundary region of the Fc hinge fragment such that binding of the antibody to staphylococcal protein A (SpA) is impaired relative to SpA binding of the native Fc hinge domain. This approach is described in more detail in US Patent No. 6,165,745.

[0087] According to another embodiment of the invention, the degree of glycosylation of the antibody is modified. For example, a glycosylated antibody may be produced (ie, if the antibody is not glycosylated). The degree of glycosylation can be changed, for example, to increase the affinity of the antibody for an antigen. Such carbohydrate modifications can be accomplished, for example, by changing one or more glycosylation sites within the antibody sequence. For example, one or more amino acid substitutions may be made that result in the elimination of one or more glycosylation sites in the variable region framework, thereby eliminating glycosylation at that site. Such aglycosylation may result in increased affinity of the antibody for the antigen. See, for example, US Patent Nos. 5,714,350 and 6,350,861.

[0088] Additionally or alternatively, an antibody with an altered glycosylation pattern can be produced, such as a hypofucosylated antibody containing a reduced amount of fucosyl residues, or an antibody having an increased content of structures with a GlcNac residue at the branch point. These altered glycosylation patterns have been demonstrated to enhance the antibody's ability to exhibit antibody-dependent cellular cytotoxicity (ADCC). Such carbohydrate modifications can be accomplished by, for example, expressing the antibody in a host cell with an altered glycosylation system. Cells with an altered glycosylation system have been described in the art and can be used as host cells to express a recombinant antibody of the invention therein, thereby producing an altered glycosylation antibody. For example, the Ms704, Ms705 and Ms709 cell lines do not contain the fucosyltransferase gene, FUT8 (α(1,6)-fucosyltransferase), and thus the antibodies expressed in the Ms704, Ms705 and Ms709 cell lines do not contain fucose on olevoids. Ms704, Ms705 and Ms709 FUT8-/- cell lines were generated by targeting the FUT8 gene in CHO/DG44 cells using two replacement vectors (see US Patent Publication No. 20040110704 and Yamane-Ohnuki et al., (2004) Biotechnol Bioeng 87:614-22). As another example, European patent EP 1 176 195 describes a cell line with a functionally disrupted FUT8 gene, which encodes a fucosyltransferase, such that the antibodies expressed in such a cell line are hypofucosylated due to the reduction or removal of α-1 bound, 6-linked enzyme. European patent EP 1 176 195 also describes cell lines that have little or no enzymatic activity for the addition of fucose to N-acetylglucosamine that binds to the Fc region of the antibody, for example the rat myeloma cell line YB2/0 (ATCC CRL 1662). PCT International Application Publication WO 03/035835 describes a variant of the CHO cell line - Lec13 cells - with a reduced ability to attach fucose to Asn(297)-linked carbohydrates, which also leads to hypofucosylation of antibodies expressed in the specified host cell (see also Shields et al., (2002) J Biol Chem 277:26733-26740). Antibodies with a modified glycosylation profile can also be produced in chicken eggs, as described in PCT International Application Publication WO 06/089231. Alternatively, antibodies with a modified glycosylation profile can be produced in plant cells such as Lemna. Methods for producing antibodies in a plant system are described in the US patent application corresponding to Alston & Bird LLP, patent number 040989/314911, filed August 11, 2006. PCT International Application Publication WO 99/54342 describes cell lines engineered to express glycoprotein-modifying glycosyltransferases (e.g., β(1,4)-N-acetylglucosaminyltransferase III (GnTIII)) such that antibodies expressed in said engineered cell lines contain an increased number of structures with a GlcNac residue at the branch point, which leads to increased ADCC activity of antibodies (see also Umana et al., (1999) Nat. Biotech. 17:176-180). Alternatively, the fucose residues of the antibody can be cleaved using the enzyme fucosidase; for example, fucosidase α-L-fucosidase removes fucosyl residues from an antibody (Tarentino et al., (1975) Biochem. 14:5516-23).

[0089] Another modification of the antibody described herein that is contemplated by the present invention is pegylation. The antibody may be pegylated, for example, to increase the biological half-life (eg, serum half-life) of the antibody. For PEGylation, an antibody or fragment thereof is typically reacted with a polyethylene glycol (PEG), such as a reactive ester or aldehyde derivative of PEG, under conditions in which one or more PEG groups are attached to the antibody or antibody fragment. Preferably, the pegylation is carried out through an acylation reaction or an alkylation reaction with a reactive PEG molecule (or similar reactive water-soluble polymer). As used herein, the term “polyethylene glycol” is intended to include any of the forms of PEG that have been used to derivatize other proteins, such as mono(C ₁ -C ₁₀ )alkoxy or aryloxy polyethylene glycol or polyethylene glycol maleimide. In certain embodiments, the antibody to be pegylated is an aglycosylated antibody. Methods for pegylation of proteins are known in the art and can be used for antibodies according to the invention. See, for example, European patents EP 0 154 316 and EP 0 401 384.

[0090] Physical properties of the antibody

[0091] Antibodies of the invention can be characterized by various physical properties to identify and/or distinguish between different classes.

[0092] For example, antibodies may contain one or more glycosylation sites in a light or heavy chain variable region. Such glycosylation sites may result in increased immunogenicity of the antibody or a change in its pK due to altered antigen binding (Marshall et al., (1972) Annu Rev Biochem 41:673-702; Gala and Morrison (2004) J. Immunol 172:5489-94; Wallick et al., (1988) J. Exp Med 168:1099-109; Spiro (2002) Glycobiology 12:43R-56R; Parekh et al., (1985) Nature 316:452-7; Mimura et al., ( 2000) Mol Immunol 37:697-706). Glycosylation is known to occur in motifs containing the NXS/T sequence. In some examples, an anti-PD-1 antibody without variable region glycosylation is preferred, which can be achieved either by selecting antibodies that do not contain a variable region glycosylation motif or by mutating residues in the region of glycosylation.

[0093] In a preferred embodiment, the antibodies do not contain asparagine isomerism sites. Deamidation of asparagine can occur at the N-G or D-G sequences and result in the formation of an isoaspartic acid residue, which introduces a bond into the polypeptide chain and reduces its stability (isoaspartic acid effect).

[0094] Each antibody has a unique isoelectric point (pI), which generally falls within the pH range between 6 and 9.5. The pI value for an IgG1 antibody is typically within the pH range of 7-9.5, and the pI value for an IgG4 antibody is typically within the pH range of 6-8. It has been suggested that antibodies with a pI value outside the normal range may exhibit some degree of unfolding and instability in vivo . Thus, an anti-PD-1 antibody having a pI value within the normal range is preferred, which can be achieved by selecting antibodies having a pI within the normal range or by mutating charged surface residues.

[0095] Nucleic acid molecules encoding antibodies of the invention

[0096] In another aspect, the invention provides nucleic acid molecules that encode the variable regions or CDR regions of the heavy and/or light chains of antibodies according to the invention. The nucleic acids may be present in whole cells, in a cell lysate, or in partially purified or substantially pure form. A nucleic acid is “isolated” or “reduced to a substantially pure state” when it is purified from other cellular components or other impurities, such as other cellular nucleic acids or proteins, using standard methods. The nucleic acid according to the invention may be, for example, DNA or RNA and may or may not contain intronic sequences. According to a preferred embodiment of the invention, the nucleic acid is a cDNA molecule.

[0097] Nucleic acids according to the invention can be obtained using standard molecular biology techniques. In the case of hybridoma-expressed antibodies (e.g., hybridoma-derived transgenic mice containing human immunoglobulin genes, as further described below), cDNA molecules encoding the light and heavy chains of said hybridoma-derived antibody can be produced using standard PCR amplification or cDNA cloning methods. In the case of antibodies obtained from an immunoglobulin gene library (eg, using phage display methods), the nucleic acid encoding such antibodies can be obtained from the gene library.

[0098] Preferred nucleic acid molecules of the invention include nucleic acids encoding anti-PD-1 monoclonal antibody V _H and V _L sequences or CDR regions. Once DNA fragments encoding the V _H and V _L segments have been obtained, the fragments can be further manipulated using standard recombinant DNA techniques, for example, to convert variable region genes into full-length antibody chain genes, Fab fragment genes, or scFv genes. In these procedures, a V _L - or V _{H -} coding DNA fragment is operably linked to another DNA fragment encoding another protein, such as a constant region or mobile linker of an antibody. The term "operably linked" when used in this context is intended to mean that two DNA fragments are joined in such a way that the amino acid sequences encoded by the two DNA fragments remain in the same reading frame.

[0099] Isolated DNA encoding the V _H region can be converted into a full-length heavy chain gene by operably linking the V _H encoding DNA to another DNA molecule encoding the heavy chain constant regions ( _CH1 , _CH2 and _CH3 ). The human heavy chain constant region gene sequences are known in the art, and DNA fragments comprising these regions can be obtained by standard PCR amplification. The heavy chain constant region may be an IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM, or IgD constant region, but is most preferably an IgG1 or IgG4 constant region. For a heavy chain Fab gene, the _VH -encoding DNA may be operably linked to another DNA molecule encoding only the heavy chain _CH1 constant region.

[00100] Isolated DNA encoding the V _L region can be converted into a full-length light chain gene (as well as a light chain Fab gene) by operably linking the V _L encoding DNA to another DNA molecule encoding the light chain constant region C _L . Human light chain constant region gene sequences are known in the art, and DNA fragments comprising these regions can be obtained by standard PCR amplification. In preferred embodiments, the light chain constant region may be a kappa or lambda chain constant region.

[00101] To create the scFv gene, DNA fragments encoding V _H and V _L are operably linked to another fragment encoding a flexible linker, for example, encoding the amino acid sequence (Gly4-Ser)3, such that the V _H and V _L sequences can expressed as a continuous single-chain protein, the V _L and V _H regions of which are connected by a mobile linker (see, for example, Bird et al., (1988) Science 242:423-426; Huston et al., (1988) Proc. Natl. Acad Sci. USA 85:5879-5883; McCafferty et al., (1990) Nature 348:552-554).

[00102] Preparation of a monoclonal antibody according to the invention

[00103] Monoclonal antibodies (mAbs) according to the present invention can be produced using a well-known somatic cell hybridization method (hybridoma) according to Kohler and Milstein (1975) Nature 256: 495. Other embodiments for the production of monoclonal antibodies include viral or oncogenic transformation B-lymphocytes and phage display methods. Hybrid or humanized antibodies are also well known in the art. See, for example, US Pat. No. 4,816,567; 5 225 539; 5 530 101; 5 585 089; 5,693,762 and 6,180,370, the contents of which are specifically incorporated herein by reference in their entirety.

[00104] Generation of transfectomes producing monoclonal antibodies according to the invention

[00105] Antibodies of the invention can also be produced in a transfectome host cell using, for example, a combination of recombinant DNA and gene transfection techniques, as is well known in the art (see, for example, Morrison, S. (1985) Science 229: 1202). In one embodiment, DNA encoding portions or full-length light and heavy chains obtained using standard molecular biology techniques is inserted into one or more expression vectors such that the genes are operably linked to transcriptional or translational regulatory sequences. As used herein, the term “operably linked” is intended to mean that an antibody gene is ligated into a vector such that transcriptional and translational control sequences within the vector perform their intended function of regulating transcription and translation of the antibody gene.

[00106] The term “regulatory sequence” is intended to include promoters, enhancers, and other expression control elements (eg, polyadenylation signals) that control transcription and translation of antibody genes. Such regulatory sequences are described, for example, in Goeddel, Gene Expression Technology. Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). Preferred regulatory sequences for expression in mammalian host cells include viral elements that direct high level protein expression in said mammalian cells, such as promoters and/or enhancers derived from cytomegalovirus (CMV), simian virus 40 (SV40), adenovirus, e.g. , adenovirus major late promoter (AdMLP) and polyoma. Alternatively, non-viral regulatory sequences such as the ubiquitin promoter or the β-globin promoter can be used. In addition, there are regulatory elements consisting of sequences from various sources, such as the SRα promoter system, which contains sequences from the SV40 early scan and the long terminal repeat of human T-cell leukemia virus type 1 (Takebe et al., (1988) Mol. Cell Biol 8:466–472). The expression vector and expression control sequences are selected so that they are compatible with the expression system of the host cell used.

[00107] The antibody light chain gene and the antibody heavy chain gene can be inserted into the same or separate expression vectors. In preferred embodiments, the variable regions are used to create full-length antibody genes of any isotype by inserting them into expression vectors already encoding the heavy chain and light chain constant regions of the desired isotype, such that the V _H segment is operably linked to the C _H segment (segments) within the vector and the V _L segment was functionally connected to the C _L segment within the vector. Additionally or alternatively, the recombinant expression vector may encode a signal peptide that promotes secretion of the antibody chain from the host cell. The antibody chain gene can be cloned into a vector such that the signal peptide is linked in frame to the amino terminus of the antibody chain gene. The signal peptide may be an immunoglobulin signal peptide or a heterologous signal peptide (ie, a signal peptide from a non-immunoglobulin protein).

[00108] In addition to antibody chain genes and regulatory sequences, recombinant expression vectors of the invention may contain additional sequences, such as sequences that regulate replication of the vector in host cells (eg, origins of replication) and selectable marker genes. The selectable marker gene facilitates the selection of host cells into which the vector has been inserted (see, for example, US Pat. Nos. 4,399,216; 4,634,665 and 5,179,017). For example, the selectable marker gene typically provides the host cell into which the vector has been introduced with resistance to drugs such as G418, hygromycin, or methotrexate. Preferred selectable marker genes include the dihydrofolate reductase (DHFR) gene (for use in dhfr host cells with metatrexate selection/amplification) and the neo-gene (for G418 selection).

[00109] To express light and heavy chains, the expression vector(s) encoding said heavy and light chains are transfected into a host cell using standard methods. The various forms of the term "transfection" are intended to include the wide variety of methods commonly used to introduce exogenous DNA into a prokaryotic or eukaryotic host cell, for example, electroporation, calcium phosphate precipitation, DEAE-dextran transfection, and the like. Although it is theoretically possible to express the antibodies of the invention in both prokaryotic and eukaryotic host cells, it is most preferred to express the antibodies in eukaryotic cells, most preferably mammalian host cells, since such eukaryotic cells, particularly mammalian cells, are more likely to assembly and secretion of correctly folded and immunologically active antibody is more likely to occur compared to prokaryotic cells.

[00110] Preferred mammalian host cells for expressing recombinant antibodies of the invention include Chinese hamster ovary (CHO) cells (including dhfr-CHO cells described in Urlaub and Chasin, (1980) Proc. Natl. Acad. Sci. USA 77:4216 -4220 used with a DHFR selectable marker, for example as described in RJ Kaufman and PA Sharp (1982) J Mol Biol 159:601-621), NSO myeloma cells, COS cells and SP2 cells. In particular, for use with NSO myeloma cells, another preferred expression system is the GS gene expression system described in WO 87/04462, WO 89/01036 and EP 338 841. When recombinant expression vectors encoding antibody genes are introduced into a mammalian host cell, antibody production is achieved by culturing said host cells for a period of time sufficient to permit expression of the antibody in said host cells, or, more preferably, secretion of the antibody into a culture medium in which said cell is grown -the owner. Antibodies can be recovered from the culture medium using standard protein purification methods.

[00111] Immunoconjugates

[00112] Antibodies of the invention can be conjugated to a therapeutic agent to form an immunoconjugate, such as an antibody-drug conjugate (ADC). Suitable therapeutic agents include cytotoxins, alkylating agents, DNA minor groove binding agents, DNA intercalators, DNA crosslinkers, histone deacetylase inhibitors, nuclear export inhibitors, proteasome inhibitors, topoisomerase I or II inhibitors, heat shock protein inhibitors, tyrosine kinase inhibitors, antibiotics, and antimitotic agents. In CALS, the antibody and therapeutic agent are preferably conjugated via a cleavable linker, such as a peptidyl, diulfide, or hydrazone linker. More preferably, the linker is a peptidyl linker such as Val-Cit, Ala-Val, Val-Ala-Val, Lys-Lys, Pro-Val-Gly-Val-Val, Ala-Asn-Val, Val-Leu-Lys , Ala-Ala-Asn, Cit-Cit, Val-Lys, Lys, Cit, Ser or Glu. CALS can be prepared as described in US Pat. No. 7,087,600; 6,989,452 and 7,129,261; publication of an international application according to PCT WO 02/096910; publication of international application WO 07/038 658; publication of international application WO 07/051 081; publication of international application WO 07/059 404; publication of international application WO 08/083 312 and publication of international application WO 08/103 693; US Patent Publications 20060024317; 20060004081 and 20060247295; the description of which is incorporated herein by reference.

[00113] Bispecific molecules

[00114] In another aspect, the present invention provides bispecific molecules comprising one or more antibodies of the invention linked to at least one other functional molecule, e.g., another peptide or protein (e.g., another antibody or receptor ligand) to create a bispecific molecule , which binds to at least two different binding sites or target molecules. Thus, as used herein, the term “bispecific molecule” includes molecules that have three or more specificities.

[00115] According to an embodiment of the invention, the bispecific molecule has a third specificity in addition to the Fc binding specificity and the PD-1 binding specificity. Said third specificity may be an enhancement factor (EF) specificity, for example a molecule that binds to a surface protein involved in cytotoxic activity and thereby enhances the immune response towards the target cell. For example, a molecule targeting an enhancing factor may bind to a cytotoxic T cell (e.g., via CD2, CD3, CD8, CD28, CD4, PD-1, or ICAM-1) or other immune cell, resulting in an enhanced immune response against the cell -targets.

[00116] Bispecific molecules can have many different shapes and sizes. A bispecific molecule at one end of the size range retains the traditional shape of an antibody, except that instead of two binding groups having identical specificity, it contains two binding groups with different specificities. Bispecific molecules at the opposite end of the size range consist of two single-chain antibody fragments (scFv's) linked via a peptide chain, the so-called Bs(scFv)2 construct. Bispecific molecules of intermediate size include two different F(ab) fragments linked via a peptidyl linker. Bispecific molecules of these and other forms can be obtained using genetic engineering, somatic hybridization or chemical methods. See, for example, Kufer et al. cited above; Cao and Suresh, Bioconjugate Chemistry, 9 (6), 635-644 (1998); and van Spriel et al., Immunology Today , 21 (8), 391-397 (2000), and references cited therein.

[00117] Oncolytic virus encoding and containing antibody

[00118] An oncolytic virus preferentially infects and kills cancer cells. The antibodies of the present invention can be used in conjunction with oncolytic viruses. Alternatively, oncolytic viruses encoding the antibodies of the present invention can be introduced into the human body.

[00119] Pharmaceutical compositions

[00120] According to another aspect, the present invention provides a pharmaceutical composition containing one or more antibodies according to the present invention, presented together with a pharmaceutically acceptable carrier. The antibodies may be dosed separately if the composition contains more than one antibody. The composition may optionally contain one or more additional pharmaceutically active ingredients, such as another antibody or drug, such as an anticancer drug.

[00121] The pharmaceutical composition may contain any number of excipients. Excipients that may be used include carriers, surfactants, thickening or emulsifying agents, solid binders, dispersion or suspension additives, solubilizers, coloring agents, flavoring agents, coatings, disintegrants, lubricants, sweeteners, preservatives, isotonic agents and their combinations. The selection and use of appropriate excipients is discussed in Gennaro, ed., Remington: The Science and Practice of Pharmacy , 20th Ed. (Lippincott Williams & Wilkins 2003), the description of which is incorporated herein by reference.

[00122] Preferably, the pharmaceutical composition is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (eg, by injection or infusion). Depending on the route of administration, the active ingredient may be coated with a material to protect it from acids and other natural conditions that may cause it to inactivate. The phrase "parenteral administration" as used herein refers to routes of administration other than intestinal and topical administration, typically by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intraarticular, intraorbital, intracardiac, intracutaneous, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion. Alternatively, the antibody of the invention can be administered by a non-parenteral route, such as topical, epidermal or mucosal administration, for example, intranasally, orally, vaginally, rectally, sublingually or topically.

[00123] Pharmaceutical compositions can be presented in the form of sterile aqueous solutions or dispersions. They may also be presented in the form of a microemulsion, liposome, or other ordered structure suitable for administering a high concentration of drug.

[00124] The amount of active ingredient that can be combined with the carrier material to produce a unit dosage form will vary depending on the subject being treated and the particular route of administration and is generally that amount of the composition that produces a therapeutic effect. In general, of one hundred percent, the amount ranges from about 0.01% to about ninety-nine percent active ingredient, preferably from about 0.1% to about 70%, most preferably from about 1% to about 30% active ingredient in combination with a pharmaceutically acceptable carrier.

[00125] Dosage regimens are tailored to achieve the optimal desired response (eg, therapeutic response). For example, a single bolus dose may be administered, multiple divided doses may be administered over a period of time, or the dose may be proportionally decreased or increased according to the needs of the therapeutic situation. It is particularly preferred to provide the composition for parenteral administration in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units adapted as unit dosages for the subjects to be treated; each unit contains a predetermined amount of active ingredient calculated to produce the desired therapeutic effect, together with the required pharmaceutical carrier. Alternatively, the antibody can be administered in a sustained release dosage form, which requires less frequent dosing.

[00126] For administration of the antibody, the dose may range from about 0.0001 to 100 mg/kg, typically from 0.01 to 5 mg/kg of host body weight. For example, doses may be 0.3 mg/kg body weight, 1 mg/kg body weight, 3 mg/kg body weight, 5 mg/kg body weight, or 10 mg/kg body weight, or within the range of 1-10 mg/kg body weight. kg. An example treatment regimen includes administration once a week, once every two weeks, once every three weeks, once every four weeks, once a month, once every 3 months, or once every three to 6 months. Preferred dosing regimens for the anti-PD-1 antibody of the invention include 1 mg/kg body weight or 3 mg/kg body weight via intravenous administration, wherein the antibody is administered using one of the following dosing protocols: (i) every four weeks for six doses , then every three months; (ii) every three weeks; (iii) a single dose of 3 mg/kg body weight followed by a dose of 1 mg/kg body weight every three weeks. In some methods, the dose is adjusted to achieve a plasma antibody concentration of about 1-1000 μg/ml, and in some methods about 25-300 μg/ml.

[00127] A "therapeutically effective dose" of an anti-PD-1 antibody of the invention preferably results in a reduction in the severity of disease symptoms, an increase in the frequency and duration of disease-free periods of time, or the prevention of impairment or failure caused by disease involvement. For example, for treating subjects having a tumor, a "therapeutically effective dose" preferably inhibits tumor growth by at least about 20%, more preferably by at least about 40%, more preferably by at least about 60%, and further more preferably, at least about 80% relative to untreated subjects. A therapeutically effective amount of a therapeutic antibody may reduce tumor size or otherwise alleviate symptoms in a subject, which is typically a human or may be another mammal.

[00128] The pharmaceutical composition may be a controlled release dosage form, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid can be used. See, for example, Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.

[00129] Therapeutic compositions can be administered using medical devices, such as (1) needleless subcutaneous injection devices (see, for example, US Pat. Nos. 5,399,163; 5,383,851; 5,312,335; 5,064,413; 4,941,880 ; 4,790,824; and 4,596,556); (2) microinfusion pumps (US Patent No. 4,487,603); (3) transdermal devices (US Patent No. 4,486,194); (4) infusion devices (US Patent Nos. 4,447,233 and 4,447,224) and (5) osmotic devices (U.S. Patent Nos. 4,439,196 and 4,475,196); the description of which is incorporated herein by reference.

[00130] In certain embodiments, the monoclonal antibodies of the invention may be presented in a form to provide appropriate in vivo distribution. For example, to ensure passage of a therapeutic antibody of the invention across the blood-brain barrier, the antibody may be provided in the form of liposomes, which may further contain targeting moieties to enhance selective transport to specific cells or organs. See, for example, US Pat. No. 4,522,811; 5,374,548; 5 416 016; and 5,399,331; VV Ranade (1989) J Clin Pharmacol 29:685; Umezawa et al., (1988) Biochem. Biophys. Res. Commun. 153:1038; Bloeman et al., (1995) FEBS Lett .357:140; M. Owais et al., (1995) Antimicrob. Agents Chemother. 39:180; Briscoe et al., (1995) Am. J. Physiol. 1233:134; Schreier et al., (1994) J. Biol. Chem. 269:9090; Keinanen and Laukkanen (1994) FEBS Lett. 346:123; and Killion and Fidler (1994) Immunomethods 4:273.

[00131] Use and methods according to the invention

[00132] The antibodies (compositions, bispecific antibodies, immunoconjugates and other forms, including oncolytic viruses) of the present invention have many in vitro and in vivo applications, including, for example, enhancing immune responses by blocking PD-1. Antibodies can be administered to cells in culture, in vitro or ex vivo , or to human subjects, for example, in vivo , to enhance immunity in various situations. Accordingly, in one aspect, the invention provides a method of modifying an immune response in a subject, comprising administering to said subject an antibody or antigen-binding portion thereof of the invention such that the immune response in said subject is modified. Preferably, the immune response is enhanced, stimulated or positively regulated.

[00133] Preferred subjects include patients who are people in need of an enhanced immune response. The methods are particularly suitable for treating patients who are individuals suffering from a disorder that can be treated by enhancing an immune response (eg, a T-cell mediated immune response). According to a specific embodiment of the invention, the methods are particularly suitable for treating cancer in vivo . To achieve antigen-specific immune enhancement, anti-PD-1 antibodies may be administered together with the antigen of interest, or the antigen may already be present in the subject being treated (eg, a subject having a tumor or virus). When anti-PD-1 antibodies are administered along with other agents, they can be administered in any order or simultaneously.

[00134] Given the ability of the anti-PD-1 antibodies of the invention to inhibit the binding of PD-1 to PD-L1 and/or PD-L2 molecules and stimulate antigen-specific T cell responses, the invention also provides in vitro and in vivo methods for using antibodies to stimulation, enhancement or positive regulation of antigen-specific T-cell responses. For example, the invention provides a method of stimulating an antigen-specific T-cell response, comprising reacting said T-cell with an antibody of the invention such that an antigen-specific T-cell response is stimulated. Any suitable indicator of antigen-specific T-cell response can be used to measure it.

[00135] Non-limiting examples of such suitable indicators include increased T cell proliferation in the presence of an antibody and/or increased cytokine production in the presence of an antibody. According to a preferred embodiment of the invention, the production of interleukin-2 by an antigen-specific T cell is stimulated.

[00136] The invention also provides a method of stimulating an immune response (e.g., an antigen-specific T-cell response) in a subject, comprising administering an antibody of the invention to the subject such that the immune response (e.g., an antigen-specific T-cell response) is stimulated. at the subject. According to a preferred embodiment of the invention, the subject is a tumor-bearing subject, and an antitumor immune response is stimulated. According to another preferred embodiment of the invention, the subject is a subject having the virus, and an immune antiviral response is stimulated.

[00137] In another embodiment, the invention provides methods for inhibiting the growth of tumor cells in a subject, comprising administering to the subject an antibody of the invention such that tumor growth is suppressed in the subject. According to another embodiment, the invention provides methods for treating a viral infection in a subject, comprising administering to the subject an antibody of the invention such that the viral infection in the subject is treated.

[00138] These and other methods of the invention are discussed in more detail below.

[00139] Cancer

[00140] Blocking PD-1 with antibodies can result in an enhanced immune response against cancer cells in a patient. In one aspect, the present invention relates to treating a subject in vivo using an anti-PD-1 antibody such that the growth of cancerous tumors is inhibited. Anti-PD-1 antibody can be used alone to inhibit the growth of cancerous tumors. Alternatively, an anti-PD-1 antibody may be used in conjunction with other immunogenic agents used in cancer treatments, such as oncolytic viruses or other antibodies, as described below.

[00141] Accordingly, in one embodiment, the invention provides a method of inhibiting the growth of tumor cells in a subject, comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antibody or antigen-binding portion thereof. Preferably, the antibody is a murine, hybrid or humanized anti-PD-1 antibody.

[00142] Preferred cancers that can be inhibited using the antibodies of the invention include cancers that are typically sensitive to immunotherapy. Non-limiting examples of preferred cancers for treatment include melanoma (eg, metastatic malignant melanoma), renal cancer (eg, clear cell carcinoma), prostate cancer (eg, hormone-refractory prostate adenocarcinoma), breast cancer, colon cancer, and lung cancer (eg, non-small cell lung cancer), primary or metastatic. Additionally, the invention includes refractory or relapsed malignant tumors, the growth of which can be suppressed using antibodies according to the invention.

[00143] Examples of other cancers that can be treated using the methods of the invention include bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer areas, stomach cancer, testicular cancer, fallopian tube carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, non-Hodgkin's lymphoma, esophageal cancer, small intestinal cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, ureteral cancer, penial cancer, chronic or acute leukemia, including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, childhood solid tumors, lymphocytic lymphomas, bladder cancer, kidney or ureteral cancer , renal pelvis carcinoma, central nervous system (CNS) neoplasm, primary CNS lymphomas, tumor angiogenesis, spinal tumor, brainstem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphomas, environmentally induced cancers, including tumors caused by asbestos and combinations of these cancers. The present invention is also useful for the treatment of metastatic cancers, particularly metastatic cancers expressing PD-1 (Iwai et al. (2005) Int. Immunol . 17:133-144).

[00144] Optionally, anti-PD-1 antibodies can be combined with immunogenic agents such as cancer cells, purified tumor antigens (including recombinant proteins, peptides and carbohydrate molecules) and cells transfected with genes encoding immunostimulatory cytokines (He et al (2004) J Immunol 173:4919-28). Non-limiting examples of tumor vaccines that can be used include melanoma antigen peptides, such as gp100 peptides, MAGE antigens, Trp-2, MART1, and/or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF.

[00145] Blocking PD-1 is likely to be more effective when combined with a vaccination protocol. Many experimental approaches for cancer vaccination have been developed (see Rosenberg, S., 2000, Development of Cancer Vaccines, ASCO Educational Book Spring: 60-62; Logothetis, C., 2000, ASCO Educational Book Spring: 300-302; Khayat, D. 2000, ASCO Educational Book Spring: 414-428; Foon, K. 2000, ASCO Educational Book Spring: 730-738; see also Restifo, N. and Sznol, M., Cancer Vaccines , Ch. 61, pp. 3023-3043 in DeVita et al. (eds.), 1997, Cancer: Principles and Practice of Oncology, fifth edition). In one of these strategies, the vaccine is prepared using autologous or allogeneic tumor cells. These cell-based vaccines have been shown to be most effective when tumor cells are induced to express GM-CSF. GM-CSF has been shown to be a potent activator of antigen presentation for tumor vaccination (Dranoff et al. (1993) Proc. Natl. Acad. Sci. USA 90: 3539-43).

[00146] Research into gene expression patterns and large-scale gene expression in various tumors has led to the identification of so-called tumor-specific antigens (Rosenberg, SA (1999) Immunity 10: 281-7). In many cases, these tumor-specific antigens are differentiation antigens expressed in tumors and in the cells from which the tumor arose, for example, melanocyte antigens gp100, MAGE antigens and Trp-2. More importantly, it can be shown that many of these antigens can be targets of tumor-specific T cells found in the host. Blocking PD-1 can be used in conjunction with a set of recombinant proteins and/or peptides expressed in the tumor to trigger an immune response to these proteins. Normally, the immune system perceives these proteins as self-antigens and is thus tolerant to them. The tumor antigen may include the protein telomerase, which is required for chromosome telomere synthesis and which is expressed in more than 85% of human cancers and only in a limited number of somatic tissues (Kim et al. (1994) Science 266: 2011-2013). These somatic tissues can be protected from immune attack in various ways. Tumor antigen may also be "neo-antigens" expressed in cancer cells as a result of somatic mutations that result in a change in protein sequence or the creation of fusion proteins between two unrelated sequences (ie bcr-abl in the Philadelphia chromosome), or idiotype from B-cell tumors.

[00147] Other tumor vaccines may include proteins from viruses implicated in human cancers, such as human papillomaviruses (HPV), hepatitis viruses (HBV and HCV), and Kaposi's sarcoma-associated herpes virus (KHSV). Another form of tumor-specific antigen that can be used in conjunction with PD-1 blockade is purified heat shock proteins (HSPs) isolated from the tumor tissue itself. These heat shock proteins contain protein fragments from tumor cells and are highly effective in delivery to antigen presenting cells to induce an antitumor immune response (Suot & Srivastava (1995) Science 269:1585-1588; Tamura et al. (1997) Science 278: 117-120).

[00148] Dendritic cells (DCs) are active antigen-presenting cells that can be used to trigger antigen-specific responses. DCs can be generated ex vivo and loaded with various protein and peptide antigens, as well as tumor cell extracts (Nestle et al. (1998) Nature Medicine 4: 328-332). DCs can also be genetically transduced to express these tumor antigens. DCs have also been fused directly to tumor cells for immunization (Kugler et al. (2000) Nature Medicine 6:332-336). As a vaccination method, DC immunization can be effectively combined with PD-1 blockade to promote stronger antitumor responses.

[00149] Blocking PD-1 can also be combined with standard cancer treatments. Blocking PD-1 can be effectively combined with chemotherapy regimens. These examples may allow a reduction in the dose of the chemotherapeutic reagent administered (Mokyr et al. (1998) Cancer Research 58: 5301-5304). An example of such a combination is an anti-PD-1 antibody in combination with decabazine for the treatment of melanoma. Another example of such a combination is an anti-PD-1 antibody in combination with interleukin-2 (IL-2) for the treatment of melanoma. The scientific rationale for the combined use of PD-1 blockade and chemotherapy is that cell death, which is a consequence of the cytotoxic effects of most chemotherapeutic compounds, should result in increased levels of tumor antigen in the antigen presentation pathway. Other combination therapies that, together with PD-1 blockade, may produce a synergistic effect mediated by cell death are radiation, surgery, and endocrine shutdown. Each of these protocols creates a source of tumor antigen in the host. Angiogenesis inhibitors can also be combined with PD-1 blockade. Inhibition of angiogenesis results in tumor cell death, providing tumor antigen to the host antigen presentation pathway.

[00150] PD-1 blocking antibodies can also be used in combination with bispecific antibodies that target Fcα or Fcγ receptor expressing effector cells to tumor cells (see, for example, US Pat. Nos. 5,922,845 and 5,837,243). Bispecific antibodies can be used to target two separate antigens. For example, bispecific antibodies against Fc receptor/antitumor antigen (eg, Her-2/neu) have been used to target macrophages to tumor sites. Such targeting may induce more efficient activation of tumor-specific responses. The T cell component of these responses will be enhanced by blocking PD-1. Alternatively, the antigen can be delivered directly to DCs by using bispecific antibodies that bind to the tumor antigen and a dendritic cell-specific cell surface marker.

[00151] Tumors evade immune surveillance through a wide variety of mechanisms. Many of these mechanisms can be overcome by inactivating proteins that are expressed by tumors and that are immunosuppressive. These proteins include, among others, TGF-β (Kehrl et al. (1986) J. Exp. Med. 163: 1037-1050), IL-10 (Howard &O'Garra (1992) Immunology Today 13: 198-200) and Fas ligand (Hahne et al. (1996) Science 274: 1363-1365). Antibodies to each of these factors can be used in combination with anti-PD-1 antibodies to counteract the effects of the immunosuppressive agent and promote antitumor immune responses in the host.

[00152] Other antibodies that activate the host immune response can be used in combination with anti-PD-1 antibodies. These antibodies include molecules on the surface of dendritic cells (DCs) that activate DC function and antigen presentation. Antibodies against CD40 can effectively compensate for T helper cell activity (Ridge et al. (1998) Nature 393: 474-478) and can be used in conjunction with antibodies against PD-1 (Ito et al. (2000) Immunobiology 201 (5) 527 -40). Activating antibodies against T cell co-stimulatory molecules such as CTLA-4 (eg, US Pat. No. 5,811,097), OX-40 (Weinberg et al. (2000) Immunol 164: 2160-2169), 4-1BB (Melero et al. al (1997) Nature Medicine 3: 682-685 (1997) and ICOS (Hutloff et al (1999) Nature 397: 262-266) may also mediate increased levels of T cell activation.

[00153] There are also several experimental treatment protocols that involve ex vivo activation and expansion of antigen-specific T cells and adoptive transfer of these cells to a recipient to stimulate the antitumor effect of antigen-specific T cells (Greenberg & Riddell (1999) Science 285: 546 -51). These methods can also be used to activate T cell responses to infectious agents such as CMV. Ex vivo activation in the presence of anti-PD-1 antibody can increase the number and activity of adoptively transferred T cells.

[00154] Infectious diseases

[00155] Other methods of the invention are used to treat patients who have been exposed to specific toxins or pathogens. Accordingly, another aspect of the present invention provides a method of treating an infectious disease in a subject, comprising administering to said subject an antibody against PD-1 or an antigen-binding portion thereof such that the subject is treated for said infectious disease. Preferably, the antibody is a hybrid or humanized antibody.

[00156] Similar to the use of antibody-mediated PD-1 blockade in tumors as discussed above, it can be used alone or as an adjuvant in combination with vaccines to stimulate an immune response to pathogens, toxins, and self-antigens. Examples of pathogens for which this therapeutic approach may be particularly useful include pathogens for which no effective vaccine currently exists or pathogens for which standard vaccines are not fully effective. These pathogens include, but are not limited to, HIV, hepatitis virus (A, B and C), influenza virus, herpes virus, Giardia, Malaria, Leishmania, Staphylococcus aureus, Pseudomonas aeruginosa. Blocking PD-1 in particular is useful to combat established infections caused by agents, such as HIV, presenting altered antigens during infection. These new epitopes are recognized as foreign during the administration of an anti-human PD-1 antibody, thereby inducing a strong T cell response that is not suppressed by negative signals mediated by PD-1.

[00157] Some examples of pathogenic viruses that cause infections that are treatable using the methods of the invention include HIV, hepatitis (A, B or C), herpes virus (for example, VZV, HSV-1, HAV-6, HSV-II and CMV, Epstein-Barr virus), adenovirus, influenza virus, flaviviruses, echoviruses, rhinoviruses, Kaksaki virus, coronavirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, human T-lymphocytic virus (HTLV), dengue virus, papillomavirus, molluscan virus, poliovirus, rabies virus, John Cunningham (JC) virus and arboviral encephalitis virus.

[00158] Some examples of pathogenic bacteria causing infections that are treatable using the methods of the invention include chlamydia, rickettsia, mycobacteria, staphylococci, streptococci, pneumococci, meningococci and gonococci, klebsiella, proteus, seratium, pseudomonas, legionella, diphtheria bacteria , salmonella, rod bacterium, the bacterium that causes cholera, tetanus, botulism, anthrax, plague, leptospirosis and Lyme disease.

[00159] Some examples of pathogenic fungi causing infections that are treatable using the methods of the invention include Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus (fumigatus, niger, etc.) etc.), Genus Mucorales (mucor, absidia, rhizopus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis and Histoplasma capsulatum.

[00160] Some examples of pathogenic parasites causing infections treatable using the methods of the invention include Entamoeba histolytica, Balantidium coli, Naegleriafowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei , Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, Nippostrongylus brasiliensis.

[00161] In all of the above methods, blocking PD-1 can be combined with other forms of immunotherapy, such as treatment with cytokines (eg, interferons, GM-CSF, G-CSF, IL-2) or therapy with a bispecific antibody that provides enhanced presentation tumor antigens (see, for example, Holliger (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak (1994) Structure 2:1121-1123).

[00162] Autoimmune reactions

[00163] Antibodies against PD-1 can induce and enhance autoimmune responses. Indeed, the induction of antitumor responses by tumor cell and peptide vaccines indicates that many antitumor responses involve autoreactivity (van Elsas et al. (2001) J. Exp. Med . 194:481-489; Overwijk, et al. (1999) ) Proc. Natl. Acad. Sci. USA 96: 2982-2987; Hurwitz, (2000), supra; Rosenberg & White (1996) J. Immunother Emphasis Tumor Immunol 19 (1): 81-4). Thus, it may be possible to consider the use of blocking PD-1 along with various self-proteins to develop vaccination protocols to effectively stimulate immune responses against said self-proteins to treat the disease.

[00164] Other self proteins can also be used as targets, for example, IgE for the treatment of allergies and asthma and TNFα for the treatment of rheumatoid arthritis. Finally, antibody responses to various hormones can be induced by the use of anti-PD-1 antibody. Neutralizing antibody responses to sex hormones can be used for contraception. Neutralizing antibody responses to hormones and other soluble factors that are required for the growth of specific tumors can also be considered as possible targets for vaccination.

[00165] Similar methods as described above for the use of anti-PD-1 antibodies can be used to induce therapeutic autoimmune responses to treat patients suffering from impaired accumulation of other self-antigens, such as cytokines such as TNFα and IgE.

[00166] Combination therapy

[00167] In another aspect, the invention provides combination therapy methods in which an anti-PD-1 antibody (or an antigen-binding portion thereof) of the present invention is co-administered with one or more additional antibodies that are effective in stimulating immune responses, thereby , to further enhance, stimulate or positively regulate immune responses in a subject. In one embodiment, the invention provides a method of stimulating an immune response in a subject, comprising administering to said subject an anti-PD-1 antibody and one or more additional immunostimulatory antibodies, such as an anti-LAG-3 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA antibody. -4 such that the immune response in the subject is stimulated, for example, to inhibit tumor growth or to stimulate an antiviral response. In another embodiment, the subject is administered an anti-PD-1 antibody and an anti-LAG-3 antibody. In another embodiment, the subject is administered an anti-PD-1 antibody and an anti-PD-L1 antibody. In another embodiment, the subject is administered an anti-PD-1 antibody and an anti-CTLA-4 antibody. In another embodiment, the at least one additional immunostimulatory antibody (eg, anti-PD-1 antibody, anti-PD-L1 antibody, and/or anti-CTLA-4 antibody) is a human antibody. Alternatively, the at least one additional immunostimulatory antibody may be, for example, a hybrid or humanized antibody (eg, a mouse-derived anti-LAG-3 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody).

[00168] In another embodiment, the invention provides a method of treating a hyperproliferative disease (eg, cancer) comprising administering an anti-PD-1 antibody and an anti-CTLA-4 antibody to a subject. In further embodiments, the anti-PD-1 antibody is administered at a subtherapeutic dose, the anti-CTLA-4 antibody is administered at a subtherapeutic dose, or both are administered at a subtherapeutic dose. In another embodiment, the present invention provides a method of modifying an adverse event associated with treatment of a hyperproliferative disease with an immunostimulatory agent, comprising administering an anti-PD-1 antibody and a subtherapeutic dose of an anti-CTLA-4 antibody to a subject. According to specific embodiments of the invention, the subject is a human. In other embodiments, the anti-CTLA-4 antibody is a human monoclonal antibody sequence 10D1 (described in PCT International Application Publication WO 01/14424) and the anti-PD-1 antibody is a murine monoclonal antibody sequence such as an anti-PD antibody -1 C1H5 described in this application. Other anti-CTLA-4 antibodies included in the methods of the present invention include, for example, those described in the following references: International Application Publication WO 98/42752; publication of international application WO 00/37504; US Patent No. 6,207,156; Hurwitz et al., (1998) Proc. Natl. Acad. Sci. USA 95(17):10067-10071; Camacho et al., (2004) J. Clin. Oncology 22(145): Abstract No. 2505 (antibody CP-675206); and Mokyr et al., (1998) Cancer Res. 58:5301–5304. In specific embodiments, the anti-CTLA-4 antibody binds to human CTLA-4 with a K _D value of 5x10 ^-8 M or less, binds to human CTLA-4 with a K _D value of 1x10 ^-8 M or less, binds with human CTLA-4 with a K _D value of 5x10 ^-9 M or less, or contacts with human CTLA-4 with a K _D value of between 1x10 ^-8 M and 1x10 ^-10 M or less.

[00169] In another embodiment, the present invention provides a method of treating a hyperproliferative disease (eg, cancer) comprising administering an anti-PD-1 antibody and an anti-LAG-3 antibody to a subject.

[00170] In another embodiment, the present invention provides a method of treating a hyperproliferative disease (eg, cancer) comprising administering an anti-PD-1 antibody and an anti-PD-L1 antibody to a subject.

[00171] Blocking PD-1 and one or more second target antigens, such as CTLA-4 and/or LAG-3 and/or PD-L1, with antibodies can result in an enhanced immune response to cancer cells in a patient. Cancers whose growth can be inhibited using the antibodies of the present invention include cancers typically sensitive to immunotherapy. Representative examples of cancers to be treated with the combination therapy of the present invention include those cancers specifically listed above in the discussion of anti-PD-1 antibody monotherapy.

[00172] In certain embodiments, the combination of therapeutic antibodies discussed herein can be administered simultaneously as a single composition in a pharmaceutically acceptable carrier or simultaneously in separate compositions wherein each antibody is presented in a pharmaceutically acceptable carrier. According to another embodiment of the invention, the combination of therapeutic antibodies can be administered sequentially.

[00173] Moreover, if the combination therapy involves sequential administration of more than one dose, the order of the sequential administration can be changed or maintained at each time of administration. Sequential administrations can be combined with simultaneous administrations or any combination thereof.

[00174] Tumors evade host immunosurveillance through a wide variety of mechanisms. Many of these mechanisms can be overcome by inactivating proteins that are expressed by tumors and that are immunosuppressive. These mechanisms include, among others, TGF-β (Kehrl et al., (1986) J. Exp. Med. 163: 1037-1050), IL-10 (Howard &O'Garra (1992) Immunology Today 13: 198-200) , and Fas ligand (Hahne et al., (1996) Science 274: 1363-1365). In another example, antibodies to each of these elements can be further combined with a combination of anti-PD-1 and anti-CTLA-4 and/or anti-LAG-3 and/or anti-PD-L1 antibodies to counteract the effects of immunosuppressive agents and promote host antitumor immune responses.

[00175] Other antibodies that can be used to activate host immunological responses can further be used in conjunction with a combination of anti-PD-1 and anti-CTLA-4 and/or anti-LAG-3 and/or anti-PD-L1 antibodies. These antibodies include antibodies against molecules on the surface of dendritic cells that activate DC function and antigen presentation. Anti-CD40 antibodies (Ridge et al., supra) can be used together with a combination of anti-PD-1 and anti-CTLA-4 antibodies and/or anti-LAG-3 and/or anti-PD-L1 antibodies (Ito et al., supra). Other activating antibodies to T cell costimulatory molecules (Weinberg et al., supra, Melero et al., supra, Hutloff et al., supra) may also provide increased levels of T cell activation.

[00176] As discussed above, bone marrow transplantation is currently used to treat various hematopoietic tumors. Combined blockade of PD-1 and CTLA-4 and/or LAG-3 and/or PD-L1 can be used to improve the efficacy of donor transplanted tumor-specific T cells.

[00177] Some experimental treatment protocols involve ex vivo activation and expansion of antigen-specific T cells and adoptive transfer of these cells to recipients of antigen-specific T cells against a tumor (Greenberg & Riddell, supra). These methods can also be used to activate T cell responses to infectious agents such as CMV. It is expected that ex vivo activation in the presence of anti-PD-1 and anti-CTLA-4 and/or anti-LAG-3 and/or anti-PD-L1 antibodies may increase the number and activity of adoptively transferred T cells.

[00178] In specific embodiments, the present invention provides a method of modifying an adverse event associated with treatment of a hyperproliferative disease (eg, cancer) with an immunostimulatory agent, comprising administering an anti-PD-1 antibody and a subtherapeutic dose of an anti-CTLA-4 antibody and/or anti-LAG-3 and/or anti-PD-L1 to the subject. For example, the methods of the present invention provide a method of reducing the incidence of immunostimulating therapeutic antibody-induced colitis or diarrhea by administering a non-absorbable steroid to a patient. Since any patient who receives an immunostimulatory therapeutic antibody is at risk of developing colitis or diarrhea caused by such antibody, the entire population of these patients is suitable for therapy in accordance with the methods of the present invention. Although steroid administration has been used to treat inflammatory bowel disease (IBD) and prevent exacerbations of IBD, it has not been used to prevent (reduce the incidence of) IBD in patients who have not been diagnosed with IBD. Significant side effects associated with steroids (even non-absorbable steroids) have limited their prophylactic use.

[00179] In additional embodiments, the combined blocking of PD-1 and CTLA-4 and/or LAG-3 and/or PD-L1 (i.e., the use of immunostimulatory therapeutic antibodies against PD-1 and CTLA-4 and/or anti-LAG-3 and/or anti-PD-L1 antibodies) can be further combined with the use of any non-absorbable steroid. As used herein, a “non-absorbable steroid” is a glucocorticosteroid that undergoes extensive first-pass metabolism such that, once metabolized in the liver, the bioavailability of said steroid is low, i.e. less than about 20%. According to one embodiment of the invention, the non-absorbable steroid is budesonide. Budesonide is a topical glucocorticosteroid that is extensively metabolized, primarily in the liver, after oral administration. ENTOCORT EC™ (Astra-Zeneca) is a pH- and time-dependent oral formulation of budesonide designed to optimize ileal drug delivery throughout the entire length of the colon. ENTOCORT EC™ is approved in the United States for the treatment of mild to moderate Crohn's disease affecting the ileum and/or ascending colon. The usual oral dose of ENTOCORT EC™ for the treatment of Crohn's disease is 6 to 9 mg/day. ENTOCORT EC™ is released in the intestine before absorption and retention in the intestinal mucosa. After passing through the intestinal mucosa of the target tissue, ENTOCORT EC™ undergoes extensive metabolism by the cytochrome P450 system in the liver to metabolites with negligible glucocorticosteroid activity. Thus, its bioavailability is low (approximately 10%). The low bioavailability of budesonide results in an improved therapeutic response compared to other glucocorticosteroids that undergo less extensive first-pass metabolism. Budesonide causes fewer adverse effects, including less suppression of the hypothalamic-pituitary axis, compared to systemic corticosteroids. However, long-term administration of ENTOCORT EC™ may result in systemic corticosteroid effects such as hypercortisolism and adrenal suppression. CM. PDR 58 ^th ed. 2004; 608-610.

[00180] In other further embodiments, the combined blocking of PD-1 and CTLA-4 and/or LAG-3 and/or PD-L1 (i.e., the use of anti-PD-1 and anti-CTLA-4 immunostimulatory therapeutic antibodies and/or anti-LAG-3 and/or anti-PD-L1 antibodies) together with the use of a non-absorbable steroid can be further combined with the use of a salicylate. Salicylates include 5-ASA agents such as: sulfasalazine (AZULFIDINE™, Pharmacia &UpJohn); olsalazine (DIPENTUM™, Pharmacia &UpJohn); balsalazide (COLAZAL™, Salix Pharmaceuticals, Inc.); and mesalamine (ASACOL™, Procter & Gamble Pharmaceuticals; PENTASA™, Shire US; CANASA™, Axcan Scandipharm, Inc.; ROWASA™, Solvay).

[00180] In accordance with the methods of the present invention, the salicylate administered in combination with anti-PD-1 and anti-CTLA-4 antibodies and/or anti-LAG-3 and/or anti-PD-L1 antibodies and a non-absorbable steroid may include any overlapping or sequential administration of a salicylate and a nonabsorbable steroid to reduce the incidence of immune-stimulating antibody-induced colitis. Thus, for example, methods of reducing the incidence of colitis caused by an immunostimulatory antibody in accordance with the present invention include simultaneous or sequential administration of salicylate and a non-absorbable steroid (eg, salicylate is administered 6 hours after administration of the non-absorbable steroid) or any combination thereof. Additionally, in accordance with the present invention, the salicylate and the non-absorbable steroid may be administered by the same route (eg, both are administered orally) or by different routes (eg, the salicylate is administered orally and the non-absorbable steroid is administered rectally), which may differ. from the method(s) used to administer the combination of anti-PD-1 and anti-CTLA-4 antibodies and/or anti-LAG-3 and/or anti-PD-L1 antibodies.

[00182] The present invention is further illustrated by the following examples, which are not intended to further limit the present invention. The contents of all figures and all references, Genbank sequences, patents and published patent applications cited throughout this application are expressly incorporated herein by reference.

[00183] Examples

[00184] Example 1 Generation of mouse monoclonal antibodies against PD-1 using hybridoma technology

[00185] Immunization

[00186] Mice were immunized according to the method described in E Harlow, D. Lane, Antibody: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1998. Human tagged recombinant PD-1 protein C-terminal IgG1-Fc (Acro biosystems, #PD-1-H5257, containing extracellular domain, AA Leu 25 - Gln 167) was used as an immunogen. Human PD-1-his protein (Sino biological, #10377-H08H) was used to determine antiserum titer and to screen for hybridomas secreting antigen-specific antibodies.

[00187] Specifically, each animal was injected with 25 μg of human PD1-Fc protein in Freund's complete adjuvant (Sigma, St. Louis, MO, USA) and then stimulated 2 to 3 times by injecting 25 μg of human PD1-Fc protein into Freund's incomplete adjuvant (Sigma, St. Louis, MO, USA) depending on the antiserum titer. Antiserum titer was measured by ELISA-based screening using recombinant human PD1-his protein. Briefly, diluted serum (60 μl) was added to each well and incubated at 37°C for 40 minutes. The plates were then washed 4 times, HRP-conjugated goat anti-mouse IgG (Jackson Immuno research, Cat#115-036-071) was used for detection and the optical density (OD) indicative of binding was observed at 450 nm. Animals with high titers were given a final additional dose by intraperitoneal injection until the hybridoma fused.

[00188] Hybridoma fusion and screening

[00189] Cells from a murine myeloma cell line (SP2/0-Ag14, ATCC#CRL-1581) were cultured until they reached logarithmic growth phase just before confluence. Spleen cells from immunized mice were obtained under sterile conditions and fused with myeloma cells according to the method described in Kohler G, and Milstein C, "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature, 256: 495-497( 1975). The fused “hybrid cells” were then distributed into 96-well plates in DMEM/20% FBS/HAT. Surviving hybridoma colonies were observed under a microscope seven to ten days after fusion. After two weeks, the supernatant from each well was screened by ELISA using recombinant human PD1-his protein. Briefly, ELISA plates were coated with 60 μl of human PD1-his (Sino biological, #10377-H08H, 2.0 μg/ml in PBS) overnight at 4°C. The plates were washed 4 times with PBS-T and blocked with 200 μl blocking buffer (5% skim milk in PBS-T). The diluted hybridoma supernatant (60 μl) was added to each well and incubated at 37°C for 40 minutes. The plates were then washed 4 times, HRP-conjugated goat anti-mouse IgG (Jackson Immuno research, Cat#115-036-071) was used for detection and the OD indicative of binding was observed at 450 nm. A positive hybridoma secreting an antibody that binds to human PD1-his was then selected and transferred to 24-well plates. Hybridoma clones producing antibodies that showed high specific binding and PD1/PDL1 blocking activity were subcloned and antibodies produced by these subclones were purified by Protein A affinity chromatography. Briefly, a Protein A Sepharose column (from Bestchrom (Shanghai) Biosciences, Cat#AA0273), washed with PBS buffer in 5-10 column volumes. Cell supernatants were passed through the columns and then the columns were washed using PBS buffer until protein absorbance reached basal levels. The column was eluted with elution buffer (0.1 M glycine-HCl, pH 2.7), which was immediately collected in 1.5 ml tubes containing neutralization buffer (1 M Tris-HCl, pH 9.0). Fractions containing IgG were pooled and dialyzed in PBS overnight at 4°C.

[00190] Example 2 Determination of affinity of mouse monoclonal antibodies against PD-1 using the BIACORE surface plasmon resonance method

[00191] The purified anti-PD-1 mouse monoclonal antibodies (mAb) generated in Example 1 were characterized, containing the heavy/light chain variable region sequences as described in Table 1 above and the heavy/light chain constant region sequences SEQ ID NO : 129 and 130, respectively, for binding affinity and kinetics using the Biacore T200 system (GE healthcare, Pittsburgh, PA, USA).

[00192] Briefly, goat anti-mouse IgG (GE healthcare, Cat#BR100839, human antibody capture kit) was covalently coupled to a CM5 chip (carboxymethyldextran coated chip) via primary amines using a standard amine coupling kit (GE healthcare, Pittsburgh, Pennsylvania, USA) proposed by Biacore. Unreacted fragments on the biosensor surface were blocked with ethanolamine. Purified anti-PD-1 antibodies and nivolumab (OPDIVO®) at a concentration of 66.7 nM were then applied onto the chip at a flow rate of 10 μL/min. Then, recombinant human PD-1-his protein (Sino biological, #10377-H08H) or cynomolgus PD-1-his protein (Acro biosystems, #PD-1-C5223) in HBS EP buffer (suggested by Biacore) was applied to the chip at a flow rate of 30 µl/min. Antigen-antibody association kinetics were observed for 2 minutes and dissociation kinetics were observed for 10 minutes. Association and dissociation curves were fitted to a 1:1 Langmuir binding model using the BIA scoring program.

[00193] The values of k _a , k _d and K _D were determined and shown in Table 2 below.

Table 2. Binding kinetics of mouse anti-PD-1 monoclonal antibodies to human or cynomolgus PD-1 as determined by Biacore assay Kinetics according to Biacore human PD-1 PD-1 cynomolgus macaque K _{a Kd} K _D K _{a Kd} K _D Clone (M ^-1 s ^-1 ) (s ^-1 ) (M) (M ^-1 s ^-1 ) (s ^-1 ) (M) D1F2 1.94E+05 2.03E-04 1.05E-09 2.00E+05 0.006324 3.17E-08 C1F5 3.53E+05 1.31E-04 3.72E-10 1.38E+05 0.002489 1.81E-08 C1E1 1.72E+05 5.88E-05 3.42E-10 2.03E+05 7.89E+04 3.90E-09 D1A1 1.88E+05 3.86E-04 2.06E-09 2.10E+05 0.002358 1.13E-08 D1F1 2.04E+05 5.77E-04 2.83E-09 2.60E+04 0.002919 1.12E-07 C1E2 1.53E+05 4.42E-04 2.88E-09 2.38E+05 0.002978 1.25E-08 C1A1 1.68E+05 1.89E-04 1.13E-09 3.48E+05 3.31E-03 9.50E-09 C1F4 1.56E+05 3.59E-04 2.30E-09 3.01E+05 0.005208 1.73E-08 D2C2 1.73E+05 3.07E-04 1.77E-09 2.06E+04 0.00238 1.16E-07 2G2 1.63E+05 4.36E-04 2.68E-09 1.40E+05 1.83E-03 1.30E-08 C1C5 2.31E+05 2.03E-04 8.80E-10 3.22E+05 4.70E-03 1.46E-08 OPDIVO® 4.33E+05 1.41E-03 3.25E-09 / / /

[00194] Antibodies of the present invention specifically bound to human PD-1 with a lower K _D value compared to nivolumab, indicating their higher affinity for human PD-1.

[00195] Example 3 Anti-PD-1 Mouse Monoclonal Antibody Binding Activity

[00196] 96-well microplates were coated with 2 μg/ml goat anti-mouse IgG Fcγ antibody (Jackson Immuno Research, #115-006-071, 100 μl/well) in PBS and incubated overnight at 4°C. The plates were washed 4 times with wash buffer (PBS+0.05% Tween-20, PBS-T) and then blocked with 200 μl/well blocking buffer (5% (w/v) skim milk in PBS-T) for 2 hours at 37°C. The plates were washed again and incubated with purified anti-PD-1 antibodies from Example 1 at a concentration of 100 μl/well and nivolumab (0.004-66.7 nM, 5-fold serial dilutions in 2.5% skim milk in PBS-T) for 40 minutes at 37°C and then washed again 4 times. Plates containing captured anti-PD-1 antibodies were incubated with biotin-labeled human PD-1-Fc protein (SEQ ID NO: 100, 60 nM in 2.5% skim milk in PBS-T, 100 μl/well) in for 40 minutes at 37°C, washed 4 times and incubated with streptavidin-conjugated horseradish peroxidase (HRP, 1:10000 dilution in PBS-T, Jackson Immuno Research, #016-030-084, 100 μl/well) for 40 minutes at 37°C. After the final wash, the plates were incubated in the presence of TMB ELISA substrate (100 μl/well, Innoreagents). The reaction was stopped after 15 minutes at 25°C with 1 M H ₂ S0 ₄ at a concentration of 50 μl/well, and the absorbance was read at 450 nm. Data were analyzed using Graphpad Prism and _EC50 values were recorded.

[00197] The results are summarized in Table 3 below.

Table 3. Binding activity of anti-PD-1 antibodies to human PD-1 Clone Capture ELISA (EC ₅₀ , nM) D1F2 0.19 C1F5 0.16 C1E1 0.16 D1A1 0.2 D1F1 0.24 C1E2 0.2 C1A1 0.18 C1F4 0.25 D2C2 0.2 2G2 0.18 C1C5 0.16 OPDIVO® 0.21

[00198] The result showed that the antibodies of the present invention specifically bound to human PD-1, with several clones having lower EC ₅₀ values compared to nivolumab.

[00199] Example 4 Functional blocking assays using ELISA and reporter assays

[00200] 4.1 Ligand blocking ELISA assay

[00201] The ability of the anti-PD-1 antibody of the present invention to block the PD-1-PD-L1 interaction was measured using a competitive ELISA assay. Briefly, human PD-L1-Fc proteins (SEQ ID NO:101) were coated into 96-well microplates at a concentration of 2 μg/ml PBS and incubated overnight at 4°C. The next day, plates were washed with wash buffer (PBS+0.05% Tween-20, PBS-T) and blocked with 5% skim milk in PBS-T for 2 hours at 37°C. The plates were then washed again using wash buffer.

[00202] Dilutions of the anti-PD-1 antibodies of the present invention or nivolumab (starting at a concentration of 100 nM with 4-fold serial dilutions) were prepared in a solution of biotin-labeled human PD1-Fc (SEQ ID NO: 100, 10 nM at 2.5% skim milk in PBS-T) and incubated at room temperature for 40 minutes, then antibody/PD-1-Fc-biotin mixtures (100 μl/well) were added to PD-L1 coated plates. After incubation at 37°C for 40 minutes, the plates were washed 4 times using wash buffer. Streptavidin-conjugated HRP was then added at a concentration of 100 μl/well and incubated for 40 min at 37°C to detect biotin-labeled human PD-1 bound to PD-L1. The plates were washed again using wash buffer. Finally, TMB substrate was added and the reaction was stopped using 1M H ₂ SO ₄ and absorbance was read at 450 nm. Data were analyzed using Graphpad Prisme software and _IC50 values were recorded.

[00203] 4.2 ELISA standard sample blocking assay

[00204] The ability of the anti-PD-1 antibodies of the present invention to block a standard sample was measured by human nivolumab-PD-1 binding using a competitive ELISA assay. Briefly, nivolumab was applied to 96-well microplates at a concentration of 2 μg/ml in PBS and incubated overnight at 4°C. The next day, plates were washed with wash buffer and blocked with 5% nonfat milk in PBS-T for 2 hours at 37°C. During blocking, biotin-labeled human PD-1-Fc (SEQ ID NO:100, 10 nM in 2.5% skim milk in PBS-T) was mixed with each of the antibodies tested (137 pM-100 nM, 3-fold serial dilutions) and incubated for 40 minutes at 25°C. After washing, PD-1/antibody mixtures (100 μl/well) were added to nivolumab-coated plates and incubated for 40 minutes at 37°C. The plates were washed again with wash buffer and then streptavidin (SA)-HRP was added at a concentration of 100 μl/well and incubated for 40 minutes at 37°C to detect biotin-labeled human PD-1 bound to Opdivo ^® . The plates were eventually washed using wash buffer. TMB substrate was added and the reaction was stopped using 1M H ₂ SO ₄ and absorbance was read at 450 nm. Data were analyzed using Graphpad Prism and _IC50 values were recorded.

[00205] 4.3 Cellular functional assays

[00206] The activity of antibodies blocking the PD-1/PD-L1 interaction on the cell membrane was assessed using a cell-based reporter assay. This analysis included two genetically engineered cell lines - a PD-1 effector cell line (Genscript, GS-J2/PD-1) stably expressing human PD-1 and the luciferase reporter gene triggered by the NFAT reporter element (NFAT-RE), and PD -L1 cell line (Genscript, GS-C2/PD-L1, APC cells) stably expressing human PD-L1 and an engineered cell surface antigen peptide/major histocompatibility complex (MHC) protein. When the two cell lines were cocultured, inhibition of T-cell receptor (TCR)-mediated luciferase expression in PD-1 effector cells (via the NFAT pathway) occurred as a result of the PD-1/PD-L1 interaction.

[00207] Cellular functional analysis was performed as follows. Briefly, PD-L1 cells in logarithmic growth phase were seeded in 384-well cell culture plates at a density of 5* ¹⁰⁵ /ml. The next day, anti-PD-1 antibodies of the present invention or nivolumab were diluted (starting at 333.3 nM, 5-fold serial dilutions) in assay buffer (RPMI 1640+1% FBS). Meanwhile, the medium from the PD-L1 cells in 384-well plates was decanted, and then dilutions of anti-PD-1 antibodies (20 μl/well) and PD-1 effector cells (at a density of 6) were added to the 384-well cell culture plates. .25*10 ⁵ /ml, 20 µl/well). After coculture at 37°C for six hours, plates were removed from the incubator and luminescence for each well was read according to the manufacturer's instructions using the One-Glo Luciferase Assay System (Promega, #E6120). Dose response curves were analyzed using Graphpad Prism and EC ₅₀ values were recorded.

[00208] The results of the three analyzes are summarized in Table 4 below.

Table 4. Ability of anti-PD-1 antibodies to block PD-1/PD-L1 interaction Functional blocking assays Competitive ELISA (IC ₅₀ , nM) Reporter gene activation (EC ₅₀ , nM) Clone Human PD-1/ Human PD-L1 Opdivo®/PD-1 human Human PD-1 cells (NFAT-luc)/human PD-L1 cells D1F2 0.21 1.4 7,349 C1F5 0.21 0.87 7,579 C1E1 0.26 1.1 9.114 D1A1 0.22 1.28 9.128 D1F1 0.2 2.13 10.84 C1E2 0.25 1.49 11.13 C1A1 0.27 1.4 12.14 C1F4 0.43 2.26 13.24 D2C2 0.21 1.89 14.67 2G2 0.32 14.45 17.86 C1C5 0.23 1.34 23.36 OPDIVO® 0.12 3.79 13.62

[00209] It can be seen that the antibodies of the present invention were able to block the human PD-1/human PD-L1 interaction, with several clones having lower EC ₅₀ or IC ₅₀ values compared to nivolumab.

[00210] The data also showed that the antibodies of the present invention were able to block the human PD-1/nivolumab interaction, where antibodies from clone 2G2 provided partial blocking, indicating that they bound to the same or similar epitope as nivolumab.

[00211] Example 5 Generation and Characterization of Hybrid Antibodies

[00212] The heavy and light chain variable domains of the mouse anti-PD1 mAb C1E1 were cloned in frame with the human IgGl heavy chain and human kappa light chain constant regions, respectively. The heavy chain variable region and the light chain variable region had the amino acid sequences shown in SEQ ID NOs: 67 and 80, respectively, while the amino acid sequences of the human IgGl heavy chain constant regions and the human kappa light chain were shown in SEQ ID NOs: 97 and 98, respectively. . The activity of the resulting fusion antibodies was confirmed using capture binding ELISA, competitive ELISA and cellular functional reporter assays in accordance with the protocols described in the previous examples. The data showed that the C1E1 fusion antibody had activities comparable to those of the reference standard (OPDIVO®), as shown in Table 5 below.

Table 5. Binding and functional activity of hybrid antibodies Clone ID Capture binding ELISA (EC ₅₀ , nM) Ligand blocking ELISA, PD1/PDL1 ( _IC50 , nM) Standard sample blocking ELISA ( _IC50 , nM) Cellular functional reporter assay ( _IC50 , nM) Hybrid C1E1 0.23 0.53 0.20 8.53 OPDIVO® 0.37 0.41 0.38 10.32

[00213] Example 6 Humanization of Mouse Anti-PD-1 Monoclonal Antibody C1E1

[00214] The mouse anti-PD1 antibody C1E1 was selected for humanization and additional studies. Humanization of the mouse antibody was performed using a well established CDR grafting method as described in detail below.

[00215] To select acceptor scaffolds for humanizing the murine C1E1 antibody, the murine C1E1 light and heavy chain variable region sequences were BLASTed against the human immunoglobulin gene database. Human germ lines IGVH and IGVK with maximum homology to mouse C1E1 were selected as acceptor scaffolds for humanization. The murine antibody heavy/light chain variable region CDRs were inserted into selected scaffolds and the residue(s) in said scaffolds were further mutated to produce more candidate heavy chain/light chain variable regions.

[00216] Vectors containing nucleotide sequences encoding humanized C1E1 heavy chain/light chain variable regions and human IgGl heavy chain and human kappa light chain constant regions were transiently transfected into 50 ml of 293F suspension cell culture at a ratio of light chain-containing constructs to heavy chain constructs of 60%:40% in the presence of 1.2 mg/ml PEI. Cell supernatants were collected after six days in shake flasks, spun to pellet cells, and filtered through a 0.22-μm pore size filter to separate the IgG. Antibodies were purified using Protein A affinity chromatography. Briefly, a column packed with Protein A Sepharose (from Bestchrom (Shanghai) Biosciences, Cat#AA0273) were washed using PBS buffer in 5-10 column volumes. Cell supernatants were passed through the columns and then the columns were washed using PBS buffer until protein absorbance reached basal levels. Columns were eluted using elution buffer (0.1 M glycine-HCl, pH 2.7), which was immediately collected in 1.5 ml tubes containing neutralization buffer (1 M Tris-HCl, pH 9.0). Fractions containing IgG were pooled and dialyzed in PBS overnight at 4°C.

[00217] In total, 10 humanized antibodies were produced, 8 of which were further characterized, namely huC1E1-V1 - huC1E1-V7 and huC1E1-V10. The amino acid sequences of the variable regions of the heavy chain/light chain 8 of these antibodies are summarized in Table 1 above, and the sequences of the constant regions of the human IgGl heavy chain and the human kappa light chain are listed in SEQ ID NO: 97 and 98, respectively.

[00218] The binding affinity of huC1E1-V1 - huC1E1-V7 to human PD1 was assessed using the BIACORE method as described in Example 2, and the K _D values of the affinity assay are summarized in Table 6 below. The binding activity of the huC1E1-V10 antibody to human PD1 was assessed using a capture binding ELISA assay as described in Example 3, in which a goat anti-human IgG-Fab capture antibody was used to capture IgG (Jackson ImmunoResearch, Cat#109-005-097 ), and the EC ₅₀ values of the binding assay are summarized in Table 7. All 8 humanized antibodies had comparable affinities to the C1E1 fusion antibody.

Table 6. Affinity of humanized mAb C1E1 mAb human PD1 Biacore (KD, M) huC1E1-V1 3.88E-09 huC1E1-V2 2.49E-09 huC1E1-V3 4.52E-09 huC1E1-V4 2.95E-09 huC1E1-V5 3.37E-09 huC1E1-V6 3.05E-09 huC1E1-V7 6.36E-09 huC1E1-V10 9.68E-10 Hybrid C1E1 1.83E-09 OPDIVO® 1.49E-08

Table 7. Binding activity of humanized mAb C1E1 mAb human PD1 Capture binding ELISA (EC ₅₀ , nM) huC1E1-V10 0.44 Hybrid C1E1 0.16 OPDIVO® 1.19

[00219] The humanized huC1E1-V10 antibody was then screened for affinity for human and cynomolgus PD1 using the Biacore assay and a capture binding ELISA assay, and was screened for functional activity using a competitive ELISA and cell reporter assay in accordance with the protocols described in Examples 2 - 4. As shown in Table 8, huC1E1-V10 showed comparable in vitro activity values to the C1E1 fusion antibody.

Table 8. Binding and functional activity of humanized mAb C1E1 Short description mAb binding analysis functional analysis PD1 Human PD1 cynomolgus macaque Competitive ELISA (IC ₅₀ , nM) Cellular reporter assay (EC ₅₀ , nM) Binding ELISA (EC ₅₀ , nM) Biacore (KD, M) Biacore (KD, M) PD1/PDL1 ligand blocking, ELISA Standard blocking, ELISA huC1E1-V10 0.34 9.68E-10 8.92E-10 0.88 0.35 11.26 chC1E1 0.23 8.81E-10 8.45E-10 0.53 0.20 8.53 OPDIVO® 0.37 8.17-09 1.40E-08 0.41 0.38 10.32

[00220] Example 7 Physicochemical Properties of Humanized Antibody C1E1

[00221] The physicochemical properties of the humanized anti-PD1 antibody huC1E1-V10 were tested using protein thermal shift assay, cIEF method, SEC method and freeze-thaw method as described below.

[00222] Protein thermal shift assay to determine Tm

[00223] Thermal stability of the humanized anti-PD1 antibody huC1E1-V10 was measured using the GloMelt™ Thermal Shift Protein Stability Assay Kit (Biotium, Cat#33022-T, lot#: 181214). Briefly, GloMelt™ dye was allowed to thaw and reach room temperature. The ampoule containing the dye was vortexed and centrifuged. A 10× dye solution was prepared by adding 5 μL of a 200× dye solution to 95 μL of PBS. 2 μl of a 10× dye solution and 10 μg of antibody were added to a total reaction volume of 20 μl. The parameters for running the melt curve analysis program were set, detailed in Table 9. The tubes were quickly centrifuged and placed in a real-time PCR cycler (Roche, LightCycler 480 II). The results were analyzed using Microsoft Excel 2010.

Table 9. Parameters for the melting curve analysis program Program stage Temperature Linear speed Retention time Initial retention 25°C N.A. 30 s Melting curve 25-99°C 0.1°C/s N.A.

[00224] cIEF method for determining pI

[00225] Capillary isoelectric focusing (cIEF) was used to determine the pI and charge heterogeneity of the humanized anti-PD1 antibody huC1E1-V10. Briefly, 35 μL 0.1% MC, 4 μL pH3-10 Pharmlyte, 2 μL 0.5 mol/L Arg, 1 μL Mark-7.05, and 1 μL Mark-9.99 were added to a tube containing 20 µg of antibody in PBS, then added ddH ₂ O to 100 µl. The electrophoresis program consisted of two phases: an initial separation for 1 minute at 1500 V followed by a separation for 6 minutes at 3000 V. After 5 minutes of detection exposure, the data were analyzed using Maurice™Compass™ software (Proteinsimple Inc., USA).

[00226] SEC method for determining aggregation

[00227] The percentage of monomers was assessed using size exclusion chromatography (SEC) (Agilent Technologies, 1260 Infinity II). The antibodies, which were contained in an aqueous mobile phase, were passed through a porous resin, which was a stationary phase packed into a column. Column retention time was a function of the hydrodynamic size of the protein and the pore size of the packed resin bed. Smaller molecules can fit into smaller pores in the resin and are retained longer compared to larger molecules. Upon elution from the column, proteins were detected by UV absorption. The mobile phase was a phosphate-buffered saline solution. Absorbance was monitored at 280 nm. The flow rate was 0.8 ml/min. The injection volume was 40 μL of sample at a concentration of 1 mg/mL. The column temperature was room temperature. The autosampler temperature was 2-8°C. The total run time was 25 minutes.

[00228] Freeze-thaw method for determining stability

[00229] Solutions of an antibody at a concentration of 1 mg/ml in a dosage form(s) of 1xPBS (containing 137 mmol/L NaCl, 2.7 mmol/L KCl, 10 mmol/L Na ₂ HPO ₄ , 12H ₂ O, 2 mmol/L KH ₂ PO ₄ ), frozen at -80°C for at least 24 hours and then thawed at room temperature for 30-60 minutes. The freeze-thaw cycle was repeated 5 times for each sample. After specific freeze-thaw cycles, such as the second, third, and fourth, a portion of the solution was collected for SEC analysis before refreezing.

[00230] Instability leading to denaturation was assessed using the GloMelt™ Thermal Shift Protein Stability Kit. As shown in Figure 1, the humanized anti-PD1 antibody huC1E1-V10 exhibited a high melting temperature (Tm), typically 78°C, and a minor peak at 69.5°C was also observed. Analysis of huC1E1-V10 by cIEF showed that the % abundance of the major isoform was approximately 81.5%, the % abundance of the acidic species was approximately 11.0%, and the % abundance of the basic species was approximately 7.5%. pI values were calculated using Maurice™Compass™ software. The pI value for the huC1E1-V10 antibody was 8.36. The pI value of the humanized antibody huC1E1-V10 was significantly greater than 7, thus suggesting that the antibody would have a significant positive charge at neutral pH. SEC analysis of huC1E1-V10 showed that the % monomer content was 100.0% (see Figure 2). Freeze-thaw stability was assessed using size exclusion chromatography (SEC). The huC1E1-V10 antibody showed no obvious increase in the level of aggregation over time and no precipitation or turbidity was observed after 5 repeated freeze-thaw cycles.

[00231] Example 8 In vivo antitumor efficacy of murine antibody C1E1

[00232] The in vivo antitumor activity of the murine C1E1 antibody was assessed in NCG mice. Briefly, NCG mice were subcutaneously injected with 4x10 ⁶ human A375 melanoma cells mixed with 5x10 ⁵ tumor-reactivated peripheral blood mononuclear cells (PBMCs) in the right axilla for 1 day. Tumor volume was measured twice a week for three weeks using an electronic caliper and calculated as (length × width ² )/2. Twenty-four tumor-bearing mice were selected and randomized into four groups on day 14. Animals were intraperitoneally injected with vehicle (5% glucose solution), mouse C1E1 antibody, mouse C1E1-Fab antibody, and nivolumab, respectively, at a dose of 3 mg/kg on days 14, 21, and 28. The mouse C1E1 antibody contained a mouse heavy chain variable region and a human IgG1 constant region, as well as a mouse light chain variable region and a human Ck constant region, having the sequences shown in SEQ ID NOs: 67, 97, 80 and 98, respectively, while mouse C1E1 -Fab contained a murine heavy chain variable domain and a human IgG1 CH1 constant domain, and a light chain variable domain and a human Ck1 constant domain having the sequences set forth in SEQ ID NOs: 67, 99, 80 and 98, respectively.

[00233] Mice were euthanized on day 35 and tumors were collected and weighed. Tumor growth suppression was calculated (%TGI = (1-mean tumor volume in each treatment group/mean tumor volume in the control group) × 100%).

[00234] All treatments were well tolerated by tumor-bearing animals. As can be seen from Table 10, treatment with 3 mg/kg murine C1E1 and 3 mg/kg murine C1E1-Fab treatment resulted in significantly better efficacy compared to 3 mg/kg nivolumab in the human A375 melanoma xenograft model.

Table 10. Antitumor efficacy of mouse antibody C1E1 in a xenograft model of human melanoma cells A375 Group number Medicine Dose Tumor volume ^a (mm ³ ) %TGI Tumor weight (g) 1 Filler n/a 509.22±132.69 - 0.61±0.20 2 Mouse C1E1 3 mg/kg 116±40.33* 77.22% 0.13±0.06 3 Mouse C1E1-Fab 3 mg/kg 91.38±33.17* 82.05% 0.11±0.04 4 OPDIVO® 3 mg/kg 276.47±124.61 45.71% 0.28±0.12

^a Compared with vehicle control group by Student's t test, *P < 0.05.

[00235] Example 9 In vivo antitumor efficacy of herpes virus T3011 with integrated murine C1E1 encoding sequences

[00236] The antitumor efficacy of herpes virus T3011 with integrated sequences encoding the murine antibody C1E1 was assessed in the B16F10-hPD-L1 melanoma xenograft model.

[00237] Herpes virus T3011 is genetically a herpes simplex virus type 1 (HSV-1) modified by deleting the inverted repeat region and replacing it with the human IL-12 gene (see, for example, PCT/CN2016/080025) in addition to inserting the sequence Fab fragment of C1E1 into the genomic region between UL3 and UL4. The C1E1 Fab sequences contain a mouse heavy chain variable domain and a human IgG1 CH1 constant domain, and a mouse light chain variable domain and a human Cappa1 constant domain having the sequences shown in SEQ ID NOs: 67, 99, 80 and 98, respectively.

[00238] Briefly, female humanized B-hPD-1 mice were subcutaneously injected into the right anterior flank with B16F10-hPD-L1 melanoma cells at a concentration of 1x10 ⁵ . When the tumor volume reached approximately 90 mm ³ , the mice were randomized into five groups, 8 mice in each group. These mice were intratumorally injected with vehicle (5% glucose solution), T3011 (5×10 ⁶ PFU/mouse), T3011 (1×10 ⁷ PFU/mouse), T3011 (3×10 ⁷ PFU/mouse) and NV1020 (3× 10 ⁷ PFU/mouse, a recombinant HSV-based oncolytic virus developed by MediGene (formerly NeuroVir) for the potential treatment of cancer (see, for example, Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther. 2010 Sep;21(9):1119-28) respectively.Tumor volume was measured twice a week.

[00239] Twelve days after drug administration, mice were euthanized and tumors were collected, weighed and photographed. The relative tumor volume (RTV = TVn/TV ₀ , where TVn represents the tumor volume on day n and TV ₀ represents the tumor volume on day 0), tumor growth suppression ratio (TGI% = 1 - the average tumor volume in each treatment group) were calculated /average tumor volume in the control group) × 100% ) and tumor weight reduction ratio (IR _TW = (1-average tumor weight in each treatment group / average tumor weight in the control group) × 100%).

[00240] As shown in Table 11 below, T3011 with integrated sequences encoding the murine antibody C1E1 provided apparent antitumor dose-dependent activity. Administration of T3011 showed better antitumor efficacy compared to administration of NV1020 at a dose of 3×10 ⁷ PFU/mouse.

Table 11. Antitumor efficacy of herpes virus T3011 with integrated sequences encoding murine C1E1 in the B16F10-hPD-L1 melanoma xenograft model Group number Medicine Dose Tumor volume ^a (mm ³ ) TGI (%) IR _TW 1 Filler n/a 3396±836 - - 2 T3011 5×10 ⁶ PFU/mouse 1724±471* 50.6% 18.9% 3 T3011 1×10 ⁷ PFU/mouse 1365±361* 61.4% 28.4% 4 T3011 3×10 ⁷ PFU/mouse 458±128** 88.9% 73.6% 5 NV1020 3×10 ⁷ PFU/mouse 1277±423* 64.1% 41.2%

^a Compared with vehicle control group by Student's t test, *P<0.05 and **P<0.01.

[00241] Example 10 In Vivo Antitumor Efficacy of Humanized Antibody C1E1

[00242] The effect of the humanized antibody C1E1 on tumor growth was assessed in the MC38 xenograft model. Briefly, female B-hPD-1 mice were injected subcutaneously into the right posterior flank with 5 x 10 ⁵ cells. When tumor volumes reached approximately 100-150 mm ³ , mice were randomized into 7 groups, 8 mice per group. Animals were intraperitoneally administered vehicle (PBS), huC1E1-V10 and OPDIVO®, respectively, at a dose of 1 mg/kg, 3 mg/kg or 10 mg/kg twice a week for three weeks. The humanized antibody huC1E1-V10 contained a heavy chain variable region and a constant region, and a light chain variable region and a constant region having the sequences shown in SEQ ID NOs: 69, 97, 86 and 98, respectively. Tumor volume was measured during the study.

[00243] Twenty-three days after the start of treatment, mice were euthanized and tumors were collected, weighed and photographed. The tumor volume growth suppression ratio (TGI _TV ) was calculated and the data is shown in Table 12.

[00244] As shown in Table 12 below, all treatments were well tolerated by tumor-bearing animals. Treatment with HuC1E1-V10 resulted in dose-dependent antitumor activity in the MC38 xenograft model, which was comparable to OPDIVO®.

Table 12. Antitumor efficacy of huC1E1-V10 in the MC38 xenograft model Group number Medicine Treatment group Tumor volume ^a (mm ³ ) TGI _TV (%) 1 Filler n/a 3438±571 - 2 huC1E1-V10 1 mg/kg 2357±410 32.6 3 huC1E1-V10 3 mg/kg 1335±241** 63.4 4 huC1E1-V10 10 mg/kg 1189±250** 67.8 5 OPDIVO® 1 mg/kg 1255±139** 65.9 6 OPDIVO® 3 mg/kg 1444±190** 60.2 7 OPDIVO® 10 mg/kg 703±151** 82.5

^a Compared with vehicle control group by Student's t test, *P<0.05 and **P<0.01.

[00245] It should be understood that while the invention has been described above in connection with one or more embodiments, it is intended that the present invention is not limited to the embodiments indicated and that the description includes all alternatives, modifications and equivalents that may be included within the scope and spirit of the appended claims. All references cited herein are also incorporated by reference in their entirety.

[00246] The sequences described in this application are summarized below.

Description/Sequence/SEQ ID NO VH-CDR1 for C1E1, huC1E1-V1 - huC1E1-V7 and huC1E1-V10
GFTFSSYL (SEQ ID NO: 1) VH-CDR2 for C1E1, huC1E1-V1 - huC1E1-V7 and huC1E1-V10
ISGGGGDT (SEQ ID NO: 2) VH-CDR3 for C1E1, huC1E1-V1 - huC1E1-V7 and huC1E1-V10
VRFGGAGYYWYFD (SEQ ID NO: 3) VH-CDR1 for D1F2
GFTFSSYT (SEQ ID NO: 4) VH-CDR2 for D1F2
ISGGGSNI (SEQ ID NO: 5) VH-CDR3 for D1F2
VLNYAYAMDYWGQ (SEQ ID NO: 6) VH-CDR1 for C1F5
GFAFSSYD (SEQ ID NO: 7) VH-CDR2 for C1F5
ITGGGSSS (SEQ ID NO: 8) VH-CDR3 for C1F5
ASPYLSYFDYWGQ (SEQ ID NO: 9) VH-CDR1 for D1A1
GFTFSNYA (SEQ ID NO: 10) VH-CDR2 for D1A1
ISGGGGNI (SEQ ID NO: 11) VH-CDR3 for D1A1
ASPYANYVWYLDV (SEQ ID NO: 12) VH-CDR1 for D1F1
GFTFSSNT (SEQ ID NO: 13) VH-CDR2 for D1F1
ISGGGVNT (SEQ ID NO: 14) VH-CDR3 for D1F1
ARHGNYNYYGMDY (SEQ ID NO: 15) VH-CDR1 for C1E2
GYTFTNYW (SEQ ID NO: 16) VH-CDR2 for C1E2
IYPGGGYT (SEQ ID NO: 17) VH-CDR3 for C1E2
ARGYGTNYWYFDV (SEQ ID NO: 18) VH-CDR1 for C1A1
GFSLSTSGMG (SEQ ID NO: 19) VH-CDR2 for C1A1
IWWDDDK (SEQ ID NO: 20) VH-CDR3 for C1A1
ARTGGFITTGYWY (SEQ ID NO: 21) VH-CDR1 for C1F4
GYKFTDYA (SEQ ID NO: 22) VH-CDR2 for C1F4
ISTYSGDV (SEQ ID NO: 23) VH-CDR3 for C1F4
SRLGITAGFAYWG (SEQ ID NO: 24) VH-CDR1 for D2C2
GFTFSSNT (SEQ ID NO: 25) VH-CDR2 for D2C2
ISGGGVDT (SEQ ID NO: 26) VH-CDR3 for D2C2
ARHGNYNYYGMDY (SEQ ID NO: 27) VH-CDR1 for 2G2
GFTFSYYG (SEQ ID NO: 28) VH-CDR2 for 2G2
ISSGSSFT (SEQ ID NO: 29) VH-CDR3 for 2G2
TRREGIYDASWDY (SEQ ID NO: 30) VH-CDR1 for C1C5
GYTFTNYG (SEQ ID NO: 31) VH-CDR2 for C1C5
INTYSGEP (SEQ ID NO: 32) VH-CDR3 for C1C5
VRQGDFDYEDAMD (SEQ ID NO: 33) VL-CDR1 for C1E1, huC1E1-V1 - huC1E1-V7 and huC1E1-V10
RASKSVDDSGISFMH (SEQ ID NO: 34) VL-CDR2 for C1E1, huC1E1-V1 - huC1E1-V7 and huC1E1-V10
AASNQGS (SEQ ID NO: 35) VL-CDR3 for C1E1, huC1E1-V1 - huC1E1-V7 and huC1E1-V10
HQTKEVPWT (SEQ ID NO: 36) VL-CDR1 for D1F2
RASQDISNFLN (SEQ ID NO: 37) VL-CDR2 for D1F2
YTSRLQS (SEQ ID NO: 38) VL-CDR3 for D1F2
QQGSSLPWT (SEQ ID NO: 39) VL-CDR1 for C1F5
RASQSISNNLH (SEQ ID NO: 40) VL-CDR2 for C1F5
GSQSMS (SEQ ID NO: 41) VL-CDR3 for C1F5
QQSNSWPLT (SEQ ID NO: 42) VL-CDR1 for D1A1
RASQDISNYLN (SEQ ID NO: 43) VL-CDR2 for D1A1
YTSRLHS (SEQ ID NO: 44) VL-CDR3 for D1A1
QQSNALPWT (SEQ ID NO: 45) VL-CDR1 for D1F1
RASESVDNSGISFMN (SEQ ID NO: 46) VL-CDR2 for D1F1
TASNQGS (SEQ ID NO: 47) VL-CDR3 for D1F1
QQSYEVPWT (SEQ ID NO: 48) VL-CDR1 for C1E2
KASQSVSNDVA (SEQ ID NO: 49) VL-CDR2 for C1E2
YAFHRYT (SEQ ID NO: 50) VL-CDR3 for C1E2
QQDYSSPYT(SEQ ID NO: 51) VL-CDR1 for C1A1
RASQDISNYLI (SEQ ID NO: 52) VL-CDR2 for C1A1
YTSRLHS (SEQ ID NO: 53) VL-CDR3 for C1A1
QQHKTLPWT (SEQ ID NO: 54) VL-CDR1 for C1F4
KASQNVRTAVA (SEQ ID NO: 55) VL-CDR2 for C1F4
LASNRHT (SEQ ID NO: 56) VL-CDR3 for C1F4
LQHWNYPYT (SEQ ID NO: 57) VL-CDR1 for D2C2
RASESVDNSGISFMN (SEQ ID NO: 58) VL-CDR2 for D2C2
IASNHGS (SEQ ID NO: 59) VL-CDR3 for D2C2
QQSYEVPWT (SEQ ID NO: 60) VL-CDR1 for 2G2
RSSQSIIRSNGNTYLE (SEQ ID NO: 61) VL-CDR2 for 2G2
KVSNRFS (SEQ ID NO: 62) VL-CDR3 for 2G2
FQGSHVPWT (SEQ ID NO: 63) VL-CDR1 for C1C5
RSSQSIVHSNGHIYLE (SEQ ID NO: 64) VL-CDR2 for C1C5
KVSKRFS (SEQ ID NO: 65) VL-CDR3 for C1C5
FQGSHGT (SEQ ID NO: 66) VH for C1E1
EVMLVESGGGLVKPGGSLKLSCAASGFFSSYLMSWVRQTPEKRLEWVATISGGGGDTYFPDSVKGRFTISRDNVKNNLYLQMSSLRSEDTALYYCVRFGGAGYYWYFDVWGAGTTVTVSS (SEQ ID NO: 67)
GAAGTGATGCTGGTGGAGTCTGGGGGAGGGTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGGATTCACGTTCAGTAGTTATCTTATGTCTTGGGTTCGCCAGACTCCGGAGAAGAGGCTGGAGTGGGTCGCAACCATTAGTGGTGGTGGTGGTGACACCTACTTTCCAGACAGTGTGAAGGGTCGATTCACCATCTCCAGAGACAATGTCAAGAACAACCTG TACCTGCAAATGAGCAGTCTTAGGTCTGAGGACACGGCCTTGTATTACTGTGTAAGATTTGGGGGCGCTGGTTACTACTGGTATTTCGATGTCTGGGGCGCAGGGACCACGGTCACCGTCTCCTCA (SEQ ID NO: 102) VH for huC1E1-V1, huC1E1-V3 - huC1E1-V7
EVQLVESGGGVVQPGRSLRLSCAASGFFSSYLMSWVRQAPGKGLEWVATISGGGGDTYFPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRFGGAGYYWYFDVWGAGTLVTVSS (SEQ ID NO: 68) VH for huC1E1-V2 and huC1E1-V10
EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYLMSWVRQAPGKGLEWVATISGGGGDTYFPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRFGGAGYYWYFDVWGQGTLVTVSS (SEQ ID NO: 69)
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATCTTATGTCCTGGGTCCGCCAGGCTCCAGGCAAGGGGCTAGAGTGGGTGGCAACTATATCAGGTGGTGGAGGTGACACATACTTCCCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATC TGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGTGAGATTCGGTGGTGCTGGTTACTACTGGTACTTTGACGTCTGGGGCCAAGGAACCCTGGTCACCGTCTCGAGT (SEQ ID NO: 103) VH for D1F2
EVMLVESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVRQTPEKRLEWVATISGGGSNIYYPDSVEGRFTVSRDNARNTLYLHMSSLRSEDTALYYCVLNYAYAMDYWGQGTSVTVSS (SEQ ID NO: 70)
GAAGTGATGCTGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAGCTATACCATGTCTTGGGTTCGCCAGACTCCGGAGAAGAGGCTGGAGTGGGTCGCAACCATTAGTGGTGGTGGTAGTAACATCTACTATCCAGACAGTGTGGAGGGTCGATTCACCGTCTCCAGAGACAATGCCAGGAACACCCTG TACCTGCATATGAGCAGTCTGAGGTCTGAGGACACGCCTTATATTACTGTGTCCTTAACTACGCCTATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA (SEQ ID NO: 104) VH for C1F5
EVQLVESGGGLVKPGGSLKLSCAASGFAFSSYDMSWVRQTPEKRLEWVAYITGGGSSSFYPDTVKGRFTISRDNSKNTLYLQMTSLRSEDTAMYYCASPYLSYFDYWGQGTTLTVSS (SEQ ID NO: 71)
GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGGATTCGCTTTCAGTAGCTATGACATGTCTTGGGTTCGCCAGACTCCGGAAAGAGGCTGGAGTGGGTCGCATACATTACTGGTGGTGGTAGTAGTTCCTTCTATCCAGACACTGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACCCTGTATTTG CAAATGACCAGTCTGAGGTCTGAGGACACAGCCATGTATTACTGTGCAAGCCCCTACTTATCCTACTTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA (SEQ ID NO: 105) VH for D1A1
EVMLVESGGGLVKPGGSLKLSCAASGTFFSNYAMSWVRQTPEKRLEWVATISGGGGNIYYPDSVKGRFTISRDNARNNTLYLQMSSLRSEDTALYYCASPYANYVWYLDVWGAGTTVTVSS (SEQ ID NO: 72)
GAAGTGATGCTGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAACTATGCCATGTCTTGGGTTCGCCAGACTCCGGAGAAGAGGCTGGAGTGGGTCGCAACCATTAGTGGTGGTGGTGGTAACATCTACTATCCAGACAGTGTGAAGGGTCGATTCACCATCTCCAGAGACAATGCCAGGAACACCCTGTACC TGCAAATGAGCAGTCTGAGGTCTGAGGACACGGCCTTGTATTATTGTGCAAGCCCGTATGCTAACTACGTATGGTACCTCGATGTCTGGGGCGCAGGGACCACGGTCACCGTCTCCTCA (SEQ ID NO: 106) VH for D1F1
EVMLVESGGGLVKPGGSLKLSCAASGFTFSSNTMSWVRQTPEKRLEWVAAISGGGVNTYYPDSVKGRFTISRDNARNNTLYLQMSSLRSEDTALYYCARHGNYNYYGMDYWGQGTSVTVSS (SEQ ID NO: 73)
GAAGTGATGCTGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAGCAATACCATGTCTTGGGTTCGCCAGACTCCGGAGAAGAGGCTGGAGTGGGTCGCAGCCATTAGTGGTGGTGGTGTTAACACCTACTATCCAGACAGTGTGAAGGGTCGATTCACCATCTCCAGAGACAATGCCAGGAACACCCTGTA CCTGCAAATGAGCAGTCTGAGGTCTGAGGACACGGCCCTGTATTACTGTGCAAGACATGGTAACTACAATTACTATGGTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA (SEQ ID NO: 107) VH for C1E2
QVQLQQSGAELVRPGTSVKISCKASGYTFTNYWLGWVKQRPGHGLEWIGDIYPGGGYTNYNENFKGKATLTADTSSSTAYMQLSSLTSEDSAVFFCARGYGTNYWYFDVWGAGTTVTVSS (SEQ ID NO: 74)
CAGGTCCAGTTGCAGCAGTCTGGAGCTGAGCTGGTAAGGCCTGGGACTTCAGTGAAGATATCCTGCAAGGCTTCTGGCTACACCTTCACTAACTACTGGCTAGGTTGGGTAAAACAGAGGCCTGGACATGGACTTGAGTGGATTGGAGATATTTACCCTGGAGGTGGTTATACTAACTACAATGAGAACTTCAAGGGCAAGGCCACACTGACTGCAGACACATCCTCCAGCACTGCCTACATGCAGCTC AGTAGCCTGACATCTGAGGACTCTGCTGTCTTTTTCTGTGCAAGAGGCTACGGTACTAATTACTGGTACTTCGATGTCTGGGGCGCAGGGACCACGGTCACCGTCTCCTCA (SEQ ID NO: 108) VH for C1A1
QVTLKESGPGILKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDDDKFYNPSLKSQLTISKDTSRNQVFLKITSVDTADTATYYCARTGGFITTGYWYFDVWGAGTTVTVSS (SEQ ID NO: 75)
CAAGTTACTCTAAAAGAGTCTGGCCCTGGGATATTGAAGCCCTCACAGACCCTCAGTCTGACTTGTTCTTTCTCTGGGTTTTCACTGAGCACTTCTGGTATGGGTGTAGGCTGGATTCGTCAGCCTTCAGGGAAGGGTCTGGAGTGGCTGGCACACATTTGGTGGGATGATGATAAGTTCTATAACCCATCCCTGAAGAGCCAGCTCACAATCTCCAAGGATACCTCCAGAAACCAGGTTTTCCCTCAAG ATCACCAGTGTGGACACTGCAGATACTGCCACTTACTACTGTGCTCGAACCGGGGGGTTTATTACTACGGGCTACTGGTACTTCGATGTCTGGGGCGCCAGGGACCACGGTCACCGTCTCCTCA (SEQ ID NO: 109) VH for C1F4
QVQLQQSGAELVRPGVSVKISCKGSGYKFTDYAMHWVRQSHAKSLEWIGIISTYSGDVSFNQNFKGKATMTVDKSSSTAYMELARLTSEDSAIYYCSRLGITAGFAYWGQGTLVTVSA (SEQ ID NO: 76)
CAGGTCCAGCTGCAACAGTCTGGGGCTGAGCTGGTGAGGCCTGGGGTCTCAGTGAAGATTTCCTGCAAGGGTTCTGGCTACAAATTCACTGATTATGCTATGCACTGGGTGAGGCAGAGTCATGCAAAGAGTCTAGAGTGGATTGGAATTATTAGTACTTACTCTGGTGACGTTAGTTTCAACCAGAACTTCAAGGGCAAGGCCACAATGACTGTAGACAAATCCTCCAGCACAGCCTATATGGA ACTTGCCAGACTGACATCTGAGGATCTCTGCCATCTATTACTGTTCAAGACTGGGGATTACGGCGGGGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA (SEQ ID NO: 110) VH for D2C2
EVMLVESGGGLVKPGGSLKLSCAASGFTFSSNTMSWVRQTPEKRLEWVAAISGGGVDTYYPDSVKGRFTISRDNARNNTLYLQMSSLRSEDTALYYCARHGNYNYYGMDYWGQGTSVTVSS (SEQ ID NO: 77)
GAAGTGATGCTGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAGCAATACCATGTCTTGGGTTCGCCAGACTCCGGAGAAGAGGCTGGAGTGGGTCGCAGCCATTAGTGGTGGTGGTGTTGACACCTACTATCCAGACAGTGTGAAGGGTCGATTCACCATCTCCAGAGACAATGCCAGGAACACCCTGTA CCTGCAAATGAGCAGTCTGAGGTCTGAGGACACGGCCCTGTATTACTGTGCAAGACATGGTAACTACAATTACTATGGTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA (SEQ ID NO: 111) VH for 2G2
EVQLVESGGDLVKPGGSLKLSCTASGFTFSYYGMSWVRQTPDKRLEWVATISSGSSFTYSPDSVKGRFTISRDNAKNTLYLQMNSLKSEDTAIYYCTRREGIYDASWDYSMDYWGQGTSVTVSS (SEQ ID NO: 78)
GAGGTGCAACTGGTGGAGTCTGGGGGAGACTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTACAGCCTCTGGATTCACTTTCAGTTACTATGGCATGTCTTGGGTTCGCCAGACTCCAGACAAGAGGCTGGAATGGGTCGCAACCATTAGTAGTGGTAGTAGTTTCACCTACTCTCCAGACAGTGTGAAGGGGCGATTCACCATCTCCAGAGACAATGCCAAGAACACCCTGTACCTACA AATGAACAGTCTGAAGTCTGAGGACACAGCCATTTATTACTGTACAAGACGAGAGGGGATCTATGATGCTTCCTGGGATTATTCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA (SEQ ID NO: 112) VH for C1C5
QIQLVQSGPELKKPGETVKISCKASGYTFTNYGINWVKQAPGKGLKWMGWINTYSGEPTYSDDFKGRFAFSLETSASTAYLQINNLKNEDTSTYFCVRQGDFDYEDAMDYWGQGTSVTVSS (SEQ ID NO: 79)
CAGATCCAGTTGGTGCAGTCAGGACCTGAGCTGAAGAAGCCTGGAGAGACAGTCAAGATCTCCTGCAAGGCTTCTGGGTATACCTTCACAAACTATGGAATAAACTGGGTGAAGCAGGCTCCAGGAAAGGGTTTTAAAGTGGATGGGCTGGATAAAACACCTATAGTGGAGAGCCAACATATTCTGATGACTTCAAGGGACGCTTTGCCTTCTCTTTGGAAACCTCTGCCAGCACTGCCTATTTGCAG ATCAACAACCTCAAAAATGAGGACACGTCTACATATTTCTGTGTAAGACAGGGGGACTTTGATTACGAGGATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA (SEQ ID NO: 113) VL for C1E1
DIVLTQSPASLAVSLGQRATISCRASKSVDDSGISFMHWFQQKPGQPPKLLIYAASNQGSGVPARFRGSGSGTDFSLNIHPMEEDDTAMYFCHQTKEVPWTFGGGTKLEIK (SEQ ID NO: 80)
GACATTGTGCTGACCCAATCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCACCATCTCCTGCAGAGCCAGCAAAAGTGTTGATGATTCTGGCATTAGTTTTATGCACTGGTTCCAACAGAAACCAGGACAGCCACCCAAACTCCTCATCTATGCTGCATCCAACCAAGGATCCGGGGTCCCTGCCAGGTTTCGTGGCAGTGGGTCTGGGACAGACTTCAGCCTCAACATCCATCCTATGGAGG AGGATGATACTGCAATGTATTTCTGTCACCAAACTAAGGAGGTTCCGTGGACGTTCGGTGGAGGCACAAGCTGGAAATCAAA (SEQ ID NO: 114) VL for huC1E1-V1 and huC1E1-V2
EIVLTQSPATLSLSPGERATLSCRASKSVDDSGISFMHWFQQKPGQPPRLLIYAASNQGSGVPARFSGSGSGTDFTLTISSLEPEDFAVYFCHQTKEVPWTFGQGTKVEIK (SEQ ID NO: 81) VL for huC1E1-V3
EIVLTQSPATLSLSPGERATLSCRASKSVDDSGISFMHWYQQKPGQPPRLLIYAASNQGSGVPARFSGSGSGTDFTLTISSLEPEDFAVYFCHQTKEVPWTFGQGTKVEIK (SEQ ID NO: 82) VL for huC1E1-V4
EIVLTQSPATLSLSPGERATLSCRASKSVDDSGISFMHWFQQKPGQAPRLLIYAASNQGSGVPARFSGSGSGTDFTLTISSLEPEDFAVYFCHQTKEVPWTFGQGTKVEIK (SEQ ID NO: 83) VL for huC1E1-V5
EIVLTQSPATLSLSPGERATLSCRASKSVDDSGISFMHWFQQKPGQPPRLLIYAASNQGSGIPARFSGSGSGTDFTLTISSLEPEDFAVYFCHQTKEVPWTFGQGTKVEIK (SEQ ID NO: 84) VL for huC1E1-V6
EIVLTQSPATLSLSPGERATLSCRASKSVDDSGISFMHWFQQKPGQPPRLLIYAASNQGSGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQTKEVPWTFGQGTKVEIK (SEQ ID NO: 85) VL for huC1E1-V7 and huC1E1-V10
EIVLTQSPATLSLSPGERATLSCRASKSVDDSGISFMHWYQQKPGQAPRLLIYAASNQGSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQTKEVPWTFGQGTKVEIK (SEQ ID NO: 86)
GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTAAGTCTGTTGACGACAGTGGTATCAGCTTCATGCACTGGTATCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGCTGCATCCAACCAGGGCTCTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGA GCCTGAAGATTTTGCAGTTTATTACTGTCATCAGACTAAAGGAGGTGCCTTGGACGTTCGGCCAAGGGACCAAGGTGGAGATCAAA (SEQ ID NO: 115) VL for D1F2
DIQMTQTTSSLSASLGDRVTISCRASQDISNFLNWYQQKPDGTVKLLIYYTSRLQSGVPSRFSGTGSGTDYSLTISNLEQEDLATYFCQQGSSLPWTFGGGTKLEIK (SEQ ID NO: 87)
GATATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAGTCACCATCAGTTGCAGGGCCAGTCAGGACATTAGCAATTTTTTAAACTGGTATCAGCAGAAACCAGATGGAACTGTTAAACTCCTGATCTACTACACATCAAGATTACAGTCAGGAGTCCCATCAAGGTTCAGTGGCACTGGGTCTGGGACAGATTATTCTCTCACCATTAGCAACCTGGAACAAGAAGATCT TGCCACTTACTTTTTGCCAACAGGGTAGTTCGCTTCCGTGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA (SEQ ID NO: 116) VL for C1F5
DIVLTQSPATLSVTPGDSVSLSCRASQSISNNLHWYQQKSHESPRLLIKYGSQSMSGIPSRFSGSGSGTDFTLVINSVETEDFGMYFCQQSNSWPLTFGAGTKLELK (SEQ ID NO: 88)
GATATTGTGCTAACTCAGTCTCCAGCCACCCTGTCTGTGACTCCAGGAGATAGCGTCAGTCTTTCCTGCAGGGCCAGCCAAAGTATTAGCAACAACCTACACTGGTATCAACAAAAATCACATGAGTCTCCAAGGCTTCTCATCAAGTATGGTTCCCAGTCCATGTCTGGGATCCCCTCCAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACTCTCGTTATCAACAGTGTGGAGACTGAAG ATTTGGAATGTATTTCTGTCAACAGAGTAACAGCTGGCCTCTCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAA (SEQ ID NO: 117) VL for D1A1
DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDFSLTISNLEEEDIATYFCQQSNALPWTFGGGTKLEIK (SEQ ID NO: 89)
GATATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAGTCACCATCAGTTGCAGGGCAAGTCAGGACATTAGCAATTATTTAAACTGGTATCAGCAGAAACCAGATGGAACTGTTAAACTCCTGATCTACTACACATCAAGATTACACTCAGGAGTCCCATCAAGGTTCAGTGGCAGTGGGTCTGGAACAGATTTTTTCTCACCATTAGCAACCTGGAAGAAGAAGATATTG CCACTTACTTTTGCCAACAGAGTAATGCGCTTCCGTGGACGTTCGGTGGAGGCACCAAACTGGAAATCAAA (SEQ ID NO: 118) VL for D1F1
DIVLTQSPASLVVSLGQRATISCRASESVDNSGISFMNWFQQKPGQPPKLLIYTASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDSAMYFCQQSYEVPWTFGGGTKLEIK (SEQ ID NO: 90)
GACATTGTGCTGACCCAATCTCCAGCTTCTTTGGTTGTGTCTCTAGGGCAGAGGGCCACCATCTCCTGCAGAGCCAGCGAAAGTGTTGATAATTCTGGCATTAGTTTTATGAACTGGTTCCAACAGAAACCAGGACAGCCACCCAAACTCCTCATCTATACTGCATCCAACCAAGGATCCGGGGTCCCTGCCAGTTTAGTGGCAGTGGGTCTGGGACAGACTTCAGCCTCAACATCCATCCTATG GAGGAGGATGATTCTGCAATGTATTTCTGTCAGCAAAGTTATGAGGTTCCTTGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA (SEQ ID NO: 119) VL for C1E2
SIVMTQTPKFLLVSAGDRVTITCKASQSVSNDVAWYQQKPGQSPKLLIYYAFHRYTGVPDRFTGSGYGTDFTFTISTVQAEDLAVYFCQQDYSSPYTFGGGTKLEIK (SEQ ID NO: 91)
AGTATTGTGATGACCCAGACTCCCAAATTCCTGCTTGTATCAGCAGGAGACAGGGTTACCATAACCTGCAAGGCCAGTCAGAGTGTGAGTAATGATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATATACTATGCATTTCATCGCTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCACTTTCACCATCAGCACTGTGCAGGCTGAAGACCT GGCAGTTTATTTCTGTCAGCAGGATTATAGCTCTCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA (SEQ ID NO: 120) VL for C1A1
DIQMTQTTSSLSASLGDRVTISCRASQDISNYLIWYQQKTDGTLKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQHKTLPWTFGGGTKLEIK (SEQ ID NO: 92)
GATATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAGTCACCATCAGTTGCAGGGCAAGTCAGGACATTAGCAATTATTTAATCTGGTATCAGCAGAAAACAGATGGAACTCTTAAACTCCTGATCTACTACACATCAAGATTACACTCAGGAGTCCCATCAAGGTTCAGTGGCAGTGGGTCTGGAACAGATTATTCTCTCACCATTAGCAACCTGGAGCAAGAAGATATTG CCACTTACTTTTGCCAGCAGCATAAAACGCTTCCGTGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA (SEQ ID NO: 121) VL for C1F4
DIVMTQSQKFMSTSVGDRVTITCKASQNVRTAVAWYQQKPGQSPKALIYLASNRHTGVPDRFTGSGSGTDFTLTISNVQSKDLADYFCLQHWNYPYTFGGGTKLEIK (SEQ ID NO: 93)
GACATTGTGATGACCCAGTCTCAAAAAATTCATGTCCACATCAGTAGGAGACAGGGTCACCATCACCTGCAAGGCCAGTCAGAATGTTCGTACTGCTGTAGCCTGGTATCAACAGAAACCAGGGCAGTCTCCTAAAGCACTGATTTACTTGGCATCCAACCGGCACACTGGAGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACAGATTTCACTCTCACCATTAGCAATGTGCAATCTAAAGACCTG GCAGATTATTTCTGTCTGCAACATTGGAATTATCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA (SEQ ID NO: 122) VL for D2C2
DIVLTQSPASLAVSLGQRATISCRASESVDNSGISFMNWFQQKPGQSPKLLIYIASNHGSGVPARFSGSGSGTDFSLNIHPMEEDDSAMYFCQQSYEVPWTFGGGTKLEIK (SEQ ID NO: 94)
GACATTGTGCTGACCCAATCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCACCATCTCCTGCAGAGCCAGCGAAAGTGTTGATAATTCTGGCATTAGTTTTATGAACTGGTTCCAACAGAAACCAGGACAGTCACCCAAACTCCTCATCTATATTGCATCCAACCACGGATCCGGGGTCCCTGCCAGGTTTAGTGGCAGTGGGTCTGGGACAGACTTCAGCCTCAACATCCATCCTATGGA GGAGGATGATTCTGCAATGTATTTCTGTCAGCAAAGTTATGAGGTTCCTTGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA (SEQ ID NO: 123) VL for 2G2
DVLMTQTPLSLPVSLGDQASISCRSSQSIIRSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEADDLGLYYCFQGSHVPWTFGGGTKLEIK (SEQ ID NO: 95)
GATGTTTTGATGACCCAAACTCCACTCTCCCTGCCTGTCAGTCTTGGAGATCAAGCCTCCATCTCTTGCAGATCTAGTCAGAGCATTATACGTAGTAATGGAAACACCTATTTAGAATGGTACCTGCAGAAACCAGGCCAGTCTCCAAAGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAGC AGAGTGGAGGCTGACGATCTGGGACTTTATTACTGCTTTCAAGGTTCACATGTTCCGTGGACGTTCCGGTGGAGGCACCAAGCTGGAAATCAAA (SEQ ID NO: 124) VL for C1C5
DVLMTQSPLSLPVSLGDQASISCRSSQSIVHSNGHIYLEWYLQKPGQSPKLLIYKVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHGTFGGGTKLEIK (SEQ ID NO: 96)
GATGTTTTGATGACCCAAAGTCCACTCTCCCTGCCTGTCAGTCTTGGAGATCAAGCCTCCATCTCTTGCAGATCTAGTCAGAGTATTGTACATAGTAATGGACACATCTATTTAGAATGGTACCTGCAGAAACCAGGCCAGTCTCCAAAGCTCCTGATCTACAAAGTTTCCAAGCGATTTTCTGGGGTCCCAGACAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGAT CAGCAGAGTGGAGGCTGAGGATCTGGGAGTTTATTACTGCTTTCAAGGTTCACATGGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA (SEQ ID NO: 125) Human IgG1 heavy chain constant region
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 97)
GCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCT GCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTG GAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGAC CTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGCCTCTCCCTGTCTCCGGGTAAA (SEQ ID NO: 126) Human kappa light chain constant region
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 98)
CGTACGGTGGCGGCGCCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACA CAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT (SEQ ID NO: 127) Human IgG1 heavy chain CH1 region
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV (SEQ ID NO:99)
Gcctccaccaagggcccatcggtcttccccctggcaccctcctccaagagcacctctgggggcacagcggccctgggctgcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaactcaggcgccctgaccagcggcgtgcacaccttcccggctgtcctacagtcctcaggactctactccctcagcagcgtggtgaccg tgccctccagcagcttgggcacccagacctacatctgcaacgtgaatcacaagcccagcaacaccaaggtggacaagaaagtt (SEQ ID NO: 128) Human PD-1-Fc
LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL (SEQ ID NO:100) Human PD-L1-Fc
FTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCT FRRLDPEENHTAELVIPELPLAHPPNERTEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 101) Heavy chain constant region for mouse antibodies
AKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFK CRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTTCSVLHEGLHNHHTEKSLSHSPGK (SEQ ID NO: 129) Light chain constant region for mouse antibodies
RADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSSTSPIVKSFNRGEC (SEQ ID NO: 130) SEQ ID NO:1-101, 129 and 130: amino acid sequence; SEQ ID NO:102-128: nucleotide sequence

--->

LIST OF SEQUENCES

<110> Immvira Co., Limited

<120> PD-1 BINDING ANTIBODIES AND METHODS OF THEIR APPLICATION

<130> 55532 00004

<150>US62/657927

<151> 2018-04-15

<160> 130

<170> Patent In version 3.5

<210> 1

<211> 8

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR1 for C1E1, huC1E1-V1 - huC1E1-V7 and huC1E1-V10

<400> 1

Gly Phe Thr Phe Ser Ser Tyr Leu

15

<210> 2

<211> 8

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR2 for C1E1, huC1E1-V1 - huC1E1-V7 and huC1E1-V10

<400> 2

Ile Ser Gly Gly Gly Gly Asp Thr

15

<210> 3

<211> 13

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR3 for C1E1, huC1E1-V1 - huC1E1-V7 and huC1E1-V10

<400> 3

Val Arg Phe Gly Gly Ala Gly Tyr Tyr Trp Tyr Phe Asp

1 5 10

<210> 4

<211> 8

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR1 for D1F2

<400> 4

Gly Phe Thr Phe Ser Ser Tyr Thr

15

<210> 5

<211> 8

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR2 for D1F2

<400> 5

Ile Ser Gly Gly Gly Ser Asn Ile

15

<210> 6

<211> 13

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR3 for D1F2

<400> 6

Val Leu Asn Tyr Ala Tyr Ala Met Asp Tyr Trp Gly Gln

1 5 10

<210> 7

<211> 8

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR1 for C1F5

<400> 7

Gly Phe Ala Phe Ser Ser Tyr Asp

15

<210> 8

<211> 8

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR2 for C1F5

<400> 8

Ile Thr Gly Gly Gly Ser Ser Ser

15

<210> 9

<211> 13

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR3 for C1F5

<400> 9

Ala Ser Pro Tyr Leu Ser Tyr Phe Asp Tyr Trp Gly Gln

1 5 10

<210> 10

<211> 8

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR1 for D1A1

<400> 10

Gly Phe Thr Phe Ser Asn Tyr Ala

15

<210> 11

<211> 8

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR2 for D1A1

<400> 11

Ile Ser Gly Gly Gly Gly Asn Ile

15

<210> 12

<211> 13

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR3 for D1A1

<400> 12

Ala Ser Pro Tyr Ala Asn Tyr Val Trp Tyr Leu Asp Val

1 5 10

<210> 13

<211> 8

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR1 for D1F1

<400> 13

Gly Phe Thr Phe Ser Ser Asn Thr

15

<210> 14

<211> 8

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR2 for D1F1

<400> 14

Ile Ser Gly Gly Gly Val Asn Thr

15

<210> 15

<211> 13

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR3 for D1F1

<400> 15

Ala Arg His Gly Asn Tyr Asn Tyr Tyr Gly Met Asp Tyr

1 5 10

<210> 16

<211> 8

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR1 for C1E2

<400> 16

Gly Tyr Thr Phe Thr Asn Tyr Trp

15

<210> 17

<211> 8

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR2 for C1E2

<400> 17

Ile Tyr Pro Gly Gly Gly Tyr Thr

15

<210> 18

<211> 13

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR3 for C1E2

<400> 18

Ala Arg Gly Tyr Gly Thr Asn Tyr Trp Tyr Phe Asp Val

1 5 10

<210> 19

<211> 10

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR1 for C1A1

<400> 19

Gly Phe Ser Leu Ser Thr Ser Gly Met Gly

1 5 10

<210> 20

<211> 7

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR2 for C1A1

<400> 20

Ile Trp Trp Asp Asp Asp Lys

15

<210> 21

<211> 13

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR3 for C1A1

<400> 21

Ala Arg Thr Gly Gly Phe Ile Thr Thr Gly Tyr Trp Tyr

1 5 10

<210> 22

<211> 8

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR1 for C1F4

<400> 22

Gly Tyr Lys Phe Thr Asp Tyr Ala

15

<210> 23

<211> 8

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR2 for C1F4

<400> 23

Ile Ser Thr Tyr Ser Gly Asp Val

15

<210> 24

<211> 13

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR3 for C1F4

<400> 24

Ser Arg Leu Gly Ile Thr Ala Gly Phe Ala Tyr Trp Gly

1 5 10

<210> 25

<211> 8

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR1 for D2C2

<400> 25

Gly Phe Thr Phe Ser Ser Asn Thr

15

<210> 26

<211> 8

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR2 for D2C2

<400> 26

Ile Ser Gly Gly Gly Val Asp Thr

15

<210> 27

<211> 13

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR3 for D2C2

<400> 27

Ala Arg His Gly Asn Tyr Asn Tyr Tyr Gly Met Asp Tyr

1 5 10

<210> 28

<211> 8

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR1 for 2G2

<400> 28

Gly Phe Thr Phe Ser Tyr Tyr Gly

15

<210> 29

<211> 8

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR2 for 2G2

<400> 29

Ile Ser Ser Gly Ser Ser Phe Thr

15

<210> 30

<211> 13

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR3 for 2G2

<400> 30

Thr Arg Arg Glu Gly Ile Tyr Asp Ala Ser Trp Asp Tyr

1 5 10

<210> 31

<211> 8

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR1 for C1C5

<400> 31

Gly Tyr Thr Phe Thr Asn Tyr Gly

15

<210> 32

<211> 8

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR2 for C1C5

<400> 32

Ile Asn Thr Tyr Ser Gly Glu Pro

15

<210> 33

<211> 13

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH-CDR3 for C1C5

<400> 33

Val Arg Gln Gly Asp Phe Asp Tyr Glu Asp Ala Met Asp

1 5 10

<210> 34

<211> 15

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR1 for C1E1, huC1E1-V1 - huC1E1-V7 and huC1E1-V10

<400> 34

Arg Ala Ser Lys Ser Val Asp Asp Ser Gly Ile Ser Phe Met His

1 5 10 15

<210> 35

<211> 7

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR2 for C1E1, huC1E1-V1 - huC1E1-V7 and huC1E1-V10

<400> 35

Ala Ala Ser Asn Gln Gly Ser

15

<210> 36

<211> 9

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR3 for C1E1, huC1E1-V1 - huC1E1-V7 and huC1E1-V10

<400> 36

His Gln Thr Lys Glu Val Pro Trp Thr

15

<210> 37

<211> 11

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR1 for D1F2

<400> 37

Arg Ala Ser Gln Asp Ile Ser Asn Phe Leu Asn

1 5 10

<210> 38

<211> 7

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR2 for D1F2

<400> 38

Tyr Thr Ser Arg Leu Gln Ser

15

<210> 39

<211> 9

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR3 for D1F2

<400> 39

Gln Gln Gly Ser Ser Leu Pro Trp Thr

15

<210> 40

<211> 11

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR1 for C1F5

<400> 40

Arg Ala Ser Gln Ser Ile Ser Asn Asn Leu His

1 5 10

<210> 41

<211> 6

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR2 for C1F5

<400> 41

Gly Ser Gln Ser Met Ser

15

<210> 42

<211> 9

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR3 for C1F5

<400> 42

Gln Gln Ser Asn Ser Trp Pro Leu Thr

15

<210> 43

<211> 11

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR1 for D1A1

<400> 43

Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn

1 5 10

<210> 44

<211> 7

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR3 for D1A1

<400> 44

Tyr Thr Ser Arg Leu His Ser

15

<210> 45

<211> 9

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR3 for D1A1

<400> 45

Gln Gln Ser Asn Ala Leu Pro Trp Thr

15

<210> 46

<211> 15

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR1 for D1F1

<400> 46

Arg Ala Ser Glu Ser Val Asp Asn Ser Gly Ile Ser Phe Met Asn

1 5 10 15

<210> 47

<211> 7

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR2 for D1F1

<400> 47

Thr Ala Ser Asn Gln Gly Ser

15

<210> 48

<211> 9

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR3 for D1F1

<400> 48

Gln Gln Ser Tyr Glu Val Pro Trp Thr

15

<210> 49

<211> 11

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR1 for C1E2

<400> 49

Lys Ala Ser Gln Ser Val Ser Asn Asp Val Ala

1 5 10

<210> 50

<211> 7

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR2 for C1E2

<400> 50

Tyr Ala Phe His Arg Tyr Thr

15

<210> 51

<211> 9

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR3 for C1E2

<400> 51

Gln Gln Asp Tyr Ser Ser Pro Tyr Thr

15

<210> 52

<211> 11

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR1 for C1A1

<400> 52

Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Ile

1 5 10

<210> 53

<211> 7

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR2 for C1A1

<400> 53

Tyr Thr Ser Arg Leu His Ser

15

<210> 54

<211> 9

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR3 for C1A1

<400> 54

Gln Gln His Lys Thr Leu Pro Trp Thr

15

<210> 55

<211> 11

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR1 for C1F4

<400> 55

Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala

1 5 10

<210> 56

<211> 7

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR2 for C1F4

<400> 56

Leu Ala Ser Asn Arg His Thr

15

<210> 57

<211> 9

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR3 for C1F4

<400> 57

Leu Gln His Trp Asn Tyr Pro Tyr Thr

15

<210> 58

<211> 15

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR1 for D2C2

<400> 58

Arg Ala Ser Glu Ser Val Asp Asn Ser Gly Ile Ser Phe Met Asn

1 5 10 15

<210> 59

<211> 7

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR2 for D2C2

<400> 59

Ile Ala Ser Asn His Gly Ser

15

<210> 60

<211> 9

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR3 for D2C2

<400> 60

Gln Gln Ser Tyr Glu Val Pro Trp Thr

15

<210> 61

<211> 16

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR1 for 2G2

<400> 61

Arg Ser Ser Gln Ser Ile Ile Arg Ser Asn Gly Asn Thr Tyr Leu Glu

1 5 10 15

<210> 62

<211> 7

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR2 for 2G2

<400> 62

Lys Val Ser Asn Arg Phe Ser

15

<210> 63

<211> 9

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR3 for 2G2

<400> 63

Phe Gln Gly Ser His Val Pro Trp Thr

15

<210> 64

<211> 16

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR1 for C1C5

<400> 64

Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly His Ile Tyr Leu Glu

1 5 10 15

<210> 65

<211> 7

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR2 for C1C5

<400> 65

Lys Val Ser Lys Arg Phe Ser

15

<210> 66

<211> 7

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL-CDR3 for C1C5

<400> 66

Phe Gln Gly Ser His Gly Thr

15

<210> 67

<211> 121

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH for C1E1

<400> 67

Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Leu Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val

35 40 45

Ala Thr Ile Ser Gly Gly Gly Gly Asp Thr Tyr Phe Pro Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Asn Asn Leu Tyr

65 70 75 80

Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys

85 90 95

Val Arg Phe Gly Gly Ala Gly Tyr Tyr Trp Tyr Phe Asp Val Trp Gly

100 105 110

Ala Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 68

<211> 121

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH for huC1E1-V1, huC1E1-V3 - huC1E1-V7

<400> 68

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Leu Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ala Thr Ile Ser Gly Gly Gly Gly Asp Thr Tyr Phe Pro Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Val Arg Phe Gly Gly Ala Gly Tyr Tyr Trp Tyr Phe Asp Val Trp Gly

100 105 110

Ala Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 69

<211> 121

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH for huC1E1-V2 and huC1E1-V10

<400> 69

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Leu Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Ala Thr Ile Ser Gly Gly Gly Gly Asp Thr Tyr Phe Pro Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Val Arg Phe Gly Gly Ala Gly Tyr Tyr Trp Tyr Phe Asp Val Trp Gly

100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 70

<211> 117

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH for D1F2

<400> 70

Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20 25 30

Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val

35 40 45

Ala Thr Ile Ser Gly Gly Gly Ser Asn Ile Tyr Tyr Pro Asp Ser Val

50 55 60

Glu Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Arg Asn Thr Leu Tyr

65 70 75 80

Leu His Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys

85 90 95

Val Leu Asn Tyr Ala Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser

100 105 110

Val Thr Val Ser Ser

115

<210> 71

<211> 117

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH for C1F5

<400> 71

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser Tyr

20 25 30

Asp Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val

35 40 45

Ala Tyr Ile Thr Gly Gly Gly Ser Ser Ser Phe Tyr Pro Asp Thr Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys

85 90 95

Ala Ser Pro Tyr Leu Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr

100 105 110

Leu Thr Val Ser Ser

115

<210> 72

<211> 120

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH for D1A1

<400> 72

Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr

20 25 30

Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val

35 40 45

Ala Thr Ile Ser Gly Gly Gly Gly Asn Ile Tyr Tyr Pro Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys

85 90 95

Ala Ser Pro Tyr Ala Asn Tyr Val Trp Tyr Leu Asp Val Trp Gly Ala

100 105 110

Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 73

<211> 120

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH for D1F1

<400> 73

Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Asn

20 25 30

Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val

35 40 45

Ala Ala Ile Ser Gly Gly Gly Val Asn Thr Tyr Tyr Pro Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys

85 90 95

Ala Arg His Gly Asn Tyr Asn Tyr Tyr Gly Met Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Ser Val Thr Val Ser Ser

115 120

<210> 74

<211> 120

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH for C1E2

<400> 74

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr

1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr

20 25 30

Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile

35 40 45

Gly Asp Ile Tyr Pro Gly Gly Gly Tyr Thr Asn Tyr Asn Glu Asn Phe

50 55 60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr

65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Phe Phe Cys

85 90 95

Ala Arg Gly Tyr Gly Thr Asn Tyr Trp Tyr Phe Asp Val Trp Gly Ala

100 105 110

Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 75

<211> 124

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH for C1A1

<400> 75

Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Lys Pro Ser Gln

1 5 10 15

Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser

20 25 30

Gly Met Gly Val Gly Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu

35 40 45

Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Phe Tyr Asn Pro Ser

50 55 60

Leu Lys Ser Gln Leu Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val

65 70 75 80

Phe Leu Lys Ile Thr Ser Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr

85 90 95

Cys Ala Arg Thr Gly Gly Phe Ile Thr Thr Gly Tyr Trp Tyr Phe Asp

100 105 110

Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser

115 120

<210> 76

<211> 118

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH for C1F4

<400> 76

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Val

1 5 10 15

Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Lys Phe Thr Asp Tyr

20 25 30

Ala Met His Trp Val Arg Gln Ser His Ala Lys Ser Leu Glu Trp Ile

35 40 45

Gly Ile Ile Ser Thr Tyr Ser Gly Asp Val Ser Phe Asn Gln Asn Phe

50 55 60

Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr

65 70 75 80

Met Glu Leu Ala Arg Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr Cys

85 90 95

Ser Arg Leu Gly Ile Thr Ala Gly Phe Ala Tyr Trp Gly Gln Gly Thr

100 105 110

Leu Val Thr Val Ser Ala

115

<210> 77

<211> 120

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH for D2C2

<400> 77

Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Asn

20 25 30

Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val

35 40 45

Ala Ala Ile Ser Gly Gly Gly Val Asp Thr Tyr Tyr Pro Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys

85 90 95

Ala Arg His Gly Asn Tyr Asn Tyr Tyr Gly Met Asp Tyr Trp Gly Gln

100 105 110

Gly Thr Ser Val Thr Val Ser Ser

115 120

<210> 78

<211> 124

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH for 2G2

<400> 78

Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Lys Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Tyr Tyr

20 25 30

Gly Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp Val

35 40 45

Ala Thr Ile Ser Ser Gly Ser Ser Phe Thr Tyr Ser Pro Asp Ser Val

50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr

65 70 75 80

Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Ile Tyr Tyr Cys

85 90 95

Thr Arg Arg Glu Gly Ile Tyr Asp Ala Ser Trp Asp Tyr Ser Met Asp

100 105 110

Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser

115 120

<210> 79

<211> 121

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VH for C1C5

<400> 79

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu

1 5 10 15

Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr

20 25 30

Gly Ile Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met

35 40 45

Gly Trp Ile Asn Thr Tyr Ser Gly Glu Pro Thr Tyr Ser Asp Asp Phe

50 55 60

Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr

65 70 75 80

Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ser Thr Tyr Phe Cys

85 90 95

Val Arg Gln Gly Asp Phe Asp Tyr Glu Asp Ala Met Asp Tyr Trp Gly

100 105 110

Gln Gly Thr Ser Val Thr Val Ser Ser

115 120

<210> 80

<211> 111

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL for C1E1

<400> 80

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly

1 5 10 15

Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Asp Asp Ser

20 25 30

Gly Ile Ser Phe Met His Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro

35 40 45

Lys Leu Leu Ile Tyr Ala Ala Ser Asn Gln Gly Ser Gly Val Pro Ala

50 55 60

Arg Phe Arg Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His

65 70 75 80

Pro Met Glu Glu Asp Asp Thr Ala Met Tyr Phe Cys His Gln Thr Lys

85 90 95

Glu Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

100 105 110

<210> 81

<211> 111

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL for huC1E1-V1 and huC1E1-V2

<400> 81

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Lys Ser Val Asp Asp Ser

20 25 30

Gly Ile Ser Phe Met His Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro

35 40 45

Arg Leu Leu Ile Tyr Ala Ala Ser Asn Gln Gly Ser Gly Val Pro Ala

50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser

65 70 75 80

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Phe Cys His Gln Thr Lys

85 90 95

Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105 110

<210> 82

<211> 111

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL for huC1E1-V3

<400> 82

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Lys Ser Val Asp Asp Ser

20 25 30

Gly Ile Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro

35 40 45

Arg Leu Leu Ile Tyr Ala Ala Ser Asn Gln Gly Ser Gly Val Pro Ala

50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser

65 70 75 80

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Phe Cys His Gln Thr Lys

85 90 95

Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105 110

<210> 83

<211> 111

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL for huC1E1-V4

<400> 83

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Lys Ser Val Asp Asp Ser

20 25 30

Gly Ile Ser Phe Met His Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro

35 40 45

Arg Leu Leu Ile Tyr Ala Ala Ser Asn Gln Gly Ser Gly Val Pro Ala

50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser

65 70 75 80

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Phe Cys His Gln Thr Lys

85 90 95

Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105 110

<210> 84

<211> 111

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL for huC1E1-V5

<400> 84

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Lys Ser Val Asp Asp Ser

20 25 30

Gly Ile Ser Phe Met His Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro

35 40 45

Arg Leu Leu Ile Tyr Ala Ala Ser Asn Gln Gly Ser Gly Ile Pro Ala

50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser

65 70 75 80

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Phe Cys His Gln Thr Lys

85 90 95

Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105 110

<210> 85

<211> 111

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL for huC1E1-V6

<400> 85

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Lys Ser Val Asp Asp Ser

20 25 30

Gly Ile Ser Phe Met His Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro

35 40 45

Arg Leu Leu Ile Tyr Ala Ala Ser Asn Gln Gly Ser Gly Val Pro Ala

50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser

65 70 75 80

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys His Gln Thr Lys

85 90 95

Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105 110

<210> 86

<211> 111

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL for huC1E1-V7 and huC1E1-V10

<400> 86

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Lys Ser Val Asp Asp Ser

20 25 30

Gly Ile Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro

35 40 45

Arg Leu Leu Ile Tyr Ala Ala Ser Asn Gln Gly Ser Gly Ile Pro Ala

50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser

65 70 75 80

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys His Gln Thr Lys

85 90 95

Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105 110

<210> 87

<211> 107

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL for D1F2

<400> 87

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly

1 5 10 15

Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Phe

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile

35 40 45

Tyr Tyr Thr Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Thr Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln

65 70 75 80

Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Gly Ser Ser Leu Pro Trp

85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

100 105

<210> 88

<211> 107

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL for C1F5

<400> 88

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly

1 5 10 15

Asp Ser Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Asn Asn

20 25 30

Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile

35 40 45

Lys Tyr Gly Ser Gln Ser Met Ser Gly Ile Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Val Ile Asn Ser Val Glu Thr

65 70 75 80

Glu Asp Phe Gly Met Tyr Phe Cys Gln Gln Ser Asn Ser Trp Pro Leu

85 90 95

Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys

100 105

<210> 89

<211> 107

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL for D1A1

<400> 89

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly

1 5 10 15

Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr

20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile

35 40 45

Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Asn Leu Glu Glu

65 70 75 80

Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Ser Asn Ala Leu Pro Trp

85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

100 105

<210> 90

<211> 111

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL for D1F1

<400> 90

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Val Val Ser Leu Gly

1 5 10 15

Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Asn Ser

20 25 30

Gly Ile Ser Phe Met Asn Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro

35 40 45

Lys Leu Leu Ile Tyr Thr Ala Ser Asn Gln Gly Ser Gly Val Pro Ala

50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His

65 70 75 80

Pro Met Glu Glu Asp Asp Ser Ala Met Tyr Phe Cys Gln Gln Ser Tyr

85 90 95

Glu Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

100 105 110

<210> 91

<211> 107

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL for C1E2

<400> 91

Ser Ile Val Met Thr Gln Thr Pro Lys Phe Leu Leu Val Ser Ala Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp

20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile

35 40 45

Tyr Tyr Ala Phe His Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly

50 55 60

Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Thr Val Gln Ala

65 70 75 80

Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Pro Tyr

85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

100 105

<210> 92

<211> 107

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL for C1A1

<400> 92

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly

1 5 10 15

Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr

20 25 30

Leu Ile Trp Tyr Gln Gln Lys Thr Asp Gly Thr Leu Lys Leu Leu Ile

35 40 45

Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly

50 55 60

Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln

65 70 75 80

Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln His Lys Thr Leu Pro Trp

85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

100 105

<210> 93

<211> 107

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL for C1F4

<400> 93

Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala

20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile

35 40 45

Tyr Leu Ala Ser Asn Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly

50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser

65 70 75 80

Lys Asp Leu Ala Asp Tyr Phe Cys Leu Gln His Trp Asn Tyr Pro Tyr

85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

100 105

<210> 94

<211> 111

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL for D2C2

<400> 94

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly

1 5 10 15

Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Asn Ser

20 25 30

Gly Ile Ser Phe Met Asn Trp Phe Gln Gln Lys Pro Gly Gln Ser Pro

35 40 45

Lys Leu Leu Ile Tyr Ile Ala Ser Asn His Gly Ser Gly Val Pro Ala

50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His

65 70 75 80

Pro Met Glu Glu Asp Asp Ser Ala Met Tyr Phe Cys Gln Gln Ser Tyr

85 90 95

Glu Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

100 105 110

<210> 95

<211> 112

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL for 2G2

<400> 95

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly

1 5 10 15

Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Ile Arg Ser

20 25 30

Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser

35 40 45

Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro

50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile

65 70 75 80

Ser Arg Val Glu Ala Asp Asp Leu Gly Leu Tyr Tyr Cys Phe Gln Gly

85 90 95

Ser His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

100 105 110

<210> 96

<211> 110

<212> PROTEIN

<213> Artificial sequence

<220>

<223> VL for C1C5

<400> 96

Asp Val Leu Met Thr Gln Ser Pro Leu Ser Leu Pro Val Ser Leu Gly

1 5 10 15

Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser

20 25 30

Asn Gly His Ile Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser

35 40 45

Pro Lys Leu Leu Ile Tyr Lys Val Ser Lys Arg Phe Ser Gly Val Pro

50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile

65 70 75 80

Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly

85 90 95

Ser His Gly Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

100 105 110

<210> 97

<211> 330

<212> PROTEIN

<213> Artificial sequence

<220>

<223> human IgG1 heavy chain constant region

<400> 97

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys

1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr

20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser

35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser

50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr

65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys

85 90 95

Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys

100 105 110

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro

115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys

130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp

145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu

165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu

180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn

195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly

210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu

225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr

245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn

260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe

275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn

290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr

305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys

325 330

<210> 98

<211> 107

<212> PROTEIN

<213> Artificial sequence

<220>

<223> human kappa light chain constant region

<400> 98

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu

1 5 10 15

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe

20 25 30

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln

35 40 45

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser

50 55 60

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu

65 70 75 80

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser

85 90 95

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys

100 105

<210> 99

<211> 98

<212> PROTEIN

<213> Artificial sequence

<220>

<223> CH1 region of human IgG1 heavy chain

<400> 99

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys

1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr

20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser

35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser

50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr

65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys

85 90 95

Lys Val

<210> 100

<211> 371

<212> PROTEIN

<213> Homo sapiens

<400> 100

Leu Asp Ser Pro Asp Arg Pro Trp Asn Pro Pro Thr Phe Ser Pro Ala

1 5 10 15

Leu Leu Val Val Thr Glu Gly Asp Asn Ala Thr Phe Thr Cys Ser Phe

20 25 30

Ser Asn Thr Ser Glu Ser Phe Val Leu Asn Trp Tyr Arg Met Ser Pro

35 40 45

Ser Asn Gln Thr Asp Lys Leu Ala Ala Phe Pro Glu Asp Arg Ser Gln

50 55 60

Pro Gly Gln Asp Cys Arg Phe Arg Val Thr Gln Leu Pro Asn Gly Arg

65 70 75 80

Asp Phe His Met Ser Val Val Arg Ala Arg Arg Asn Asp Ser Gly Thr

85 90 95

Tyr Leu Cys Gly Ala Ile Ser Leu Ala Pro Lys Ala Gln Ile Lys Glu

100 105 110

Ser Leu Arg Ala Glu Leu Arg Val Thr Glu Arg Arg Ala Glu Val Pro

115 120 125

Thr Ala His Pro Ser Pro Ser Pro Arg Pro Ala Gly Gln Phe Gln Glu

130 135 140

Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro

145 150 155 160

Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys

165 170 175

Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val

180 185 190

Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp

195 200 205

Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr

210 215 220

Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp

225 230 235 240

Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu

245 250 255

Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg

260 265 270

Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys

275 280 285

Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp

290 295 300

Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys

305 310 315 320

Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser

325 330 335

Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser

340 345 350

Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser

355 360 365

Leu Ser Leu

370

<210> 101

<211> 453

<212> PROTEIN

<213> Homo sapiens

<400> 101

Phe Thr Val Thr Val Pro Lys Asp Leu Tyr Val Val Glu Tyr Gly Ser

1 5 10 15

Asn Met Thr Ile Glu Cys Lys Phe Pro Val Glu Lys Gln Leu Asp Leu

20 25 30

Ala Ala Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile Ile Gln

35 40 45

Phe Val His Gly Glu Glu Asp Leu Lys Val Gln His Ser Ser Tyr Arg

50 55 60

Gln Arg Ala Arg Leu Leu Lys Asp Gln Leu Ser Leu Gly Asn Ala Ala

65 70 75 80

Leu Gln Ile Thr Asp Val Lys Leu Gln Asp Ala Gly Val Tyr Arg Cys

85 90 95

Met Ile Ser Tyr Gly Gly Ala Asp Tyr Lys Arg Ile Thr Val Lys Val

100 105 110

Asn Ala Pro Tyr Asn Lys Ile Asn Gln Arg Ile Leu Val Val Asp Pro

115 120 125

Val Thr Ser Glu His Glu Leu Thr Cys Gln Ala Glu Gly Tyr Pro Lys

130 135 140

Ala Glu Val Ile Trp Thr Ser Ser Asp His Gln Val Leu Ser Gly Lys

145 150 155 160

Thr Thr Thr Thr Asn Ser Lys Arg Glu Glu Lys Leu Phe Asn Val Thr

165 170 175

Ser Thr Leu Arg Ile Asn Thr Thr Thr Asn Glu Ile Phe Tyr Cys Thr

180 185 190

Phe Arg Arg Leu Asp Pro Glu Glu Asn His Thr Ala Glu Leu Val Ile

195 200 205

Pro Glu Leu Pro Leu Ala His Pro Pro Asn Glu Arg Thr Glu Pro Lys

210 215 220

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu

225 230 235 240

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr

245 250 255

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val

260 265 270

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val

275 280 285

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser

290 295 300

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu

305 310 315 320

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala

325 330 335

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro

340 345 350

Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln

355 360 365

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala

370 375 380

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr

385 390 395 400

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu

405 410 415

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser

420 425 430

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser

435 440 445

Leu Ser Pro Gly Lys

450

<210> 102

<211> 363

<212> DNA

<213> Artificial sequence

<220>

<223> VH for C1E1

<400> 102

gaagtgatgc tggtggagtc tgggggagg ttagtgaagc ctggagggtc cctgaaactc 60

tcctgtgcag cctctggatt cacgttcagt agttatctta tgtcttgggt tcgccagact 120

ccggagaaga ggctggagtg ggtcgcaacc attagtggtg gtggtggtga cacctacttt 180

cccagacagtg tgaagggtcg attcaccatc tccagagaca atgtcaagaa caacctgtac 240

ctgcaaatga gcagtcttag gtctgaggac acggccttgt attactgtgt aagatttggg 300

ggcgctggtt actactggta tttcgatgtc tggggcgcag ggaccacggt caccgtctcc 360

tca 363

<210> 103

<211> 363

<212> DNA

<213> Artificial sequence

<220>

<223> VH for huC1E1-V2 and huC1E1-V10

<400> 103

gaggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60

tcctgtgcag cctctggatt caccttcagt agctatctta tgtcctgggt ccgccaggct 120

ccaggcaagg ggctagagtg ggtggcaact atatcaggtg gtggaggtga cacatacttc 180

ccagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240

ctgcaaatga acagcctgag agctgaggac acggctgtgt attactgtgt gagattcggt 300

ggtgctggtt actactggta ctttgacgtc tggggccaag gaaccctggt caccgtctcg 360

agt 363

<210> 104

<211> 351

<212> DNA

<213> Artificial sequence

<220>

<223> VH for D1F2

<400> 104

gaagtgatgc tggtggagtc tgggggaggc ttagtgaagc ctggagggtc cctgaaactc 60

tcctgtgcag cctctggatt cactttcagt agctatacca tgtcttgggt tcgccagact 120

ccggagaaga ggctggagtg ggtcgcaacc attagtggtg gtggtagtaa catctactat 180

cccagacagtg tggagggtcg attcaccgtc tccagagaca atgccaggaa caccctgtac 240

ctgcatatga gcagtctgag gtctgaggac acggccttat attactgtgt ccttaactac 300

gcctatgcta tggactactg gggtcaagga acctcagtca ccgtctcctc a 351

<210> 105

<211> 351

<212> DNA

<213> Artificial sequence

<220>

<223> VH for C1F5

<400> 105

gaagtgcagc tggtggagtc tgggggaggc ttagtgaagc ctggagggtc cctgaaactc 60

tcctgtgcag cctctggatt cgctttcagt agctatgaca tgtcttgggt tcgccagact 120

ccggagaaga ggctggagtg ggtcgcatac attactggtg gtggtagtag ttccttctat 180

cccagacactg tgaagggccg attcaccatc tccagagaca attccaagaa caccctgtat 240

ttgcaaatga ccagtctgag gtctgaggac acagccatgt attactgtgc aagcccctac 300

ttatcctact ttgactactg gggccaaggc accactctca cagtctcctc a 351

<210> 106

<211> 360

<212> DNA

<213> Artificial sequence

<220>

<223> VH for D1A1

<400> 106

gaagtgatgc tggtggagtc tgggggaggc ttagtgaagc ctggagggtc cctgaaactc 60

tcctgtgcag cctctggatt cactttcagt aactatgcca tgtcttgggt tcgccagact 120

ccggagaaga ggctggagtg ggtcgcaacc attagtggtg gtggtggtaa catctactat 180

cccagacagtg tgaagggtcg attcaccatc tccagagaca atgccaggaa caccctgtac 240

ctgcaaatga gcagtctgag gtctgaggac acggccttgt attattgtgc aagcccgtat 300

gctaactacg tatggtacct cgatgtctgg ggcgcaggga ccacggtcac cgtctcctca 360

<210> 107

<211> 360

<212> DNA

<213> Artificial sequence

<220>

<223> VH for D1F1

<400> 107

gaagtgatgc tggtggagtc tgggggaggc ttagtgaagc ctggagggtc cctgaaactc 60

tcctgtgcag cctctggatt cactttcagt agcaatacca tgtcttgggt tcgccagact 120

ccggagaaga ggctggagtg ggtcgcagcc attagtggtg gtggtgttaa cacctactat 180

cccagacagtg tgaagggtcg attcaccatc tccagagaca atgccaggaa caccctgtac 240

ctgcaaatga gcagtctgag gtctgaggac acggccctgt attactgtgc aagacatggt 300

aactacaatt actatggtat ggactactgg ggtcaaggaa cctcagtcac cgtctcctca 360

<210> 108

<211> 360

<212> DNA

<213> Artificial sequence

<220>

<223> VH for C1E2

<400> 108

caggtccagt tgcagcagtc tggagctgag ctggtaaggc ctgggacttc agtgaagata 60

tcctgcaagg cttctggcta caccttcact aactactggc taggttgggt aaaacagagg 120

cctggacatg gacttgagtg gattggagat atttaccctg gaggtggtta tactaactac 180

aatgagaact tcaagggcaa ggccacactg actgcagaca catcctccag cactgcctac 240

atgcagctca gtagcctgac atctgaggac tctgctgtct ttttctgtgc aagaggctac 300

ggtactaatt actggtactt cgatgtctgg ggcgcaggga ccacggtcac cgtctcctca 360

<210> 109

<211> 372

<212> DNA

<213> Artificial sequence

<220>

<223> VH for C1A1

<400> 109

caagttactc taaaagagtc tggccctggg atattgaagc cctcacagac cctcagtctg 60

acttgttctt tctctgggtt ttcactgagc acttctggta tgggtgtagg ctggattcgt 120

cagccttcag ggaagggtct ggagtggctg gcacacattt ggtgggatga tgataagttc 180

tataacccat ccctgaagag ccagctcaca atctccaagg atacctccag aaaccaggtt 240

ttcctcaaga tcaccagtgt ggacactgca gatactgcca cttactactg tgctcgaacc 300

ggggggttta ttactacggg ctactggtac ttcgatgtct ggggcgcagg gaccacggtc 360

accgtctcct ca 372

<210> 110

<211> 354

<212> DNA

<213> Artificial sequence

<220>

<223> VH for C1F4

<400> 110

caggtccagc tgcaacagtc tggggctgag ctggtgaggc ctggggtctc agtgaagatt 60

tcctgcaagg gttctggcta caaattcact gattatgcta tgcactgggt gaggcagagt 120

catgcaaaga gtctagagtg gattggaatt attagtactt actctggtga cgttagtttc 180

aaccagaact tcaagggcaa ggccacaatg actgtagaca aatcctccag cacagcctat 240

atggaacttg ccagactgac atctgaggat tctgccatct attactgttc aagactgggg 300

attacggcgg ggtttgctta ctggggccaa gggactctgg tcactgtctc tgca 354

<210> 111

<211> 360

<212> DNA

<213> Artificial sequence

<220>

<223> VH for D2C2

<400> 111

gaagtgatgc tggtggagtc tgggggaggc ttagtgaagc ctggagggtc cctgaaactc 60

tcctgtgcag cctctggatt cactttcagt agcaatacca tgtcttgggt tcgccagact 120

ccggagaaga ggctggagtg ggtcgcagcc attagtggtg gtggtgttga cacctactat 180

cccagacagtg tgaagggtcg attcaccatc tccagagaca atgccaggaa caccctgtac 240

ctgcaaatga gcagtctgag gtctgaggac acggccctgt attactgtgc aagacatggt 300

aactacaatt actatggtat ggactactgg ggtcaaggaa cctcagtcac cgtctcctca 360

<210> 112

<211> 372

<212> DNA

<213> Artificial sequence

<220>

<223> VH for 2G2

<400> 112

gaggtgcaac tggtggagtc tgggggagac ttagtgaagc ctggagggtc cctgaaactc 60

tcctgtacag cctctggatt cactttcagt tactatggca tgtcttgggt tcgccagact 120

ccagacaaga ggctggaatg ggtcgcaacc attagtagtg gtagtagttt cacctactct 180

cccagacagtg tgaaggggcg attcaccatc tccagagaca atgccaagaa caccctgtac 240

ctacaaatga acagtctgaa gtctgaggac acagccattt attactgtac aagacgagag 300

gggatctatg atgcttcctg ggattattct atggactact ggggtcaagg aacctcagtc 360

accgtctcct ca 372

<210> 113

<211> 363

<212> DNA

<213> Artificial sequence

<220>

<223> VH for C1C5

<400> 113

cagatccagt tggtgcagtc aggacctgag ctgaagaagc ctggagagac agtcaagatc 60

tcctgcaagg cttctgggta taccttcaca aactatggaa taaactgggt gaagcaggct 120

caggaaagg gtttaaagtg gatgggctgg ataaacacct atagtggaga gccaacatat 180

tctgatgact tcaagggacg ctttgccttc tctttggaaa cctctgccag cactgcctat 240

ttgcagatca acaacctcaa aaatgaggac acgtctacat atttctgtgt aagacagggg 300

gactttgatt acgaggatgc tatggactac tggggtcaag gaacctcagt caccgtctcc 360

tca 363

<210> 114

<211> 333

<212> DNA

<213> Artificial sequence

<220>

<223> VL for C1E1

<400> 114

gacattgtgc tgacccaatc tccagcttct ttggctgtgt ctctagggca gagggccacc 60

atctcctgca gagccagcaa aagtgttgat gattctggca ttagttttat gcactggttc 120

caacagaaac caggacagcc acccaaactc ctcatctatg ctgcatccaa ccaaggatcc 180

ggggtccctg ccaggtttcg tggcagtggg tctgggacag acttcagcct caacatccat 240

cctatggagg aggatgatac tgcaatgtat ttctgtcacc aaactaagga ggttccgtgg 300

acgttcggtg gaggcaccaa gctggaaatc aaa 333

<210> 115

<211> 333

<212> DNA

<213> Artificial sequence

<220>

<223> VL for huC1E1-V7 and huC1E1-V10

<400> 115

gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc 60

ctctcctgca gggccagtaa gtctgttgac gacagtggta tcagcttcat gcactggtat 120

caacagaaac ctggccaggc tcccaggctc ctcatctatg ctgcatccaa ccagggctct 180

ggcatcccag ccaggttcag tggcagtggg tctgggacag acttcactct caccatcagc 240

agcctagagc ctgaagattt tgcagtttat tactgtcatc agactaagga ggtgccttgg 300

acgttcggcc aagggaccaa ggtggagatc aaa 333

<210> 116

<211> 321

<212> DNA

<213> Artificial sequence

<220>

<223> VL for D1F2

<400> 116

gatatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga cagagtcacc 60

atcagttgca gggccagtca ggacattagc aattttttaa actggtatca gcagaaacca 120

gatggaactg ttaaactcct gatctactac acatcaagat tacagtcagg agtcccatca 180

aggttcagtg gcactgggtc tgggacagat tattctctca ccattagcaa cctggaacaa 240

gaagatcttg ccacttactt ttgccaacag ggtagttcgc ttccgtggac gttcggtgga 300

ggcaccaagc tggaaatcaa a 321

<210> 117

<211> 321

<212> DNA

<213> Artificial sequence

<220>

<223> VL for C1F5

<400> 117

gatattgtgc taactcagtc tccagccacc ctgtctgtga ctccaggaga tagcgtcagt 60

ctttcctgca gggccagcca aagtattagc aacaacctac actggtatca acaaaaatca 120

catgagtctc caaggcttct catcaagtat ggttcccagt ccatgtctgg gatcccctcc 180

aggttcagtg gcagtggatc agggacagat ttcactctcg ttatcaacag tgtggagact 240

gaagattttg gaatgtattt ctgtcaacag agtaacagct ggcctctcac gttcggtgct 300

gggaccaagc tggagctgaa a 321

<210> 118

<211> 321

<212> DNA

<213> Artificial sequence

<220>

<223> VL for D1A1

<400> 118

gatatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga cagagtcacc 60

atcagttgca gggcaagtca ggacattagc aattatttaa actggtatca gcagaaacca 120

gatggaactg ttaaactcct gatctactac acatcaagat tacactcagg agtcccatca 180

aggttcagtg gcagtgggtc tggaacagat ttttctctca ccattagcaa cctggaagaa 240

gaagatattg ccacttactt ttgccaacag agtaatgcgc ttccgtggac gttcggtgga 300

ggcaccaaac tggaaatcaa a 321

<210> 119

<211> 333

<212> DNA

<213> Artificial sequence

<220>

<223> VL for D1F1

<400> 119

gacattgtgc tgacccaatc tccagcttct ttggttgtgt ctctagggca gagggccacc 60

atctcctgca gagccagcga aagtgttgat aattctggca ttagttttat gaactggttc 120

caacagaaac caggacagcc acccaaactc ctcatctata ctgcatccaa ccaaggatcc 180

ggggtccctg ccaggtttag tggcagtggg tctgggacag acttcagcct caacatccat 240

cctatggagg aggatgattc tgcaatgtat ttctgtcagc aaagttatga ggttccttgg 300

acgttcggtg gaggcaccaa gctggaaatc aaa 333

<210> 120

<211> 321

<212> DNA

<213> Artificial sequence

<220>

<223> VL for C1E2

<400> 120

agtattgtga tgacccagac tcccaaattc ctgcttgtat cagcaggaga cagggttacc 60

ataacctgca aggccagtca gagtgtgagt aatgatgtag cttggtacca acagaagcca 120

gggcagtctc ctaaactgct gatatactat gcatttcatc gctacactgg agtccctgat 180

cgcttcactg gcagtggata tgggacggat ttcactttca ccatcagcac tgtgcaggct 240

gaagacctgg cagtttattt ctgtcagcag gattatagct ctccgtacac gttcggaggg 300

gggaccaagc tggaaataaa a 321

<210> 121

<211> 321

<212> DNA

<213> Artificial sequence

<220>

<223> VL for C1A1

<400> 121

gatatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga cagagtcacc 60

atcagttgca gggcaagtca ggacattagc aattatttaa tctggtatca gcagaaaaca 120

gatggaactc ttaaactcct gatctactac acatcaagat tacactcagg agtcccatca 180

aggttcagtg gcagtgggtc tggaacagat tattctctca ccattagcaa cctggagcaa 240

gaagatattg ccacttactt ttgccagcag cataaaacgc ttccgtggac gttcggtgga 300

ggcaccaagc tggaaatcaa a 321

<210> 122

<211> 321

<212> DNA

<213> Artificial sequence

<220>

<223> VL for C1F4

<400> 122

gacattgtga tgacccagtc tcaaaaattc atgtccacat cagtaggaga cagggtcacc 60

atcacctgca aggccagtca gaatgttcgt actgctgtag cctggtatca acagaaacca 120

gggcagtctc ctaaagcact gatttacttg gcatccaacc ggcacactgg agtccctgat 180

cgcttcacag gcagtggatc tgggacagat ttcactctca ccattagcaa tgtgcaatct 240

aaagacctgg cagattattt ctgtctgcaa cattggaatt atccgtacac gttcggaggg 300

gggaccaagc tggaaataaa a 321

<210> 123

<211> 333

<212> DNA

<213> Artificial sequence

<220>

<223> VL for D2C2

<400> 123

gacattgtgc tgacccaatc tccagcttct ttggctgtgt ctctagggca gagggccacc 60

atctcctgca gagccagcga aagtgttgat aattctggca ttagttttat gaactggttc 120

caacagaaac caggacagtc acccaaactc ctcatctata ttgcatccaa ccacggatcc 180

ggggtccctg ccaggtttag tggcagtggg tctgggacag acttcagcct caacatccat 240

cctatggagg aggatgattc tgcaatgtat ttctgtcagc aaagttatga ggttccttgg 300

acgttcggtg gaggcaccaa gctggaaatc aaa 333

<210> 124

<211> 336

<212> DNA

<213> Artificial sequence

<220>

<223> VL for 2G2

<400> 124

gatgttttga tgacccaaac tccactctcc ctgcctgtca gtcttggaga tcaagcctcc 60

atctcttgca gatctagtca gagcattata cgtagtaatg gaaacaccta tttagaatgg 120

tacctgcaga aaccaggcca gtctccaaag ctcctgatct acaaagtttc caaccgattt 180

tctggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac actcaagatc 240

agcagagtgg aggctgacga tctgggactt tattactgct ttcaaggttc acatgttccg 300

tggacgttcg gtggaggcac caagctggaa atcaaa 336

<210> 125

<211> 330

<212> DNA

<213> Artificial sequence

<220>

<223> VL for C1C5

<400> 125

gatgttttga tgacccaaag tccactctcc ctgcctgtca gtcttggaga tcaagcctcc 60

atctcttgca gatctagtca gagtattgta catagtaatg gacacatcta tttagaatgg 120

tacctgcaga aaccaggcca gtctccaaag ctcctgatct acaaagtttc caagcgattt 180

tctggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac actcaagatc 240

agcagagtgg aggctgagga tctgggagtt tattactgct ttcaaggttc acatgggacg 300

ttcggtggag gcaccaagct ggaaatcaaa 330

<210> 126

<211> 990

<212> DNA

<213> Artificial sequence

<220>

<223> human IgG1 heavy chain constant region

<400> 126

gctagcacca agggcccatc ggtcttcccc ctggcaccct cctccaagag cacctctggg 60

ggcacagcgg ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg 120

tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca 180

ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacccagacc 240

tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagaa agttgagccc 300

aaatcttgtg acaaaactca cacatgccca ccgtgcccag cacctgaact cctgggggga 360

ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct 420

gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg 480

tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac 540

agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag 600

gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc 660

aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggaggag 720

atgaccaaga accaggtcag cctgacctgc ctggtcaaag gcttctatcc cagcgacatc 780

gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccgtg 840

ctggactccg acggctcctt cttcctctac agcaagctca ccgtggacaa gagcaggtgg 900

cagcagggga acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg 960

cagaagagcc tctccctgtc tccgggtaaa 990

<210> 127

<211> 321

<212> DNA

<213> Artificial sequence

<220>

<223> human kappa light chain constant region

<400> 127

cgtacggtgg cggcgccatc tgtcttcatc ttcccgccat ctgatgagca gttgaaatct 60

ggaactgcct ctgttgtgtg cctgctgaat aacttctatc ccagagaggc caaagtacag 120

tggaaggtgg ataacgccct ccaatcgggt aactcccagg agagtgtcac agagcaggac 180

agcaaggaca gcacctacag cctcagcagc accctgacgc tgagcaaagc agactacgag 240

aaacacaaag tctacgcctg cgaagtcacc catcagggcc tgagctcgcc cgtcacaaag 300

agcttcaaca ggggagagtg t 321

<210> 128

<211> 294

<212> DNA

<213> Artificial sequence

<220>

<223> CH1 region of human IgG1 heavy chain

<400> 128

gcctccacca agggcccatc ggtcttcccc ctggcaccct cctccaagag cacctctggg 60

ggcacagcgg ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg 120

tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca 180

ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacccagacc 240

tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagaa agtt 294

<210> 129

<211> 324

<212> PROTEIN

<213> Artificial sequence

<220>

<223> Heavy chain constant region for mouse antibodies

<400> 129

Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala

1 5 10 15

Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr

20 25 30

Phe Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser

35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu

50 55 60

Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val

65 70 75 80

Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys

85 90 95

Ile Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro

100 105 110

Glu Val Ser Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu

115 120 125

Thr Ile Thr Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Ile Ser

130 135 140

Lys Asp Asp Pro Glu Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu

145 150 155 160

Val His Thr Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr

165 170 175

Phe Arg Ser Val Ser Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn

180 185 190

Gly Lys Glu Phe Lys Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro

195 200 205

Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln

210 215 220

Val Tyr Thr Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val

225 230 235 240

Ser Leu Thr Cys Met Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val

245 250 255

Glu Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln

260 265 270

Pro Ile Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn

275 280 285

Val Gln Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val

290 295 300

Leu His Glu Gly Leu His Asn His His Thr Glu Lys Ser Leu Ser His

305 310 315 320

Ser Pro Gly Lys

<210> 130

<211> 107

<212> PROTEIN

<213> Artificial sequence

<220>

<223> Light chain constant region for mouse antibodies

<400> 130

Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu

1 5 10 15

Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe

20 25 30

Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg

35 40 45

Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser

50 55 60

Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu

65 70 75 80

Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser

85 90 95

Pro Ile Val Lys Ser Phe Asn Arg Gly Glu Cys

100 105

<---

Claims (10)

1. Genetically modified herpes simplex virus type 1 (Herpes Simplex Virus Type 1 (HSV-1)) for the treatment of tumors, containing a polynucleotide encoding Fab anti-PD-1 antibodies, wherein said anti-PD-1 antibody comprises a heavy chain variable region comprising the heavy chain CDR1, CDR2 and CDR3 regions, and a light chain variable region comprising the light chain CDR1, CDR2 and CDR3 regions, and wherein the heavy chain CDR1, CDR2 and CDR3 regions and the light chain CDR1, CDR2 and CDR3 regions contain the amino acid sequences presented in SEQ ID NOs: 1, 2, 3, 34, 35 and 36, respectively. 2. Genetically modified HSV-1 according to claim 1, wherein the heavy chain and light chain variable regions contain amino acid sequences having at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identity to SEQ ID NOs: 67 and 80, respectively. 3. The genetically modified HSV-1 of claim 1, wherein the anti-PD-1 antibody comprises a heavy chain constant region comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 98%, 99% or 100% sequence identity to SEQ ID NOs: 97, 99 or 129, and/or a light chain constant region containing an amino acid sequence having at least 80%, 85%, 90%, 95%, 98%, 99% or 100% identity to SEQ ID NOs: 98 or 130. 4. Genetically modified HSV-1 according to claim 1, wherein the Anti-PD-1 antibody Fab contains a mouse heavy chain variable domain, a human IgG1 CH1 constant domain, a mouse light chain variable domain, and a human kappa light chain constant domain, having the sequences presented in SEQ ID NOs: 67, 99, 80 and 98, respectively. 5. Genetically modified HSV-1 according to claim 1, additionally containing the human IL-12 gene. 6. Genetically modified HSV-1 according to claim 1, where the inverted repeat region is removed. 7. Genetically modified HSV-1 according to claim 6, where the inverted repeat region is replaced by the human IL-12 gene. 8. Genetically modified HSV-1 according to any one of claims 1 to 7, wherein the polynucleotide encoding Fab is inserted between UL3 and UL4.